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SYNOPSIS 
 
 
 
 
 
 
 
 
 
 
Studies on nitrogen containing heterocyclic… 
Synopsis…                                                                                                                          1 
 
A   comprehensive summary of the work to be incorporated in the thesis entitled   
“STUDIES ON NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS       
BIOACTIVE AGENTS” has been described as under. 
 
PART-A:  STUDIES ON PYRAZINE DERIVATIVES 
PART-B: STUDIES ON 6-FLUOROCHROMAN-2-CARBOXYLIC ACID          
         DERIVATIVES 
PART-C:  X-RAY CRYSTALLOGRAPHY STUDY OF DIHYDROPYRIDINE    
  DERIVATIVE    
 
 
PART-A:  STUDIES ON PYRAZINE DERIVATIVES 
 
The primary goal of our research work is to find and develop new 
chemical entities (NCEs) which can be used against untreatable diseases, or which have 
superior properties when compared to currently available drugs. In our newly synthesized 
pyrazine derivatives is a side chain modified derivates. Ligand-free palladium-catalyzed 
Suzuki-Miyaura cross-couplings between aryl halides and aryl boronic acids performed at 
reflux temperature are presented. 
Pyrazine nucleus possesses remarkable pharmaceutical importance and 
biological activities, some of their derivatives occur as natural products. Many pyrazine 
derivatives have displayed diverse pharmacological activities like anti-inflammatory, anti 
tubercular, antitumor, calcium channel blocker etc. Pyrazine play an important role 
against various biological activities. Pharmaceutical properties of the series are improved 
via inclusion of hydroxyl-contg.sidechains.  In view of our ongoing interest in the 
synthesis of some new potentially bioactive pyrazine derivatives have been described as 
under. 
 
PART-I:  STUDIES ON 2-(PIPERIDIN-4-YLMETHOXY) PYRAZINE 
DERIVATIVES 
      
  The synthesis of 2-(piperidin-4-ylmethoxy) pyrazine derivatives has been 
attracted widespread attention due to their diverse pharmacological properties like anti-
inflammatory, anti tubercular, antibiotic, antifungal, herbicidal etc. To approach this goal 
Studies on nitrogen containing heterocyclic… 
Synopsis…                                                                                                                          2 
synthesis of some new 2-(piperidin-4-ylmethoxy) pyrazine derivatives have been 
undertaken. 
 
SECTION-I:  Synthesis and biological evaluation of (4-(((5-(4-bromophenyl) 
pyrazine-2-yl)oxy) methyl) piperidin-1-yl) (aryl) methanones. 
 
 
N
N
O
N
O
RBr
 
 
(Type I)   R= Aryl 
 
  2-(Piperidin-4-ylmethoxy) pyrazine derivatives of Type (I) have been 
synthesized by the condensation of 2-(4-bromophenyl)-5-(piperidin-4-ylmethoxy) 
pyrazine with various aromatic acids in the presence of DIPEA, HBTU and TEA. 
 
SECTION-II: Synthesis and biological evaluation of (4-(((5-(4-methoxy-3-methyl   
phenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(aryl)methanones. 
 
 
O
N
N
O
N
R
O
 
 
Type (II)  R= Aryl 
   
 
2-(Piperidin-4-ylmethoxy) pyrazine derivatives of Type (II) have been synthesized 
by the condensation of 2-(4-methoxy-3-methylphenyl)-5-(piperidin-4-ylmethoxy) 
pyrazine with various aromatic acids in the presence of DIPEA, HBTU and TEA. 
 
SECTION-III:  Synthesis and biological evaluation of (4-(((5-(2-fluoro-Pyridine-3-
yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(aryl)methanones. 
 
 
 
Studies on nitrogen containing heterocyclic… 
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N
N
N
O
N
O
RF  
Type (III)  R= Aryl 
 
  
2-(Piperidin-4-ylmethoxy) pyrazine derivatives of Type (III) have been 
synthesized by the condensation of 2-(2-fluoropyridin-3-yl)-5-(piperidin-4-ylmethoxy) 
pyrazine with various aromatic acids in the presence of DIPEA, HBTU and TEA. 
 
SECTION-IV: Synthesis and biological evaluation of Aryl(4-(((5-m-tolyl)pyrazin-2-
yl)oxy)methyl)piperidin-1-yl)methanones. 
 
 
N
N
O
N
R
O  
 
Type (IV) R= Aryl 
 
  
2-(Piperidin-4-ylmethoxy)pyrazine derivatives of Type (IV) have been 
synthesized by the condensation of 2-(piperidin-4-ylmethoxy)-5-(m-tolyl)pyrazine with 
various aromatic acids in the presence of DIPEA, HBTU and TEA. 
 
SECTION-V: Synthesis and biological evaluation of (4-(((5-(2-methoxyphenyl) 
pyrazin-2-yl)oxy)methyl) piperidin-1-yl) (aryl) methanones. 
 
 
N
N
O
N
O
RO  
 
Type (V)  R= Aryl 
 
  
Studies on nitrogen containing heterocyclic… 
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2-(Piperidin-4-ylmethoxy) pyrazine derivatives of Type (V) have been 
synthesized by the condensation of 2-(2-methoxyphenyl)-5-(piperidin-4-ylmethoxy) 
pyrazine with various aromatic acids in the presence of DIPEA, HBTU and TEA. 
 
PART-B: STUDIES ON 6-FLUOROCHROMAN-2-CARBOXYLIC ACID          
       DERIVATIVES  
 
Our strategy is based on to develop a new bioactive entity especially with 
pharmacological activities bearing heterocyclic ring system.Chroman is an aromatic 
heterocyclic organic compound. It has a bicyclic structure consisting of a six-membered 
benzene ring fused to a six-membered oxygen hetero atom.    
6-Fluorochroman-2-carboxylic acid and their derivatives constitute an important 
class of organic compounds with diverse agriculture, industrial and biological activities. 
The synthesis of this moiety has received considerable attention in recent years. 6-
Fluorochroman-2-carboxylic acid is also known as nebivolol acid and it’s a derivative of 
nebivolol drug. Nebivolol is an antihypertensive drug.  
Considering the increasing importance of chroman nucleus, we have undertaken 
the synthesis of some new thiadiazoles, oxadiazoles, aryl triazoles, thiazolidinones 
bearing chroman nucleus, which have been described as under. 
 
PART-I: STUDIES ON 1,3,4-THIADIAZOLE DERIVATIVES. 
 
 Literature survey revealed that the synthesis of compounds incorporating 1,3,4 -
thiadiazoles have resulted in many potential drugs and are known to exhibit a broad 
spectrum due to their diverse  pharmacological properties like antibiotic, antifungal, 
herbicidal, antitubercular, antitumor, antiviral, antibacterial, amoebicidal, antagonist 
agent, antipyretic etc. In thiadiazole ring system one sulphur and two nitrogen atoms are 
present in a five membered ring.  To approach this goal synthesis of some new 1,3,4-
thiadiazole have been undertaken, which have been described as under. 
 
SECTION-I: Synthesis and biological evaluation of 3-(6-fluorochroman-2-yl)- 
            6-aryl-[1,2,4]triazolo[3, 4-b][1,3,4]thiadiazoles. 
 
 
Studies on nitrogen containing heterocyclic… 
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O
N
N
N
N S
R
F
 
             Type (I)  R= Aryl 
 
  
1,3,4-Thiadiazole derivatives of Type (I) have been synthesized by the 
condensation of 4-amino-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol with 
different aromatic acids in the presence of POCl3. 
 
PART-II: STUDIES ON 1,3,4-OXADIAZOLE DERIVATIVES. 
 
 1,3,4-Oxadiazoles are associated with broad spectrum of pharmacological activity 
like anesthetic, hypnotic, antibacterial, hypoglycemic and antifungal. These valid 
observations promoted us to synthesize 1,3,4-oxadiazole derivatives with better 
therapeutic value which have been described as under. 
 
SECTION-I: Synthesis and biological evaluation of 2-(6-fluorochroman-2-yl)- 
            5-aryl-1, 3, 4-oxadiazoles. 
 
 
O
N
O
N
R
F
 
 
 Type (II)   R=Aryl 
 
  
The 1,3,4- oxadiazole derivatives of Type (II) have been synthesized by the 
condensation of 6-fluorochroman-2-carbohydrazide with various aromatic acids in the 
presence of POCl3. 
 
PART-III: STUDIES ON 4-ARYLTRIAZOLE DERIVATIVES. 
Studies on nitrogen containing heterocyclic… 
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 4-Aryltriazole derivatives have been found to be potent drug which possess a wide 
spectrum of biological activity. Different types of 1,2,4-triazole derivatives shows variety 
of pharmacological activities such as antidepressant, anti-inflammatory, biocides etc. 
Considering the increasing importance of compounds bearing 1,2,4-triazole nucleus, 
some new 1,2,4-triazole derivatives have been synthesized described as under. 
 
SECTION-I: Synthesis and biological evaluation of 5-(6-fluorochroman-2-yl)- 
            4-aryl-4H-1, 2, 4-triazole-3-thiols 
 
 
O
N
N
N
SH
R
F
 
 
Type (III) R = Aryl 
 
  
4-Aryltriazole derivatives of Type (III) have been synthesized by reaction of 
Potassium 2-[(6-fluorochroman-2-yl) carbonyl] hydrazinecarbodithioate with different 
aromatic amines. 
 
PART-IV: STUDIES ON THIAZOLIDINONE DERIVATIVES 
 
 4-Thiazolidinones are derivatives of thiazolidine, which belong to an important 
group of heterocyclic compounds, have been extensively explored for their applications in 
the field of medicine. Compound containing thiazolidinone nucleus shows wide range of 
biological activities such as antitubercular, antitumor, antileprosy, hypnotics, 
anticonvulsant and anticancer, antibacterial etc. With a view to prepare potential bioactive 
agents the syntheses of some new thiazolidinones have been undertaken, which have been 
described as under. 
 
SECTION-I:  Synthesis and biological evaluation of 6-fluoro-N-(4-oxo-2- 
arylthiazolidin-3-yl) chroman-2-carboxamides. 
 
 
Studies on nitrogen containing heterocyclic… 
Synopsis…                                                                                                                          7 
 
NH
N S
O
R
O
O
F
 
 
Type (IV) R=Aryl 
 
 
 The thiazolidinones of Type-(IV) have been prepared by condensation of 6-
fluorochroman-2-carbohydrazide with aryl aldehydes and thioglycolic acid. 
 
PART-C: X-RAY CRYSTALLOGRAPHY STUDY OF DIHYDROPYRIDINE  
       DERIVATIVE  
 
 1,4- Dihydropyridines have been known since long as calcium channel blockers. 
This structural class is also important because of their wide spectrum of biological 
activities, these include antidiabetic, nurotropic, neuromodulatory, cognition and memory 
enhancing, neuroprotective and many other properties. 
 Molecular iodine has been used as a mild and efficient catalyst for various organic 
syntheses. The classical method for the synthesis of 1,4-dihydropyridine is a one-pot 
condensation of three component in refluxing alcohol. Development of as efficient and 
versatile method for the preparation of 1,4-dihydropyridines is an active ongoing research 
area and there is scope for further improvement toward synthesis of new derivatives of 
1,4-dihydropyridines with milder reaction conditions and improved yields. This chapter 
deals with the synthesis of N-substituted dihydropyridines by molecular iodine catalyze 
and classical method. 
 
SECTION-1: Molecular iodine catalyze and classical synthesis, characterization and 
X-ray crystallographic study of diisopropyl 1, 4-dihydro-1-(4-
methoxyphenyl)-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-
dicarboxylate. 
Studies on nitrogen containing heterocyclic… 
Synopsis…                                                                                                                          8 
N
O
OO
O
O
N
+
O
-
O
 
 
 Single crystal X-ray diffraction is the most common experimental method of 
obtaining a detailed picture of a small molecule that allows resolution of individual 
atoms. 
 Single crystal of diisopropyl 1, 4-dihydro-1-(4-methoxyphenyl)-2, 6-dimethyl-4-
(3-nitrophenyl) pyridine-3,5-dicarboxylate were grown by slow evaporation technique at 
constant temperature using methanol as a solvent. Good quality single crystals were 
harvested within 45 days. The crystals are exhibiting photo conducting nature. 
 
 The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR and 1H NMR, 13C NMR spectroscopy and further 
supported by mass spectroscopy. Purity of all the compounds has been checked on thin 
layer chromatography.  
 All the compounds have been evaluated for their antibacterial activity towards 
Gram +ve and Gram -ve bacterial strains and antifungal activity towards Aspergillus 
niger at a concentration 40 μg/ml. The biological activities of the synthesized compounds 
have been compared with standard drugs. 
 
 
 
 
 
 
 
 
PART A-
STUDIES ON PYRAZINE DERIVATIVES
Studies on nitrogen containing heterocyclic… 
Pyrazine derivatives…                                                                                                      9 
 
Pyrazine contains two nitrogen atoms in its aromatic ring.1 Pyrazine play an 
important role as intermediates for perfumes,2 pharmaceuticals, agricultural chemicals3 
and food spices. Especially, amides and sulfonamides of pyrazines have been used on 
various topics as anti-tuberculosis, dyes and pigments,4 oral anti diabetics, nutrition 
supplement, insecticides and fungicides. 
 
N
N
1
2
3
4
5
6
 
 
In general pyrazine is prepared by the catalytic reaction of diamines with dioles in 
a vapour phase, dehydrogenation of piperazine or dealkylation of methyl pyrazine. 
Pyrazine and their derivatives form an important class of compounds present in several 
natural flavors and complex organic molecules, it is also responsible for flavor in 
foodstuffs, like cheese, tea coffee, cooked meats nice aroma etc.5  
 
SYNTHETIC ASPECT 
Various methods for the preparation of pyrazine derivatives have been cited in 
literature, some of them are as under. 
1. The pyrazine derivatives have synthesized by direct conversion of α-hydroxy 
ketones and α-keto oximes in the presence of a catalytic amount of ceric 
ammonium nitrate was reported by A. Shaabani et al.6 
 
O
OH
R
R
NC
NH2NC
NH2
+
CAN, Air
H2O, rt., 45 min
N
N
NC
NC
R
R
 
 
2. B. M. Latha et al.7 have synthesized pyrazine from ethylenediamine on copper 
oxide/copper chromite catalysts. 
 
NH2
NH2 N
H
N
H
2 -2NH3
-3H2
N
N
 
 
Studies on nitrogen containing heterocyclic… 
Pyrazine derivatives…                                                                                                      10 
 
3. Microwave-assisted synthesis of pyrazine derivatives from α-halo ketone in 7% 
NH3 solution was given by T. Utsukihara et al.8 
 
OR
1
R
2
X
7 % NH3 aq
Microwave
N
N
R
1
R
2
R
2
R
1
 
 
4. Synthesis of 2-methyl pyrazine from zinc-modified ferrierite (FER) catalysts was 
documented by R. Anand et al.9 
 
NH2
NH2
CH3
OH
OH
+
N
H
N
H
CH3
Intermolecular 
cyclization
deyhdrogenation
Zno-FER
N
N CH3
 
 
5. W. T. Reichle et al.10 have given the synthesis which involve the reaction of 
diketones with appropriate diamines, which gave the diazine which readily 
oxidized to the pyrazines.  
 
O
O
+
NH2
NH2
N
N
N
N
-2H2O -H2
 
 
 
THERAPEUTIC IMPORTANCE 
Over recent years there has been an increasing interest in the chemistry of 
pyrazine derivatives because of their biological significance. 
1. Analgesic11    7. Anticancer17 
2. Antiallergic12    8. Anti HIV18 
3. Antibacterial13    9. Anti hypertensive19 
4. Anti-inflammatory14   10. Cardiovascular20 
5. Antiviral15    11. Antioxidant21 
6. Diuretic16    12. Antimycobacterial22 
 
 L. E. Seitz et al.23 have synthesized and evaluated antimycobacterial activity of 
pyrazine derivatives (1). H. Foks et al.24 have synthesized and screened antibacterial 
activity of 1H-pyrazolo[3,4-b]pyrazine derivatives.  
Studies on nitrogen containing heterocyclic… 
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N
N
O
R
1
R1 = aryl
(1)  
 
Pyrazine derivative (2) with an allylsulfur moiety have hepatoprotective effects 
against toxicants. Effect of 2-AP on hepatic tumorigenesis in association with glutathione 
S-transferase (GST) induction was examined in rats exposed to aflatoxin B1 (AFB1) was 
given by T. G. Ha et al.25 
 
N
N S
CH2
(2)      
 
H. Foks et al.26 have synthesized and checked tuberculostatic activity of 4-
substituted 3,4,5,6-tetrahydro-2H-[1,2']-bis-pyrazine derivatives (3). F. Micheli et al.27 
have synthesized pyrido [2,3-b] pyrazine-8-oxide derivatives as selective glycine 
antagonist with in vivo activity. 
 
N
N
N
S
Ph
N
N
R
1
R1 = Ph, CH2Ph, Pyridine
(3)
 
 
Synthesis and evaluation of substituted N-phenylpyrazine-2-carboxamides (4) as 
herbicides and abiotic elicitors was reported by M. Dolezal et al.28 
 
N
N O
NH
CH3
CH3
CH3
R
1
R1 = Cl, I, F, CF3(4)
 
 
K. Zurbonsen and coworkers29 have studied antiproliferative, differentiating and 
apoptotic effects elicited by imidazo[1,2-a]pyrazine derivatives (5). T. Yanai et al.30 have 
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synthesized novel pyrazine compounds produced from chitin by the activity of the 
enzyme from vibrio alginolyticus TK-24. 
 
N
N N
R
2
R
1
R
4
R
3
R1 = H, Br 
R2 = Br, NH2, NHCH3, NHCH2CH3  
R3 = CN, H
R4 = H, Br, CH2OH, CH2OCH3(5)  
 
Pyrazine derivatives (6) tested against human keratinocyte cells stressed UVB 
irradiation showed high anti oxidative properties was given by J. Cavalier et al.31 
 
R1 = R2 = R3= OH, OCH3 
N
N
NH2
R
1
R
3
R
2
(6)  
 
B. A. Ellsworth et al.32 have studied structure activity relationships for a series of 
pyrazine carboxamide (7) as CB1 antagonists. Pharmaceutical properties of the series (7) 
were improved via inclusion of hydroxyl containing side chains. This structural 
modification sufficiently improved ADME properties of an orally inactive series such that 
food intake reduction was achieved in rat feeding models. 
 
N
N
CH3
CH3
O
R
1
(7)
 
 
J. W. Corbett et al.33 have synthesized indanylpyrazines (8) and reported 
corticotrophin releasing factor type-1 receptor antagonists. 
 
N
NR
1
NH
R
2
R
3
NH
N
R1 = R3 = CH3, C2H5
R2 = Propyl(8)
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N. Sinha et al.34 have synthesized and screened antimycobacterial activity of some 
pyrazine derivatives (9). K. Yoshiizumi et al.35 have synthesized and studied structure 
activity relationships of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine based hydroxamic acids 
as HB-EGF shedding inhibitors. 
 
N
N
O
N
NH Ar
O
N
(9)
 
 
Pyrazin-2-yl-formamide thiosemicarbazones (10) related to their tuberculostatic 
activity was reported by A. Olczak et al.36 
 
N
N
NH2
HNN
S
R
1
R1 = secondary amine
(10)  
 
The novel structures 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-
dicarbonitriles (11) and their promising protein kinase inhibitors with antiproliferative 
activity was given by G. G. Dubinina et al.37 
 
N
N
N
NH2
NC
NC
R
1
X
N
N
N
N
NH2
NC
NC
R
1
S OO
X = NH, N-CH3, N-CH2Ph, S
(11)
 
Synthesis and tuberculostatic activity of pyrazinyl substituted derivatives (12) was 
reported by H. Foksi et al.38 
 
N
N
N
S
N
R
1 R
2
R1 = R2 = secondary amine
(12)  
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J. Bostrom et al.39 have studied scaffold hopping, synthesis and structure activity 
relationships of 5,6-diaryl-pyrazine-2-amide derivatives (13) of CB1 receptor antagonists. 
 
N
N
Cl
Cl
Cl
O
NH
N
(13)  
 
Synthesis and biological activity of 5-aroylpyrazine-2-carboxylic acid derivatives 
(14) was given by M. Dolezal et al.40 
 
N
N
R
1
O
R
2
R1 = CN, CONH2
R2 = H, OH, Cl(14)
 
 
M. Dolezal et al.41 have synthesized and reported antimycobacterial evaluation of 
substituted pyrazine carboxamide derivatives (15). 
 
N
N
NH
O
X
R
1
R
2
R1 = H, tert-butyl
R2 = CH3, CF3, F, Cl
X = H, Cl(15)
 
 
J. Krinkova et al.42 have synthesized and evaluated biological activity of 5-alkyl-
6-(arylsulfanyl)pyrazine-2- thioamides derivatives (16). 
 
N
NR
1
CSNH2SR
2
R1 = C3H7, C4H9
R2 = CH3, C2H5, C3H7, C4H9, C6H5(16)
 
C. G. Bonde coworkers43 have synthesized and given preliminary evaluation of 
some pyrazine derivatives (17) as antimicrobial agents. 
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N
N
O
NH
O
N S
N
OR
1(17)
 
 
T. Asaki et al.44 have studied structure activity on diphenylpyrazine derivatives 
(18) of prostacyclin receptor agonists. 
 
N
N
Ph
Ph N
R
1
O
O
OH
R1 = ethyl, allyl, cyclopropyl
(18)
 
 
Synthesis and antiinflammatory activity of methyl substituted imidazo[1,2-
a]pyrazine derivatives (19) was reported by M. G. Rimoli et al.45 
 
N
N N
R
1
R
2 R
1 = CH3, CH2COOH, COOH
R2 = H, COOH(19)
 
 
Synthesis of two new hybrid metal-organic polymers using flexible pyrazine 
crystal structures were given by C. Zhang et al.46 Synthesis and biological evaluation of 
pyrido[2,3-b]pyrazine-N-oxide as selective glycine antagonists was reported by A. 
Cugola et al.47 J. E. Dowling et al.48 have synthesized of [1,2,4]triazolo[1,5-a]pyrazines 
as adenosine A2A receptor antagonists. C. A. Hargreaves and coworkers49 have studied 
tetrahydropyrido[2,3-b]pyrazine scaffolds. H. Mukaiyama et al.50 have synthesized and 
given C-SRC inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for 
treatment of acute ischemic stroke. D. R. Owen et al.51 have studied structure activity 
relationships of pyrazine derivatives as a novel non competitive mGluR1 antagonists. 
Synthesis and antimycobacterial activity of pyrazine derivatives documented by L. E. 
Seitz et al.52 Imidazo[1,2-a]pyrazine shows the bronchodilatory and cyclic nucleotide 
phosphodiesterase inhibitory activities was given by T. O. Vitse et al.53 
 
Thus the important role displayed by pyrazine and its derivatives for various 
therapeutic and biological activities prompted us to synthesize some pyrazine derivatives 
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in order to achieve compounds having better therapeutic activities, which summarized in 
this part as under.  
 
STUDIES ON PYRAZINE DERIVATIVES 
PART-I: STUDIES ON 2-(PIPERIDINE-4-YLMETHOXY)PYRAZINE 
DERIVATIVES  
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INTRODUCTION 
Pyrazine nucleus possesses remarkable pharmaceutical importance and biological 
activities, some of their derivatives occur as natural products. In view of our ongoing 
interest in the synthesis of some new potentially bioactive pyrazine derivatives (1) have 
been described as under. 
 
N
N
O
N R
2
R
1
(1)  
 
The synthesis of compound 2-(piperidin-4-ylmethoxy)pyrazine derivatives has 
been attracted widespread attention due to their diverse pharmacological properties like 
anti-inflammatory, antibiotic, antifungal, herbicidal, antitubercular, etc. To approach this 
goal synthesis of some new 2-(piperidin-4-ylmethoxy)pyrazine derivatives have been 
undertaken.  
 
 
SYNTHETIC ASPECT 
Various methods of bromination, diazotization, mitsunobu reaction, suzuki cross 
coupling and deprotection of pyrazine derivatives have been cited in literature, some of 
the methods are as under. 
BROMINATION 
1. Bromination of 2-amino pyrazine in presence of bromine and pyridine in CHCl3 
was given by S. Sevilla et al.1 
 
 
N
N NH2
N
N NH2
BrBr
CHCl3
Br2, pyridine
 
 
2. F. D. Weal et al.2 have synthesized 2-amino-5-bromopyrazine from 2-amino 
pyrazine, N-bromosuccinamide in acetonitrile solution. 
 
 
N
N NH2
NBS, CH3CN
overnight, rt
N
N NH2
Br
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3. 2-Amino pyrazine react with N-bromosuccinamide in DMSO solution to give 2-
amino-3,5 dibromo pyrazine was reported by B. Jiang et al.3 
 
N
N NH2
NBS, DMSO N
N NH2
BrBr
 
 
4. A. M. Stadler et al.4 have synthesized 2-amino-5-bromopyrazine from 2-amino 
pyrazine, N-bromosuccinamide in CH2Cl2 solution.  
 
N
N NH2
NBS
N
N NH2
Br
CH2Cl2
 
 
5. T. Itoh et al.5 have been synthesized 2-amino-5-bromopyrazine from 2-amino 
pyrazine with brominating agent.  
 
N
N NH2
N
N NH2
Br
brominating agent +
N
N NH2
BrBr
 
 
DIAZOTIAZITION  
1. Preparation of 5-bromopyrazin-2-ol from 2-amino-5-bromopyrazine, NaNO2 and 
H2SO4 was reported by F. Jing et al.6 
 
N
N NH2
Br H2SO4, NaNO2
N
N OH
Br
 
 
2. H. Mukaiyama et al.7 have prepared 5-bromopyrazin-2-ol from 2-amino-5-
bromopyrazine, NaNO2 and CH3COOH in dioxane solution.  
 
N
N NH2
Br
CH3COOH, NaNO2
N
N OH
Br
dioxane
 
 
3. S. Nobuhiro et al.8 have studies diazotization of 2-amino-5-bromopyrazine in 
sulphuric acid and sodium nitrate. 
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N
N NH2
Br H2SO4, NaNO2
N
N OH
Br
20 min 5 oC, 40 min 40 oC
 
 
4. H2SO4 and sodium nitrate react with 2-aminopyrazine to give 2-hydroxypyrazine 
which was given by Y. Jun et al.9 
 
H2SO4, NaNO2
H2O
N
N NH2
Br
Cl
N
N OH
Br
Cl
 
 
5. A. E. Erickson et al.10 have synthesized 5-bromopyrazin-2-ol from 2-amino-5-
bromopyrazine, NaNO2 and H2SO4.  
 
H2SO4, NaNO2
N
N NH2
Br N
N OH
Br
 
 
MITSUNOBU REACTION 
1. Use of sonication for the coupling of sterically hindered substrates in the phenolic 
mitsunobu reaction was reported by S. D. Lepore et al.11 
 
OH
OCH3
O
+ OH
sonication
DIAD, PPh3
THF, 25 oC, 15 min
O
OCH3
O
 
 
2. Organocatalytic mitsunobu reaction of phenol and acid in THF was documented 
by T. Y. S. But et al.12 
 
DEAD, PPh3
O
OH
O2N
+
OH
Ph
THF
O
O
O2N
Ph
 
 
3. Di-p-chlorobenzyl azodicarboxylate (DCAD) was introduced as a novel, stable 
and solid variety of mitsunobu coupling in CH2Cl2 was given by B. H. Lipshutz et 
al.13 
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OH
+
O
OH OCH3
H3CO
DCAD, PPh3
CH2Cl2, rt
O
O OCH3
H3CO  
 
4. Carbon nucleophiles in the mitsunobu reaction, mono- and dialkylation of 
bis(2,2,2-trifluoroethyl) malonates was given by J. M. Takacs et al.14 
 
R
1
OH +
H
COOCH2CF3
COOCH2CF3
H Mitsunobu conditions
R
1
COOCH2CF3
COOCH2CF3
H  
 
5. Second-generation tags for fluorous chemistry exemplified with a new fluorous 
mitsunobu reagent and fluorous triphenylphosphine in THF was reported by Q. 
Chu et al.15 
 
OH
CN
+
OH
F
N N
O(CH2)3O-t-C4F99
O O
t-C4F9O(CH2)3OO
F-TPP, THF
NC O
F
 
6.     Multipolymer solution-phase organocatalytic mitsunobu reaction of phenol  
          and   acid in THF was reported by A. M. Harned et al.16 
 
OTPP, HO-DEAD
O
OH
O2N
+
OH
Ph
THF
O
O
O2N
Ph
 
 
SUZUKI CROSS COUPLING 
1. The well known Suzuki reaction17 is the organic reaction of an aryl or vinyl-
boronic acid with an aryl or vinyl-halide catalyzed by a palladium (0) complex 
forming carbon-carbon bond. Some reported reactions are described as under. 
2. In 1981, A.Suzuki and N.Miyaura et al.18 have made a breakthrough in the 
methodology for biaryl compounds using aryl boronicacids and aryl bromide 
under homogeneous palladium catalyzed conditions in the presence of base. 
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3.  Z.Du et al.19 have reported an ultrafast and highly efficient ligand-free Suzuki-
Miyaura cross-coupling reaction between aryl bromides/iodides and aryl 
boronicacids using palladium chloride as catalyst in PEG-400/H2O in air at room 
temperature. TEM showed that palladium nanoparticles were generated in situ 
from PdCl2/PEG-400/H2O without use of other reductants. The catalyst system 
can be recycled to reuse three times with good yields. 
Ar-X Ar'-B(OH)2 Ar-Ar'
PdCl2
PEG-400/H2O, K2CO3
rt  
4.  Yu-L.Zhao et al.20 have prepared a highly practical and reliable Nickel catalyst for 
Suzuki–Miyaura coupling of aryl halides with various aryl boronicacid. 
 
5.  S.Lou et al.21 have developed Palladium/Tris(tert-butyl)phosphine-Catalyzed 
Suzuki Cross-Couplings of aryl and heteroaryl halides with aryl and heteroaryl 
boronic acids in the Presence of Water. 
 
6.  R.Zhang et al.22 have synthesized a series of novel 5-arylidenefuran-2(5H)-ones 
and 5-arylidene-4-arylfuran-2(5H)-ones via the Suzuki-Miyaura reactions. 
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7.  Y.Zhang et al.23 have been developed one-pot process for the synthesis of 8-
arylquinolines via Pd-catalyzed borylation of quinoline-8-yl halides and 
subsequent Suzuki-Miyaura coupling with aryl halides using n-BuPAd2 as ligand. 
 
8.  J.Spencer et al.24 have reported synthesis of a (piperazin-1-ylmethyl)biaryl library 
via microwave-mediated Suzuki–Miyaura cross-couplings. 
 
9.  Q.Tang et al.25 have developed Suzuki–Miyaura coupling reactions of 5-chloro-1-
phenyl-tetrazole with various functionalized aryl boronicacids in the presence of 
catalytic amounts of SPhos/Pd(OAc)2 or RuPhos/Pd(OAc)2. 
 
10.  J.-M. Begouin et al.26 have reported cobalt-catalyzed cross-coupling between aryl 
zinc halides and 2-chloropyrimidine/2-chloropyrazine prepared in situ. 
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11.  T. Itoh et al.27 have discovered a direct synthesis of hetero-biaryl compounds 
containing an unprotected NH2 group via Suzuki–Miyaura reaction by using 
Pd(OAc)2 and D-t-BPF ligand as a catalyst. 
 
12.  L.C.W. Chang et al.28 synthesized 2,6-disubstituted and 2,6,8-trisubstituted 
purines as adenosine receptor antagonists via Suzuki–Miyaura reaction. 
 
   
13. C. A.Fleckenstein et al.29 have reported an efficient Suzuki-Miyaura coupling of 
(hetero)aryl chlorides with Thiophene- and Furan boronicacids in aqueous n-
butanol.  
Y Cl
R
S
(HO)2B
O
(HO)2B
R'
or
Na2PdCl4 (1mol%)/L
(1:2)
2.0 eq. K2CO3
n-butanol/water
100 oC
Y
R
or
Y
R
S O
R'
 
14.  D. X. Yang et al.30 have reported palladium-catalyzed Suzuki-Miyaura coupling of 
Pyridyl-2-boronic esters with aryl halides using highly active and air-stable 
phosphine chloride and oxide Ligands. 
N B
O
O
FG ArX
or
HetArX N
FG
Ar
or
N HetAr
FG
Dichloropalladiuym oxide/chloride
Base, solvent
 
 
15. Microwave-assisted efficient copper-promoted N arylation of amines with 
arylboronic acids was given by S. Chen et al.31 
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NHO + PhB(OH)2
Cu(OAc)2, DBU
DMSO, MW
ONPh
 
 
16. Stepwise cross-coupling reactions in pyrazine derivatives was reported by C. 
Yang et al.32 
 
N
N
Br
NH2
OCH3
+
Pd(PPh3)4
2 M Na2CO3
N
N NH2
OCH3Ph
PhB(OH)2
 
 
17. A novel and versatile entry to asymmetrically substituted pyrazines was reported 
by V. P. Mehta et al.33 
 
N
N
X
S
R
2
R
1
+
Pd(PPh3)4, K2CO3PhB(OH)2
N
N
Ph
S
R
2
R
11,4-dioxan : H2O (1:1)
MW
 
 
18. Microwave-assisted synthesis C-C bond formation of pyrazine derivatives was 
documented by S. Sevilla et al.1 
 
N
N
Br
NH2
NH
R
1
+
Pd(dppf)2Cl.DCM
N
N
Ar
NH2
NH
R
1
toluene : EtOH (2:1), 90 oC
ArB(OH)2
 
 
19. Palladium imidazolium carbene catalyzed aryl, vinyl and alkyl suzuki-miyaura 
cross coupling synthesis was given by M. B. Andrus et al.34 
 
Ar N2
+
BF4
-
+ R
1
-B(OH)2
Pd(OAc)2, THF
N N
+
i-Pr
i-Pr
i-Pr
i-PrCl
- Ar R
1
 
 
20. New coupling partners in room temperature suzuki reaction of alkyl bromides 
under remarkable mild conditions was reported by J. H. Kirchhoff et al.35 
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R
1
Br
+ R2-B(OH)2
5 mol-% Pd(OAc)2, P(tBu)2Me
KOtBu, t-amyl alcohol
R
1
R
2
 
 
21. S. Li et al.36 have synthesized Pd(OAc)2-catalyzed room temperature suzuki cross-
coupling reaction in aqueous media under aerobic conditions.  
 
+ Ar'-B(OH)2
Pd(OAc)2, K2CO3
EtOH : H2O (2:3), 80 
oC
Ar-X Ar Ar'
 
 
22. C. Baillie et al.37 have documented and given its applications in the suzuki-
miyaura coupling of aryl chlorides in presence of ferrocenyl monophosphine 
ligand in dioxane. 
 
+ Ar'-B(OH)2
Pd(OAc)2
K3PO4, dioxane, 95 
oC
Ar-Cl Ar Ar'
Ferrocenyl monophosphine ligand
 
 
23. Suzuki-miyaura cross-coupling reaction under ligand free conditions was given by 
W. J. Liu et al.38 
 
+ Ar'-B(OH)2
Pd(OAc)2, TBAB, K2CO3
PEG-400, 110 oC
Ar-X Ar Ar'
 
 
24. Phosphine free palladium acetate catalyzed suzuki reaction in water was given by 
L. Liu et al.39 
 
+ Ar'-B(OH)2
Pd(OAc)2, Na2CO3
H2O/PEG-2000 (6:7), 50 
oC
Ar-X Ar Ar'
 
 
25. A highly active catalyst for suzuki-miyaura cross coupling reactions of heteroaryl 
compounds was reported by K. L. Billingsley et al.40  
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+ HetAr'-B(OH)2
Pd(OAc)2, K3PO4, n-butanol, 100 
oC
Ar-X Ar Ar'
R
1
R
3
R
2 PCy2  
 
26. Y. M. A. Yamada et al.41 have prepared highly active catalyst for the 
heterogeneous suzuki-miyaura reaction by assembled complex of palladium and 
non-cross-linked amphiphilic polymer. 
 
+ R2-B(OH)2
(ArPh2P)2PdCl2R1-X
Na2CO3, H2O, 100 
oC
R
1
R
2
 
 
 DEPROTECTION 
 1. B. Li et al.42 have used aqueous phosphoric acid is an effective, environmentally 
benign, selective and mild reagent for the deprotection of tert-butyl carbamates. 
 
R
1
N O
O
R
2
H3PO4
toluene, rt
R
1
NH
R
2
Aq.
 
 
 2. A stereo conservative deprotection method of amino groups was reported by D. 
M. Shendage et al.43 
 
NH
CH3
NH
O
CH3
O
O
HCl-MeOH
rt, 1 h
NH2
CH3
NH
O
CH3
 
 
 3.  Selective removal of the tert-butoxycarbonyl group from secondary amines using 
zinc bromide as the deprotecting reagent was given by S. C. Nigama et al.44 
 
N
O
O ZnBr2, CH2Cl2 NH
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 4. N. B. Narasimhulu et al.45 have studied deprotection of piperidine derivatives 
from tert-butyl piperidine and TFA in chloroform solution. 
 
CF3COOHN
O
O
CH2 NHCH2CH2Cl2, rt 
 
 
 5. Reaction of tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate in HCl in 
dioxane solution to gave 4-(prop-2-yn-1-yl)piperidine was carried out by N. D. 
Waal et al.46 
 
HCl in dioxaneN
O
O
CH
NH
CH
 
 
 6. F. Bois et al.47 have studied deprotection of (2S)-2-methylpiperidine from tert-
butyl (2R)-2-methylpiperidine-1-carboxylate, CF3COOH and anisole in 
dichloromethane solution. 
 
CF3COOH
N
O
O
CH3
NH
CH3
PhOMe, CH2Cl2
 
REACTION MECHANISM OF MITSUNOBU  
 
Ph3P
..
N N
EtO2C
CO2Et
+ .. .. N N
-
EtO2C
CO2EtPh3P
+
..
N N
EtO2C
CO2EtPh3P
+
H
+
R
O
+
H
P
NPh3
EtO2C
N
H
CO2Et
-
O
O
H
R
O H
..
R
O
+
Ph3P
+H
+
+N N
-
EtO2C
CO2EtH
N N
EtO2C
CO2EtH
H
+
R
O
+
Ph3P
-O=PPh3
+O
-
O
R
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REACTION MECHANISM OF DEPROTECTION  
 
O N
O
R
H
H
+
O N
+
O
R
H H
N H
H
R
+ CO2 +
+
 
 
REACTION MECHANISM OF SUZUKI COUPLING 
 
Pd(II) R1R2
Pd(0)
R2-X
Pd(II) XR2
Pd(II) O
t
BuR2
NaO
t
Bu
NaX
R1 B
Y 
Y 
B
-
O
t
Bu
Y 
Y 
R1
B
-
O
t
Bu
Y 
Y 
Bu
t
O
Na
+
R1 R2
NaO
t
Bu
 
 
THERAPEUTIC IMPORTANCE 
 2-(Piperidine-4-yl methoxy)pyrazine derivatives have been tested for various 
pharmacological activities, which have been summarized as under. 
1. Analgesic48 
2. Antibacterial49 
3. Antifungal50 
4. Anti-inflammatory51 
5. Antiviral52 
6. Anticancer53 
7. Anti HIV54 
 
A. V. Shindikar et al.55 have designed, synthesized, and tested in vivo activity in 
mice against mycobacterium tuberculosis H37Rv of pyrazine derivatives (2). K. J. French 
et al.56 have studied cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine based inhibitors of 
human N-myristoyltransferase-1. 
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N
N
NH
O
N
N
F
F
NH2
N
O O
OH
(2)  
 
D. Sriram et al.57 have synthesized pyrazinamide derivatives (3) and reported 
antitubercular properties. D. C. Scopes et al.58 have synthesized new k-receptor agonists 
based upon a 2-[(alkylamino)methy]piperidine nucleus. 
 
N
N
NH
O
N
N
R
1
(3)  
 
 
 Synthesis, anticancer, anti-inflammatory and analgesic activity evaluated of 
some  pyrazine derivatives have been (4) reported by S. M. Sondhi et al.59 B. S. Huegi 
et al.60 have synthesized and reported pharmacological studies on 4,4-disubstituted 
piperidine derivatives  as a potent analgesic properties. 
N
N
X
N N
S
(4)  
 
B. C. Gordon et al.61 have synthesized pharmaceutical composition containing 
piperidine derivatives (5) and doccumented their use as modulators of chemokine CCR5 
receptors. Synthesis and analgesic activity of some spiro[dibenz[b,f]oxepin]-10,4’-
piperidine] derivatives was reported by H. H. Ong et al.62 
 
NH
R
2
R
1
N
R
3
R
4
Het
(5)
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Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine 
derivatives (6) was given by R. Weis et al.63 A. Z.  Kabdraisova et al.64 have reported 
synthesis and biological activity of N-(2-thoxyethyl)piperidine derivatives of anabasin. 
Some piperidine substituted with   benzimidazoles was reported by V. Sundari et al.65 as 
bioactive substance.A. Seza et al.66 have studied antimicrobial activity of some piperidine 
substituted halogenobenzene derivatives. 
 
N
CH3
O H
(6)
 
 
S. J. Philippe et al.67 have prepared piperidine derivatives (7) and tested antibiotics 
activity. Effect of substituents on N-(1-piperidinobenzyl)acetamide and their 
antimicrobial activity was reported by N. Raman et al.68 M. Yoshifumi et al.69 have 
studied antimicrobial and anti-plaque activity of N’-alkyl-N-(2-aminoethyl)piperidine 
against dental plaque bacteria. 
 
N
M
R
4
R
3
YX
R
2
R
1
(7)   
 
Synthesis and structure activity relationships of 2-phenyl-1-[(pyridinyland 
piperidinylmethyl)amino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols (8) as antifungal agents 
was given by F. Giraud et al.70 K. K. Goel et al.71 have synthesized and screened for 
antimicrobial activity of piperidin-4-one derivatives. K. Canan et al.72 have synthesized 
and tested antimicrobial activity of some novel 2-[4-(substituted piperidin-1-
ylcarbonyl)phenyl]-1H-benzimidazole derivatives.   
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OH
N
N
N
N
R
2
N
R
1
X
X
X = Cl, F
R2 = H, CH3
R1 = H, BOC
(8)
 
 
M. Ishikawa et al.73 have synthesized and given structure activity relationships of 
N-aryl-piperidine derivatives (9) as potent (partial) agonists for human histamine H3 
receptor. M. Tibor et al.74 have studied histamine H3 receptor antagonists of 1-(4- 
Phenoxymethyl) benzyl)piperidines derivatives. 
 
N
H
N
N
R
1
R1 = H, CF3, C(CH3)3, F, NO2, 
CH(CH3)2, OCH3, NHCH3, N(CH3)2
(9)
 
 
G. D. Maynard et al.75 have synthesized and reported SAR of 4-(1H-
benzimidazole-2-carbonyl)piperidines (10) with dual histamine H1/tachykinin NK1 
receptor antagonist activity. A. G. Magid et al.76 have synthesized substituted piperidine 
derivatives as novel H1-antagonists. V. Claudio et al.77 studied antinociceptive profile of 
2,3,6-trisubstituted piperidine alkaloids. 
 
N
O
N
N
R
3
N
O
R
1
R
2
R1 = 3,4,5-(OCH3)3
R2 = 3,4-(OCH3)2, OCH3, CF3, F, Cl
R3 = aryl(10)
 
 
C. E. Gutteridge et al.78 have studied N-(3-phenylsulfonyl-3-piperidinoyl)-
phenylalanine derivatives (11) as potent, selective VLA-4 antagonists. Study of piperidine 
carboxylic acid derivatives of 10H-pyrazino[2,3-b][1,4]benzothiazine as orally active 
adhesion molecule inhibitors investigated by K. Toshihiko et al.79 
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NH
O O
OH
H3CO OCH3
S
O
R
1 O
R1 = aryl
(11)
 
 
C. G. Barber et al.80 have investigated 1-amino-1-phenyl-3-piperidinylbutanes 
(12) CCR5 antagonists for the treatment of HIV. Analgesic and antiinflammatory activity 
screening of 6-acyl-3-piperidinomethyl-2(3H)-benzoxazolone derivatives was reported by 
E. D. Demir et al.81 
 
 
 
 
 
 
 
 
S. Imamura et al.82 synthesized and reported biological evaluation of piperidine-4-
carboxamide derivatives (13) as CCR5 antagonists as anti-HIV-1 agents. Synthesis and 
biological activity of piperidinoaryl carbamides and their derivatives was reported by V. 
M. Gujrati et al.83 W. Tao et al.84 have synthesized diketopiperidine derivatives as HIV 
attachment inhibitors and reported, pharmaceutical compositions and use in the treatment 
of HIV infection and AIDS. 
 
N
R
1
N
O
N
R
3
R
2
R1 = COCH3, SO2CH3
R2 = H, Cl, CH3, OCH3
R3 = H, F(13)
 
 
R. H. K. Foster and coworkers85 have studied piperidine derivatives with 
morpholine like analgesia activity. Study of (2S)-1-(arylacetyl)-2-
(aminomethyl)piperidine derivatives and highly selective kappa opioid analgesics was 
F
F
NH
O
N
N N
N
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given by V. Vecchietti et al.86 M. Eiichi and coworkers87 have synthesized and reported 
antiallergic activity of novel pyrazine derivative. Synthesis and anti mycobacterial 
evaluation of some pyrazine-2-carboxylic acid hydrazide derivatives was documented by 
A. A. Mohamed et al.88 G. Katarzyna et al.89 have synthesized and screened antibacterial 
activity of novel pyrazine derivative obtained from amindoximes. Synthesis and 
antibacterial activity of 6-methoxypyrazine-2-carboxylic acid hydrazide derivatives was 
reported by G. Katarzyna et al.90 Synthesis and antimicrobial activity of 2,3-(substituted 
phenyl)pyrazine dicarboxamide was given by N. S. Rao et al.91 Pyrazine-2-substituted 
carboxamide derivatives synthesis, antimicrobial and leuconostoc mesenteroides growth 
inhibition activity study investigated by A. H. F. Wahab et al.92 N. B. Patel et al.93 have 
synthesized and reported antimicrobial activity of 2-[3-(arylureido)carbonyl]pyrazine 
derivatives. A study of 2-piperidino-1-ethanol and its derivatives as antimicrobial 
additives to oils was reported by S. A. Gamzaeva et al.94  
Looking to the interesting properties of 2-(piperidine-4-ylmethoxy)pyrazine, we 
have synthesized some new 2-(piperidine-4-ylmethoxy)pyrazine, which have been 
describe as under. 
 
 
PART-I: STUDIES ON 2-(PIPERIDINE-4-YLMETHOXY) PYRAZINE 
DERIVATIVES  
 
SECTION-I:  SYNTHESIS AND BIOLOGICAL EVALUATION OF  
(4-(((5-(4-BROMOPHENYL)PYRAZIN-2-YL)OXY)METHYL) 
PIPERIDIN-1-YL)(ARYL)METHANONES 
 
SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF (4-(((5-(4-
METHOXY-3-METHYLPHENYL)PYRAZIN-2-YL)OXY) 
METHYL)PIPERIDIN-1-YL)(ARYL)METHANONES 
 
SECTION-III: SYNTHESIS AND BIOLOGICAL EVALUATION OF (4-(((5-(2-
FLUOROPYRIDIN-3-YL)PYRAZIN-2-YL)OXY)METHYL) 
PIPERIDIN-1-YL)(ARYL)METHANONES 
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SECTION-IV: SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL(4-
(((5-(m-TOLYL)PYRAZIN-2-YL)OXY)METHYL)PIPERIDIN-1-
YL)METHANONES 
 
SECTION-V: SYNTHESIS AND BIOLOGICAL EVALUATION OF (4-(((5-(2-
METHOXYPHENYL)PYRAZIN-2-YL)OXY)METHYL)  
PIPERI DIN-1-YL)(ARYL)METHANONES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part – A 
[Part – I (Section-i)] 
 
Synthesis and biological evaluation of (4-
(((5-(4-(bromophenyl)pyrazin-2-yl)oxy) 
methyl) piperidin-1-yl)(aryl)methanones 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF (4-(((5-(4-BROMOPHEN-
YL)PYRAZIN-2-YL)OXY)METHYL)PIPERIDIN-1-YL)(ARYL) METHANONES 
Pyrazine nucleus possesses remarkable pharmaceutical importance and biological 
activities, some of their derivatives occur as natural products. In view of these findings, it 
appeared of interest to synthesize 2-(piperidin-4-ylmethoxy)pyrazines derivatives by the 
condensation of 2-(4-bromophenyl)-5-(piperidin-4-ylmethoxy)pyrazine with various 
aromatic acids in the presence of TEA, as shown in reaction scheme. 
 
REACTION SCHEME 
 
NBS, DCM
N
N NH2
Br
NaNO2
N
N OH
BrN
N NH2
CH3SO2Cl
Et3N, DCM
N
N O
Br
S
O
O
NO
O
OH
K2CO3
DMF
Pd(PPh3)4, K2CO3 
   
HBTU, Et3N, DMF
H2SO4
N
N
O
N
O
OBr
N
N
O
NH
Br
N
N
O
N
R
O
Br
B
OH
OH
Br
N
N
O
N
O
Br O
deprotection
DIPEA R-COOH,
HCl(g) in dioxane
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 solution on a Bruker 
AC 400 MHz spectrometer. Elemental analysis of the all the synthesized compounds 
were carried out on Euro EA 3000 elemental analyzer and the results are in agreements 
with the structures assigned.  
 
[A] Preparation of 5-Bromopyrazin-2-amine. 
To a stirred cooled to 0oC solution of 2-aminopyrazine (10.0 g, 0.105 mol) in dry 
DCM (250 ml), N-bromosuccinamide (18.72 g, 0.105 mol) was added portion wise. The 
mixture was stirred at 0oC for 24 hours. The reaction was monitored on TLC. After 
completion of the reaction, saturated aqueous solution of sodium carbonate was added 
(200 ml) to quench the reaction. The organic layer was washed with brine and dried over 
anhydrous Na2SO4. The solvent was removed in vacuo and the resulting crude product 
was purified by column chromatography on silica gel (eluent: 2 : 8 = E.A. : Hexane) to 
obtain pure product. Yield: 70 %, mp 133-135oC. 
 
[B] Preparation of 5-Bromopyrazin-2-ol. 
Sodium nitrite (8.9 g, 0.129 mol) was added portion wise with stirring to 
concentrated H2SO4 (49 ml) at 0oC and the mixture was warmed to dissolved the solid. 
The mixture was cooled to 5oC. To this a solution of 5-bromopyrazin-2-amine (15.0 g, 
0.086 mol) in concentrated H2SO4 (71 ml) was added slowly. The reaction mixture was 
stirred bellow 5oC for 30 minute and warmed to 40oC for 2 hours. The reaction mixture 
was poured onto crushed ice. The aqueous solution was extracted with ethyl acetate (250 
ml x 3) and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the 
solid product was obtained. Yield: 50 %, mp 80-82oC. 
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[C] Preparation of 5-Bromopyrazin-2-yl methanesulfonate. 
To a stirred cooled (ice bath) solution of 5-bromopyrazin-2-ol (5.0 g, 0.028 mol) 
in dry DCM (25 ml), TEA (5.85 ml, 0.042 mol) and CH3SO2Cl (2.80 ml, 0.034 mol) was 
added drop wise in solution at 0oC. The reaction mixture was stirred for 2 hours at room 
temperature (monitored by TLC), and the solvent was removed in vacuo. The product 
was filtered, washed with water and dried to give analytical pure product. Yield: 80 %, 
mp 85-87oC. 
 
[D] Preparation of  tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate. 
To a stirred suspension of K2CO3 (3.036 g, 0.022 mol) and 5-bromopyrazin-2-yl 
methanesulfonate (3.0 g, 0.011 mol) in dry DMF (30 ml), tert-butyl 4-(hydroxymethyl) 
piperidine-1-carboxylate (2.54 g, 0.011 mol) was added. The solution was heated on a 
water bath for 2 hours at 75-80oC. (monitored by TLC). The reaction mixture was poured 
onto crushed ice, thus the precipitate obtained, was filtered and washed with water to give 
pure product. Yield: 68 %, mp 99-101oC.  
 
[E] Preparation of tert-butyl 4-(((5-(4-bromophenyl)pyrazin-2-yl) oxy) methyl) 
piperidine-1-carboxylate. 
A solution of tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was further stirred for 5.0 minutes. To this 
solution (4-bromophenyl)boronic acid(0.880 g, 0.0044 mol), isopropyl alcohol (20 ml) 
was added at room temperature. To this content a solution of K2CO3 (10.0 ml, 0.02 mol) 
in water was added drop wise under nitrogen atmosphere and stirred for 5.0 minutes. 
Tetrakis(triphenylphosphine)palladium(0) (0.231 g, 0.0002 mol) was added in to the 
above reaction mixture and the reaction mixture was heated to reflux for 6 hours 
(monitored by TLC). The reaction mixture was added in to the water under stirring. The 
aqueous layer was extracted with ethyl acetate (100 ml × 3), and the combined organic 
layers were washed with water followed by brine and dried over anhydrous Na2SO4. The 
solvent was evaporated under vacuum to give crude product. The crude product was used 
in the next step without further purification. 
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[F] Preparation of 2-(4-bromophenyl)-5-(piperidin-4-ylmethoxy)pyrazine. 
A mixture of HCl(g) in dioxane (10 ml) and tert-butyl 4-(((5-(4-bromo 
phenyl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate was stirred at room 
temperature   for overnight (monitored by TLC), and the solvent was removed in vacuo. 
Water and ethyl acetate was added in to the crude product and stirred well. The organic 
layer was separated and the major impurities were removed in the organic layer. The 
aqueous layer was basified using sodium hydroxide solution and the product was 
extracted with DCM (100 ml × 3). The combined organic layers were washed with water 
followed by brine and dried over anhydrous Na2SO4. The solvent was evaporated under 
vacuum to give pure product. Yield: 63 %, mp 152-154oC.    
 
[G] General procedure for the preparation of (4-(((5-(4-(bromophenyl)pyrazin-2-
yl)oxy)methyl]piperidin-1-yl)(aryl)methanones. 
To a cooled mixture of 2-(4-bromophenyl)-5-(piperidin-4-ylmethoxy) pyrazine 
(0.2 g, 0.570 mmol) and aryl acid (0.570 mmol) in dry DMF (3 ml), HBTU[2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate](0.261 g, 0.690 
mmol), DIPEA[di isopropyl ethyl amine] (0.089 g ≅ 0.117 ml,0.690 mmol) and TEA (0.1 
ml, 0.850 mmol)  was added to basify the content at 0oC. The reaction mixture was stirred 
for 10 hours at room temperature (monitored by TLC). The reaction mixture was poured 
on to crushed ice, thus the precipitate separated was filtered and washed with water to 
give pure product. The physical constants of the products are recorded in Table-1a. 
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Table-1a: Physical constants of (4-(((5-(4-(bromophenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(aryl)methanones. 
 
 
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf  value 
1a CH3
 
C24H24BrN3O2 
 
466.37 
 
79 0.52 
1b 
CH3
 
 
C24H24BrN3O2 
466.37 67 0.51 
1c N
 
C22H21BrN4O2 
 
453.33 
 
76 0.43 
1d 
N
 
C22H21BrN4O2 
 
453.33 
 
66 0.40 
1e 
OCH3
C24H24BrN3O3 
 
482.36 
 
75 0.46 
1f 
 
C23H22BrN3O2 
 
452.34 
 
84 0.47 
1g 
NH
O
CH3 C25H25BrN4O3 
 
509.39 
 
69 0.32 
1h 
Br 
 
C24H23Br2N3O2 
 
 
545.26 
 
71 0.39 
1i 
NH2
Br 
 
C23H22Br2N4O2 
 
546.25 
 
68 0.35 
 
1j 
 
Cl
 
 
C23H21BrClN3O2 
 
 
486.78 
 
 
82 0.42 
             TLC solvent system:- E.A. : Hexane = 6 : 4 
N
N
O
N
O
RBr
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ANALYTICAL DATA 
(4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(p-tolyl)methanone 
(1a). mp 146-148oC; IR (DRS): 3072, 3031, 2975, 1645, 1563, 1523, 1440, 1352, 1299, 
1170, 1054, 883, 835, 749, 695 cm-1; MS: m/z = 466 [M]+; Anal. Calcd for 
C24H24BrN3O2: C, 61.81; H, 5.19; N, 9.01. Found: C, 61.70; H, 5.07; N, 8.90%. 
(4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(o-tolyl)methanone 
(1b). mp 176-178oC;IR (DRS): 3083, 3015, 2982, 2852, 1652, 1586, 1520, 1480, 1365, 
1254, 1169, 1063, 878, 826, 743, 699 cm-1; MS: m/z = 467 [M+1]+; Anal. Calcd for 
C24H24BrN3O2: C, 61.81; H, 5.19; N, 9.01. Found: C, 61.40; H, 5.09; N, 8.91%. 
(4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(pyridine-4-yl) 
methanone (1c). mp 234-236oC; IR (DRS): 3095, 3012, 2930, 2883, 1654, 1593, 1534, 
1454, 1356, 1266, 1164,1052, 890, 822, 723, 705 cm-1; MS: m/z = 454 [M+1]+; Anal. 
Calcd for C22H21BrN4O2: C, 58.29; H, 4.67; N, 12.36. Found: C, 58.01; H, 4.50; N, 
12.25%. 
(4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(pyridin-2-yl) 
methanone (1d). mp 167-169 oC; IR (DRS): 3066(Ar, C-H str.), 3001(Ar, C-H str.), 
2935(C-H str.), 1626(amide, C=O str.), 1531(Ar, C=C str.), 1446(Ar, C=C str.), 1346(C-
H ben), 1294(C-Br str.), 1172(C-N str.), 1049(C-N str.), 1008(C-O-C str.), 829(C-H o,p, 
ben), 750(C-H o,p, ben) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm, 1.45-1.56(m, 2H, 
CH), 1.81-1.85(d, J=12.72 Hz, 1H, CH), 1.97-2.01(d, J=12.4 Hz, 1H, CH),2.17(m, 1H, 
CH), 2.84-2.90(t, 1H, CH), 3.10-3.96 (t, 1H, CH), 3.98-4.01(d, J=12.16 Hz, 1H, CH), 
4.25-4.26(d, J=6.48 Hz, 2H, 2CH), 4.80-4.83 (d, J=12.24 Hz, 1H, CH), 7.35(m, 1H, 
ArH), 7.57-7.63(m, 3H, ArH), 7.77-7.83(m, 3H, ArH), 8.26-8.27(d, J=1.24 Hz, 1H, ArH), 
8.46-8.46(d, J= 1.24 Hz, 1H , ArH), 8.60(m, 1H, ArH). ). 13C NMR (100 MHz, CDCl3): δ 
ppm, 28.53, 35.93, 42.75, 46.42, 70.40, 114.61, 118.27, 123.07, 127.66, 132.08, 134.93, 
135.47, 137.22, 142.38, 144.26, 152.55, 159.10;MS: m/z = 452 [M-1]+; Anal. Calcd for 
C22H21BrN4O2: C, 58.29; H, 4.67; N, 12.36. Found: C, 58.05; H, 4.55; N, 12.23%. 
(4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(3-methoxyphenyl) 
methanone (1e). mp 201-203oC; IR (DRS): 3070, 2999, 2918, 2852, 1726, 1627, 1581, 
1531, 1444, 1274, 1173, 1246, 1168, 1045, 987, 889, 831, 800, 752, 707 cm-1; 1H NMR 
(400 MHz, CDCl3): δ ppm, 1.39-1.42(m, 2H, CH), 1.80-2.01(m, 2H, CH), 2.11-2.14(m,  
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1H, CH), 2.83(m, 1H, CH), 3.03(m, 1H, CH), 3.82-3.85(d, J=11.84 Hz, 4H, OCH3, CH), 
4.17-4.19(d, J=6.36 Hz, 2H, 2CH), 4.75-4.78(d, J= 11.64 Hz, 1H, CH), 6.94-6.99(m, 1H, 
ArH), 7.29-7.36(m, 1H,ArH), 7.58-7.60(d, J=8.48 Hz, 3H, ArH), 7.77-7.80(d, J=8.52 Hz, 
3H, ArH), 8.16-8.16(d, J=1.08 Hz ,1H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm, 
29.71, 35.87, 35.98, 42.35, 46.32, 55.38, 70.36, 112.30, 115.40, 118.91, 123.10, 126.21, 
127.67, 128.88, 129.61, 132.09, 134.90, 135.38, 137.23, 142.80, 144.42, 156.59, 159.65, 
170.32; MS: m/z = 483 [M+1]+; Anal. Calcd for C24H24BrN3O3: C, 59.76; H, 5.01; N, 
8.71. Found: C, 59.55; H, 4.89; N, 8.60%. 
(4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(phenyl) methanone 
(1f). mp 154-156oC; IR (DRS): 3087, 2958, 2832, 1684, 1585, 1456, 1269, 1175, 1036, 
838, 796, 742, 693 cm-1; MS: m/z = 452 [M]+; Anal. Calcd for C23H22BrN3O2: C, 61.07; 
H, 4.90; N, 9.29. Found: C, 61.01; H, 4.70; N, 9.04%. 
N-(4-(4-(((5-(4-bromophenyl)pyrazin-2-yl)oxy)methyl)piperidine-1-carbonyl)phenyl) 
acetamide (1g). mp 235-237oC; IR (DRS): 3445, 3015, 2918, 2823, 1648 1610, 1545, 
1445, 1355, 1290, 1115, 1020, 825, 796, 743, 698 cm-1; MS: m/z = 509 [M]+; Anal. Calcd 
for C25H25BrN4O3: C, 58.95; H, 4.95; N, 11.00. Found: C, 58.19; H, 4.88; N, 10.91%. 
(4-(Bromomethyl)phenyl)(4-(((5-(4-bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-
1-yl)methanone (1h). mp 157-159oC; IR (DRS): 3053, 2968, 2843, 1556, 1503, 1453, 
1354, 1258,1135, 1032, 840, 799, 735, 689 cm-1; MS: m/z = 546 [M+1]+; Anal. Calcd for 
C24H23Br2N3O2: C, 52.87; H, 4.25; N, 7.71. Found: C, 52.78; H, 4.14; N, 7.49%. 
 (2-Amino-5-bromophenyl)(4-(((5-(4-bromophenyl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-yl)methanone (1i). mp 196-198oC; IR (DRS): 3442, 3403, 3085, 2998, 
2854, 1636, 1558, 1428, 1322, 1237, 1141, 1052, 835, 769, 733, 680 cm-1; MS: m/z = 547 
[M+1]+; Anal. Calcd for C23H22Br2N4O2: C, 50.57; H, 4.06; N, 10.26. Found: C, 50.38; H, 
3.97; N, 10.20%.  
(4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(4-chlorophenyl) 
methanone (1j). mp 127-129oC; IR (DRS): 3052, 3015, 2963, 2846, 1652, 1563, 1458, 
1352, 1236, 1169, 1046, 885, 834, 756, 701 cm-1; MS: m/z = 487 [M+1]+; Anal. Calcd for 
C23H21BrClN3O2: C, 56.75; H, 4.35; N, 8.63. Found: C, 56.52; H, 4.25; N, 8.53%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(pyridin-2-yl) methanone (1d). 
 
IR Spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(3-
methoxyphenyl)methanone(1e). 
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Mass spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(pyridin-2-yl) methanone (1d). 
 
Mass spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(3-methoxyphenyl)methanone(1e).
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1H NMR spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(pyridin-2-yl) methanone (1d). 
 
Expanded spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(pyridin-2-yl) methanone (1d). 
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1H NMR spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(3-methoxyphenyl)methanone(1e).
 
Expanded spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(3-methoxyphenyl)methanone(1e).
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13C NMR spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(pyridin-2-yl) methanone (1d). 
 
13C NMR spectrum of (4-(((5-(4-Bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(3-methoxyphenyl)methanone(1e). 
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ANTIMICROBIAL ACTIVITY 
Biological evaluation of (4-(((5-(4-(bromophenyl)pyrazin-2-yl)oxy)methyl)piperidin-
1-yl)(aryl)methanones. 
All of the synthesized compounds (1a-j) were tested for their antibacterial and 
antifungal activity (MIC) in vitro by broth dilution method52-54 with two Gram-positive 
bacteria Staphylococcus aureus MTCC-96 and Streptococcus pyogenes MTCC 442, two 
Gram-negative bacteria Escherichia coli MTCC 443 and Pseudomonas aeruginosa 
MTCC 441 and three fungal strains Candida albicans MTCC 227, Aspergillus Niger 
MTCC 282 and Aspergillus clavatus MTCC 1323 taking gentamycin, ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin and greseofulvin as standard drugs. 
The standard strains were procured from the Microbial Type Culture Collection (MTCC), 
Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly synthesized 
compounds, defined as the lowest concentration of the compound preventing the visible 
growth, were determined by using micro dilution broth method according to NCCLS 
standards.38 
 
Minimal Inhibition Concentration [MIC] 
The main advantage of the Broth Dilution Method for MIC determination lies in 
the fact that it can readily be converted to determine the MIC as well. 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately subcultured (before 
inoculation) by spreading a loopful evenly over a quarter of plate of medium 
suitable for the growth of the test organism and put for incubation at 37 0C 
overnight.  
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
5. The amount of growth from the control tube before incubation (which represents 
the original inoculums) is compared.  
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Methods used for primary and secondary screening 
Each synthesized compounds were diluted in DMSO to obtain 2000 μg mL-1 
concentration, as a stock solution. Inoculum size for test strain was adjusted to 108 cfu 
(colony forming unit) per milliliter by comparing the turbidity. 
 
Primary screen: In primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 
concentrations of the synthesized compounds were taken. The active synthesized drugs 
found in this primary screening were further tested in a second set of dilution against all 
microorganisms.  
 
Secondary screen: The compounds found active in primary screening were similarly 
diluted to obtain 200 μg mL-1, 100 μg mL-1, 50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 
6.250 μg mL-1 concentrations.  
 
Reading Result: The highest dilution showing at least 99 % inhibition zone is taken as 
MIC. The result of this is much affected by the size of the inoculums. The test mixture 
should contain 108 organism/mL.     
 
                The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1b. 
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Table-1b: Antimicrobial activity of(4-(((5-(4-(bromophenyl)pyrazin-2-yl) oxy) 
methyl) piperidin-1-yl)(aryl)methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1a 100 250 250 250 250 1000 1000 
1b 125 200 500 500 500 500 500 
1c 250 250 500 250 200 500 500 
1d 250 250 62.5         100 250 >1000 >1000 
1e 500 250 125 200 500 250 1000 
1f 250 125 100 250 1000 500 1000 
1g 125 500 250 250 250 500 >1000 
1h 250 500 100 100 >1000 250 500 
1i 200 200 500 125 500 1000 >1000 
1j 125 250 100 500 250 >1000 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
 
 
 
 
 
 
 
 
 
Part – A 
[Part – I (Section-ii)] 
 
Synthesis and biological evaluation of (4-
(((5-(4-methoxy-3-methylphenyl)pyrazin-
2-yl)oxy)methyl)piperidin-1-yl)(aryl) 
methanones 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL EVALUATION OF (4-(((5-(4-METHOXY-3-
METHYLPHENYL)PYRAZIN-2-YL)OXY)METHYL)PIPERIDIN-1-YL)(ARYL) 
METHANONES 
Many pyrazine derivatives have displayed diverse pharmacological activities. In 
view of our on going interest in the synthesis of some new 2-(piperidin-4-yl methoxy) 
pyrazine derivatives have been synthesized by the condensation of 2-(4-methoxy-3-
methyl phenyl)-5-(piperidin-4-ylmethoxy)pyrazine with various aromatic acids in the 
presence of TEA. 
 
REACTION SCHEME 
 
Pd(PPh3)4, K2CO3 
   
B
OH
OH
O
toluene, IPA
N
N
O
N
O
OO
N
N
O
N
O
Br O +
deprotection
N
N
O
NH
O
HBTU, Et3N, DMF
R-COOH
N
N
O
N
O
RO DIPEA,
HCl (g) in dioxane
 
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 solution on a Bruker 
AC 400 MHz spectrometer. Elemental analysis of the all the synthesized compounds 
were carried out on Euro EA 3000 elemental analyzer and the results are in agreements 
with the structures assigned.  
 
[A] Preparation of  tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate. 
See, Part-A, Part-1, Section-I Experimental Section [D]. 
 
[B] Preparation of tert-butyl 4-(((5-(4-methoxy-3-methylphenyl)pyrazine-2-yl) 
oxy)methyl) piperidine-1-carboxylate. 
A solution of tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was stirred for further 5.0 minutes. To this 
solution (4-methoxy-3-methylphenyl)boronic  acid (0.660 g, 0.004 mol) and isopropyl 
alcohol (20 ml) was added at room temperature. To this content a solution of K2CO3 (10 
ml, 0.02 mol) in water was added dropwise under nitrogen atmosphere and stirred for 5.0 
minute. Tetrakis(tripenylphosphine)palladium(0) (0.231 g, 0.0002 mol) was added in to 
the above reaction mixture and the reaction mixture was heated to reflux for 6 hours 
(monitored by TLC). The reaction mixture was added in to the water under stirring. The 
aqueous layer was extracted with ethyl acetate (100 ml × 3), and the combined organic 
layers were washed with water followed by brine and dried over anhydrous Na2SO4. The 
solvent was evaporated under vacuum to give crude product. The crude product was used 
in the next step without further purification. 
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[C] Preparation of 2-(4-methoxy-3-methylphenyl)-5-(piperidin-4-ylmethoxy) 
pyrazine. 
A mixture of HCl(g) in dioxane (10 ml) and tert-butyl 4-(((5-(4-methoxy-3-methyl 
phenyl)pyrazine-2-yl)oxy)methyl)piperidine-1-carboxylate was stirred at room 
temperature  for overnight (monitored by TLC), and the solvent was removed in vacuo. 
Water and ethyl acetate were added in to the crude product and stirred well. The organic 
layer was separated and the major impurities were removed in the organic layer. The 
aqueous layer was basified using sodium hydroxide solution and the product was 
extracted with DCM (100 ml × 3). The combined organic layers were washed with water 
followed by brine and dried over anhydrous Na2SO4. The solvent was evaporated under 
vacuum to give pure product. Yield: 66 %, mp 136-138oC.    
 
[D] General procedure for the preparation of (4-(((5-(4-methoxy-3-methyl 
phenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(aryl)methanones. 
To a cooled mixture of 2-(4-methoxy-3-methylphenyl)-5-(piperidin-4-
ylMethoxy)pyrazine (0.2 g, 0.640 mmol) and aryl acid (0.640 mmol) in dry DMF(3ml), 
HBTU[2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate] 
(0.288 g, 0.760 mmol), DIPEA[diisopropyl ethyl amine], (0.098 g ≅ 0.129 ml,0.760 
mmol) and TEA (0.11 ml, 0.960 mmol)  was added to basify the content at 0oC. The 
reaction mixture was stirred for 10 hour at room temperature (monitored by TLC). The 
reaction mixture was poured on to crushed ice, thus the precipitate separated was filtered 
and washed with water to give pure product. The physical constants of the products are 
recorded in Table-2a. 
 
[E] Biological evaluation of (4-(((5-(4-methoxy-3-methylphenyl)pyrazin-2-yl)oxy) 
methyl)piperidin-1-yl)(aryl)methanones. 
 Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-2b. 
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Table-2a: Physical constants of (4-(((5-(4-methoxy-3-methylphenyl)pyrazin-2-yl) 
oxy)methyl)piperidin-1-yl)(aryl)methanones. 
 
 
 
  
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
2a CH3
 
 
C26H29N3O3 
 
 
431.52 
 
82 0.52 
2b 
CH3
 
 
C26H29N3O3 
 
 
431.52 
 
72 0.48 
2c N
 
 
C25H26N4O5 
 
418.48 73 0.43 
2d 
N
 
 
C25H26N4O5 
 
418.48 74 0.44 
2e 
CH3  
C26H29N3O3 
 
431.52 80 0.46 
2f 
 
 
C25H27N3O3 
 
 
417.50 
 
87 0.46 
2g 
NH
O
CH3
 
C27H30N4O4 
 
 
474.55 
 
66 0.30 
2h 
Br 
 
C26H28BrN3O3 
 
510.42 75 0.36 
2i 
NH2
Br 
 
C25H27BrN4O3 
 
 
511.41 
 
69 0.28 
 
2j 
 
Cl C25H26ClN3O3 
 
451.94 
 
77 0.46 
              TLC solvent system:- MeOH : CHCl3 = 2 : 8 
N
N
O
N
O
RO
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ANALYTICAL DATA 
(4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(p-tolyl) 
methanone (2a). mp 150-152oC;IR (DRS): 3056, 2985, 2864, 1683, 1625, 1552, 1463, 
1352, 1170, 780, 696, cm-1; MS: m/z = 431 [M]+; Anal. Calcd for C26H29N3O3: C, 72.37; 
H, 6.77; N, 9.74. Found: C, 72.09; H, 6.70; N, 9.66%. 
(4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(o-tolyl) 
methanone (2b). mp 134-138oC; IR (DRS): 2989, 2949, 2856, 1699, 1681, 1629, 1541, 
1465, 1340, 1172, 1028, 775, 651 cm-1; 1H NMR (400 MHz, DMSO): δ ppm 1.17-
1.41(m, 2H, CH), 1.71-1.79(m, 1H, CH), 1.94-1.99(m, 1H, CH), 2.11(m, 1H, CH), 2.24 
(s, 3H, CH3), 2.30(s, 3H, CH3), 2.81(m, 1H, CH), 2.99-3.05(m, 1H, CH), 3.43( d, 1H, 
CH), 3.85(s, 3H, OCH3), 4.21-4.23(d, J= 6.32 Hz, 2H, 2CH), 4.69-4.72(d, J= 12.8 Hz, 
1H, CH), 6.93-6.96(d, J= 8.36 Hz, 1H, ArH), 7.08-7.29( m, 4H, ArH), 7.74-7.76(d, J= 
9.68 Hz, 2H, ArH), 8.21(s, 1H,  ArH), 8.53(s, 1H,  ArH). 13C NMR (100 MHz, DMSO): δ 
ppm, 16.10, 18.46, 28.23, 28.75, 29.34, 35.29, 45.78, 46.31, 55.06, 69.69, 109.93, 124.44, 
125.11, 125.55, 126.05, 127.82, 127.93, 128.30, 129.89, 133.30, 133.66, 136.43, 144.47, 
157.83, 158.23, 168.63.MS: m/z = 431 [M]+; Anal. Calcd for C26H29N3O3: C, 72.37; H, 
6.77; N, 9.74. Found: C, 72.19; H, 6.56; N, 9.68%. 
 (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
(pyridine-4-yl)methanone (2c). mp 140-144oC; IR (DRS): 3046, 2985, 2846, 1678, 
1635, 1546, 1452, 1368,1166, 1045, 880, 835, 780, 754, 703 cm-1; MS: m/z = 418 [M]+; 
Anal. Calcd for C25H26N4O5: C, 68.88; H, 6.26; N, 13.39. Found: C, 68.32; H, 6.21; N, 
13.29%. 
 (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
(pyridine-2-yl)methanone (2d). mp 104-106oC; IR (DRS): 3027, 2978, 1835, 1666, 
1564, 1456, 1378, 1089, 890, 834, 754, 699 cm-1; MS: m/z = 418 [M]+; Anal. Calcd for 
C25H26N4O5: C, 68.88; H, 6.26; N, 13.39. Found: C, 68.82; H, 6.18; N, 13.26%. 
 (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(m-tolyl) 
methanone (2e). mp 96-98oC; IR (DRS): 3003(Ar, C-H str.), 2941(C-H str.), 2929(C-H 
str.), 2883(C-H str.), 2860(C-H str.), 1633(amide, C=O str.), 1533(Ar, C=C str.), 
1456(Ar, C=C str.), 1346(C-H ben), 1170(C-N str.), 1066(C-O-C str.), 1026(C-O-C str.), 
883(C-H o,p, ben), 812(C-H o,p, ben), 754(C-H o,p, ben), cm-1; 1H NMR (400 MHz, 
DMSO): δ ppm 1.24-1.31(m, 2H, CH), 1.79(m, 1H, CH), 1.91(m, 1H, CH), 2.08-2.13(m, 
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1H, CH), 2.24(s, 3H, CH3), 2.36(s, 3H, CH3), 2.80(m, 1H, CH), 3.06(m, 1H, CH), 3.67-
3.71(d, J= 19.2 Hz, 1H, CH), 3.85(s, 3H, OCH3), 4.21-4.23(d, J= 6.44 Hz, 2H, 2CH), 
4.60-4.65(d, J= 19.04 Hz, 1H, CH), 6.94-6.96(d, J= 8.32 Hz, 1H, ArH), 7.13-7.17(t, 2H, 
ArH), 7.21-7.23(d, J= 7.56 Hz, 1H, ArH), 7.27-7.31(t, 1H, ArH), 7.75-7.77(d, J= 9.32 
Hz, 2H, ArH), 8.23-8.23 (d, J=0.92 Hz, 1H, ArH), 8.54-8.55(d, J= 0.88 Hz, 1H, ArH). 
13C NMR (100 MHz, DMSO): δ ppm, 15.60, 20.94, 28.23, 28.75, 29.34, 35.27, 45.78, 
46.31, 55.08, 69.73, 109.97, 123.40, 124.46, 126.02, 126.94, 127.83, 127.94, 127.97, 
129.72, 133.68, 136.13, 136.30, 137.60, 144.45, 157.83, 158.25, 169.22; MS: m/z = 431 
[M]+; Anal. Calcd for C26H29N3O3: C, 72.37; H, 6.77; N, 9.74. Found: C, 72.17; H, 6.70; 
N, 9.69%.  
(4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(phenyl) 
methanone (2f). mp 101-102oC; IR (DRS): 3083, 3015, 2956, 2863, 1688, 1635, 1525, 
1470, 1342, 1162, 1010, 883, 764, 693 cm-1; MS: m/z = 417 [M]+; Anal. Calcd for 
C25H27N3O3: C, 71.92; H, 6.52; N, 10.06. Found: C, 71.85; H, 6.25; N, 9.90%. 
N-(4-(4-(((5-(4-methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
carbonyl)phenyl)acetamide (2g). mp 189-190oC; IR (DRS): 3460, 3028, 2976, 2846, 
1647, 1532, 1465, 1323, 1032, 1045, 838, 756, 704 cm-1; MS: m/z = 475 [M+1]+; Anal. 
Calcd for C27H30N4O4: C, 68.34; H, 6.37; N, 11.81. Found: C, 68.23; H, 6.33; N, 11.41%. 
(4-(Bromomethyl)phenyl)(4-(((5-(4-methoxy-3-methylphenyl)pyrazin-2-yl)oxy) 
methyl)piperidin-1-yl)methanone (2h). mp 137-139oC; IR (DRS): 3091, 3027, 2923, 
2856, 1641, 1523, 1470, 1347, 1056, 830, 745 cm-1; MS: m/z = 510 [M]+; Anal. Calcd for 
C26H28BrN3O3: C, 61.18; H, 5.53; N, 8.23. Found: C, 61.11; H, 5.19; N, 8.02%. 
 (2-Amino-5-bromophenyl)(4-(((5-(4-methoxy-3-methylphenyl)pyrazin-2-yl)oxy) 
methyl)piperidin-1-yl)methanone (2i). mp 135-136oC; IR (DRS): 3443, 3383, 3056, 
2947, 2856, 1656, 1544, 1426, 1330, 1041, 830, 741, 631 cm-1; MS: m/z = 513 [M+2]+; 
Anal. Calcd for C25H27BrN4O3: C, 58.71; H, 5.32; N, 10.96. Found: C, 58.69; H, 5.06; N, 
10.43%. 
 (4-Chlorophenyl)(4-(((5-(4-methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)methanone (2j). mp 208-212oC; IR (DRS): 3074, 3025, 2999, 2840, 
1659, 1522, 1466, 1336, 1170, 1054, 887, 838, 756, 703 cm-1; MS: m/z = 452 [M+1]+; 
Anal. Calcd for C25H26ClN3O3: C, 66.44; H, 5.80; N, 9.30. Found: C, 66.12; H, 5.81; N, 
9.28%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(m-tolyl)methanone(2e).
 
Mass spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(o-tolyl)methanone(2b). 
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Mass spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(m-tolyl)methanone(2e).
 
1H NMR spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(o-tolyl)methanone(2b).
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Expanded spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(o-tolyl)methanone(2b).
 
Expanded spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(o-tolyl)methanone(2b).
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1H NMR spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(m-tolyl)methanone(2e).
 
Expanded spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(m-tolyl)methanone(2e).
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Expanded spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(m-tolyl)methanone(2e).
 
13C NMR spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(o-tolyl)methanone(2b).
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13C NMR spectrum of (4-(((5-(4-Methoxy-3-methylphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)(m-tolyl)methanone(2e).
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Table-2b: Antimicrobial activity of (4-(((5-(4-methoxy-3-methylphenyl)pyrazin-2-     
         yl)oxy)methyl)piperidin-1-yl)(aryl)methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
2a 200 200 100 125 1000 500 500 
2b 500 100 250 200 250 250 500 
2c 125 100 200 200 >1000 250 250 
2d 125 125 200 200 250 1000 1000 
2e 200 200 125 100 500 1000 1000 
2f 125 125 250 250 500 500 500 
2g 500 500 250 250 1000 250 250 
2h 200 200 200 200 250 500 500 
2i 125 125 125 200 250 500 500 
2j 100 62.5 125 500 500 >1000 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
 
 
 
 
 
 
 
 
 
Part – A 
[Part – I (Section-iii)] 
 
Synthesis and biological evaluation of (4-
(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl) 
oxy)methyl)piperidin-1-yl)(aryl) 
methanones  
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SECTION-III 
SYNTHESIS AND BIOLOGICAL EVALUATION OF (4-(((5-(2-FLUORO 
PYRIDIN-3-YL)PYRAZIN-2-YL)OXY)METHYL)PIPERIDIN-1-YL)(ARYL) 
METHANONES 
Pyrazine derivatives have been attracted widespread attention due to their diverse 
pharmacological properties. Looking to this, the synthesis of 2-(piperidin-4-ylmethoxy) 
pyrazine derivatives have been under taken by the condensation of 2-(2-fluoropyridin-3-
yl)-5-(piperidin-4-ylmethoxy)pyrazine with various aromatic acids in the presence of 
TEA. 
 
REACTION SCHEME 
 
Pd(PPh3)4, K2CO3 
   
toluene, IPA
N
N
O
N
O
Br O +
deprotection
HBTU, Et3N, DMF
B
OH
OH
N
F
N
N
O
N
O
O
N
F
N
N
O
N
O
R
N
F
N
F
N
N
O
NH
R-COOHDIPEA,
HCl(g) in dioxane
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 solution on a Bruker 
AC 400 MHz spectrometer. Purity of the synthesized compounds was checked by HPLC 
Agilent 1100 series. Elemental analysis of the all the synthesized compounds were carried 
out on Euro EA 3000 elemental analyzer and the results are in agreements with the 
structures assigned.  
 
[A] Preparation of  tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate. 
See, Part-A, Part-1, Section-I Experimental Section [D]. 
 
[B] Preparation of tert-butyl 4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy) 
methyl) piperidine-1-carboxylate. 
A solution of tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was stirred for further 5.0 minutes. To this 
solution (2-fluoropyridin-3-yl)boronic acid(0.620 g, 0.0044 mol) and isopropyl alcohol 
(20 ml) was added at room temperature. To this content a solution of K2CO3 (10 ml, 0.02 
mol) in water was added dropwise under nitrogen atmosphere and stirred for 5.0 minutes. 
Tetrakis(triphenylphosphine)palladium(0) (0.231 g, 0.0002 mol) was added in to the 
above reaction mixture and the reaction mixture was heated to reflux for 7 hours 
(monitored by TLC). The reaction mixture was added in to the water under stirring. The 
aqueous layer was extracted with ethyl acetate (100 ml × 3), and the combined organic 
layers were washed with water followed by brine and dried over anhydrous Na2SO4. The 
solvent was evaporated under vacuum to give crude product. The crude product was used 
in the next step without further purification. 
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[C] Preparation of 2-(2-fluoropyridin-3-yl)-5-(piperidin-4-ylmethoxy)pyrazine. 
A   mixture of HCl(g)  in dioxane (10 ml) and tert-butyl 4-(((5-(2-fluoropyridin-3-
yl) pyrazin-2-yl)oxy)methyl) piperidine-1-carboxylate was stirred at room temperature for 
overnight (monitored by TLC), and the solvent was removed in vacuo. Water and ethyl 
acetate were added in to the crude product and stirred well. The organic layer was 
separated and the major impurities were removed in the organic layer. The aqueous layer 
was basified using sodium hydroxide solution and the product was extracted with DCM 
(100 ml × 3), and the combine organic layers were washed with water followed by brine 
and dried over anhydrous Na2SO4. The solvent was evaporated under vacuum to give 
pure product. Yield: 56 %, mp 94-96oC.    
 
[D] General procedure for the preparation of (4-(((5-(2-fluoropyridin-3-yl) 
pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(aryl)methanones. 
To a cooled mixture of 2-(2-fluoropyridin-3-yl)-5-(piperidin-4-
ylmethoxy)pyrazine (0.2 g, 0.690 mmol) and aryl acid (0.690 mmol) in dry DMF (3 ml), 
HBTU[2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate] 
(0.314 g, 0.830 mmol),DIPEA[di isopropyl ethyl amine], (0.107 g ≅ 0.141 ml,0.830 
mmol) and TEA (0.19 ml, 1.03 mmol)  was added to basify the content at 0oC. The 
reaction mixture was stirred for 10 hours at room temperature (monitored by TLC). The 
reaction mixture was poured on to crushed ice, thus the precipitate separated was filtered 
and washed with water to give pure product. The physical constants of the products are 
recorded in Table-3a. 
 
[E] Biological evaluation of (4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy) 
methyl)piperidin-1-yl)(aryl)methanones.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-3b. 
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Table-3a: Physical constants of (4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy) 
methyl)piperidin-1-yl)(aryl)methanones. 
 
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
3a CH3
 
 
C23H23FN4O2 
 
 
406.45 
 
80 0.51 
3b 
CH3
 
 
C23H23FN4O2 
 
 
406.45 
 
84 0.49 
3c N
 
 
C21H20FN5O2 
 
393.41 67 0.37 
3d 
N
 
 
C21H20FN5O2 
 
393.41 62 0.38 
3e 
OCH3  
C23H23FN4O3 
 
422.45 76 0.42 
3f 
 
 
C22H21FN4O2 
 
392.42 63 0.46 
3g 
NH
O
CH3
 
C24H24FN5O3 
 
449.47 69 0.30 
3h 
Br 
 
C23H22BrFN4O2 
 
485.34 70 0.43 
3i 
NH2
Br 
 
C22H21BrFN5O2 
 
486.33 78 0.36 
 
3j 
 
Cl
 
 
C22H20ClFN4O2 
 
426.87 77 0.43 
               TLC solvent system:- E.A. : Hexane = 6 : 4 
N
N
O
N
O
R
N
F
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ANALYTICAL DATA 
(4-(((5-(2-Fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(p-tolyl) 
methanone (3a). mp 92-94oC; IR (DRS): 3070, 2948, 2863, 1636, 1521, 1453, 1339, 
1158, 1012, 842, 801, 746, 695 cm-1; MS: m/z = 407 [M+1]+; Anal. Calcd for 
C23H23FN4O2: C, 67.97; H, 5.70; N, 13.78. Found: C, 67.91; H, 5.45; N, 13.58%. 
(4-(((5-(2-Fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(o-tolyl) 
methanone (3b). mp 86-87oC; IR (DRS): 3098, 3048, 2940, 2853, 1628, 1525, 1450, 
1329, 1175, 1017, 880, 831,740 cm-1; MS: m/z = 406 [M]+; Anal. Calcd for 
C23H23FN4O2: C, 67.97; H, 5.70; N, 13.78. Found: C, 67.88; H, 5.44; N, 13.59%. 
 (4-(((5-(2-Fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(pyridin-4-yl) 
methanone (3c). mp 164-168oC; IR (DRS): 3044, 2925, 2858, 1627, 1545, 1468, 1316, 
1170, 1033, 820, 768,720 cm-1; MS: m/z = 394 [M+1]+; Anal. Calcd for C21H20FN5O2: C, 
64.11; H, 5.12; N, 17.80. Found: C, 64.02; H, 4.96; N, 17.64%. 
(4-(((5-(2-Fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(pyridin-2-yl) 
methanone (3d). mp 260-262oC; IR (DRS): 3087, 3051, 2948, 2891, 1620, 1542, 1478, 
1298, 1150, 1031, 880, 804, 721 cm-1; MS: m/z = 394 [M+1]+; Anal. Calcd for 
C21H20FN5O2: C, 64.11; H, 5.12; N, 17.80. Found: C, 64.05; H, 5.01; N, 17.63%. 
(4-(((5-(2-Fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(3-methoxy- 
phenyl)methanone (3e). mp 108-110oC; IR (DRS): 3068, 3017, 2930, 2861, 1616, 1541, 
1460, 1299, 1131, 1016, 804, 754, 700 cm-1; MS: m/z = 422 [M]+; Anal. Calcd for 
C23H23FN4O3: C, 65.39; H, 5.49; N, 13.26. Found: C, 65.20; H, 5.39; N, 13.14%. 
(4-(((5-(2-Fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(phenyl) 
methanone (3f). mp 95-96oC; IR (DRS): 3078, 3042, 2935, 2860, 1610, 1564, 
1488,1250, 1320, 1112, 1007, 810, 768, 737 cm-1; MS: m/z = 392 [M]+; Anal. Calcd for 
C22H21FN4O2: C, 67.33; H, 5.39; N, 14.28. Found: C, 67.18; H, 5.04; N, 14.27%. 
N-(4-(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carbonyl) 
phenyl)acetamide (3g). mp 212-214oC; IR (DRS): 3329,  3248, 3024,2914, 2866, 1689, 
1645, 1612, 1531, 1448, 1350, 1263, 1176,1010, 879, 765, 711 cm-1; 1H NMR (400 MHz, 
DMSO): δ ppm, 1.24-1.36(m, 2H, CH), 1.86-1.92(m, 2H, CH), 2.08(s, 3H, OCH3), 2.11-
2.16(m, 1H, CH), 2.85-3.08( m, 2H,CH), 3.90-3.93(d, J= 13.64 Hz, 1H, CH), 4.24-
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4.26(d, J=6.4 Hz, 2H, 2CH),4.55-4.58(d, J=13.6 Hz, 1H, CH), 7.30-7.32(d, J= 8.56 Hz, 
2H, ArH), 7.40-7.43(d,d, J=2.0 Hz, J= 2.04 Hz, 1H, ArH), 7.63-7.65( d, J= 8.52 Hz, 2H, 
ArH),8.25-8.26(d, J= 1.28 Hz, 1H, ArH), 8.28-8.32( m, 1H. ArH), 8.89-8.90(d, J=1.36 
Hz, 1H, ArH), 9.35-9.36(d, J= 1.36 Hz, 1H ,ArH), 10.04(s, 1H, NH). 13C NMR (100 
MHz, DMSO): δ ppm,13.86, 22.11, 23.94, 28.52, 28.73, 28.88, 29.03, 31.31, 35.27, 
69.84, 105.39, 114.16, 118.34, 122.27, 125.21, 127.43, 129.83, 130.27, 133.87, 135.39, 
138.81, 139.83, 140.31, 141.14, 158.36, 161.21, 168.38, 169.00.; MS: m/z = 449 [M]+; 
Anal. Calcd for C24H24FN5O3: C, 64.13; H, 5.38; N, 15.58. Found: C, 64.02; H, 5.19; N, 
15.43%.         
(4-(Bromomethyl)phenyl)(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-yl)methanone (3h). mp 79-81oC; IR (DRS): 3101, 3038, 2940, 2853, 1618, 
1525, 1450, 1329, 1247,1175, 1017, 840, 768, 703, 635 cm-1; MS: m/z = 486 [M+1]+; 
Anal. Calcd for C23H22BrFN4O2: C, 56.92; H, 4.57; N, 11.54. Found: C, 56.80; H, 4.48; 
N, 11.52%. 
(2-Amino-5-bromophenyl)(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)methanone (3i). mp 245-247oC; IR (DRS): 3236(-NH2 str.), 3034(Ar,C-H 
str.), 2924(C-H str.), 2850(C-H str.),1707(amide, C=O str.),1624(amide, C=O 
str.),1575(Ar, C=C str.),1506(Ar, C=C str.),1450(Ar, C=C str.),1388(C-H ben),1246(C-Br 
str.),1174(C-F str.),1074(C-N str.),1003(C-O-C str.),893(C-H, o,p, ben), 852(C-H, o,p, 
ben), 802(C-H, o,p, ben),740(C-H o,p, ben),704(C-C o,p, ben)cm-1; 1H NMR (400 MHz, 
CDCl3): δ ppm 1.23-1.40 (m, 2H, 2CH), 1.91-1.94 (m, 1H, CH), 2.11-2.14 (m, 1H, CH), 
2.48-2.54 (m, 1H, CH), 2.94-2.99 (m, 1H, CH), 3.28-3.37 (m, 1H, CH), 3.68-3.71 (d, 
J=12.48 Hz, 1H, CH), 4.23-4.24 (d, J=6.52 Hz, 2H, 2CH), 4.54-4.57 (d, J=12.84 Hz, 1H, 
CH), 5.30 (s, 2H, NH2), 6.67-6.69 (d, J=8.52 Hz, 1H, ArH), 7.20-7.21 (m, 2H, ArH), 
7.41-7.43 (m, 1H, ArH), 7.57-7.58 (m, 1H, ArH), 7.79-7.80 (m, 1H, ArH), 8.01-8.02 (d, 
J=1.24 Hz, 1H, ArH), 8.16-8.17 (d, J=1.20 Hz, 1H, ArH);MS: m/z = 486 [M]+; Anal. 
Calcd for C22H21BrFN5O2: C, 54.33; H, 4.35; N, 14.40. Found: C, 54.06; H, 4.02; N, 
14.33%. 
(4-Chlorophenyl)(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)methanone (3j). mp 170-171oC; IR (DRS): 3066, 3053, 2978, 2851, 1622, 1510, 1442, 
1346,1245, 1165, 1037, 836, 796, 702 cm-1; MS: m/z = 427 [M+1]+; Anal. Calcd for 
C22H20ClFN4O2: C, 61.90; H, 4.72; N, 13.12. Found: C, 61.37; H, 4.65; N, 12.91%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS  
IR Spectrum of (2-Amino-5-bromophenyl)(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-
yl)oxy)methyl)piperidin-1-yl)methanone(3i).
 
IR Spectrum of N-(4-(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-carbonyl)phenyl)acetamide(3g).
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Mass spectrum of N-(4-(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-carbonyl)phenyl)acetamide(3g).
 
1H NMR spectrum of (2-Amino-5-bromophenyl)(4-(((5-(2-fluoropyridin-3-
yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone(3i).
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Expanded spectrum of (2-Amino-5-bromophenyl)(4-(((5-(2-fluoropyridin-3-
yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone(3i).
 
Expanded spectrum of (2-Amino-5-bromophenyl)(4-(((5-(2-fluoropyridin-3-
yl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone(3i).
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1H NMR spectrum of N-(4-(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-carbonyl)phenyl)acetamide(3g). 
 
Expanded spectrum of N-(4-(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-carbonyl)phenyl)acetamide(3g).
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13C NMR spectrum of N-(4-(4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-carbonyl)phenyl)acetamide(3g).
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Table-3b: Antimicrobial activity of (4-(((5-(2-fluoropyridin-3-yl)pyrazin-2-yl)oxy)    
       methyl)piperidin-1-yl)(aryl)methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
3a 62.5 100 125 100 >1000 200 250 
3b 200 125 250 250 >1000 200 200 
3c 125 250 200 100 200 250 500 
3d 200 100 250 125 200 500 200 
3e 250 250 200 100 500 1000 1000 
3f 250 62.5 100 250 250 500 200 
3g 125 100 100 200 200 >1000 1000 
3h 200 250 250 250 500 1000 1000 
3i 125 200 200 200 500 500 500 
3j 200 125 100 250 1000 250 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
 
 
 
 
 
 
 
 
 
 
Part – A 
[Part – I (Section-iv)] 
 
Synthesis and biological evaluation of 
Aryl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy) 
methyl) piperidine-1-yl)methanones. 
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SECTION-IV 
SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL(4-(((5-(m-TOLYL) 
PYRAZIN-2-YL)OXY)METHYL)PIPERIDIN-1-YL)METHANONES 
Pyrazine play an important role as intermediates for perfumes, pharmaceuticals, 
agricultural chemicals and food spices. In view of these reports, we have synthesized 2-
(piperidin-4-ylmethoxy)pyrazines derivatives by the condensation of 2-(piperidin-4-
ylmethoxy)-5-(m-tolyl)pyrazine with various aromatic acids in the presence of TEA. 
 
REACTION SCHEME 
 
 
Pd(PPh3)4, K2CO3 
   
toluene, IPA
N
N
O
N
O
Br O +
deprotection
HBTU, Et3N, DMF
R-COOH
B
OH
OH
N
N
O
N
O
O
N
N
O
NHN
N
O
N
O
R DIPEA,
HCl(g) in dioxane
 
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
 
 
 
 
 
Studies on nitrogen containing heterocyclic… 
2-(Piperidin-4-ylmethoxy)pyrazine derivatives…                                                                       79 
EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 solution on a Bruker 
AC 400 MHz spectrometer. Elemental analysis of the all the synthesized compounds 
were carried out on Euro EA 3000 elemental analyzer and the results are in agreements 
with the structures assigned.  
 
[A] Preparation of  tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate. 
See, Part-A, Part-1, Section-I Experimental Section [D]. 
 
[B] Preparation of tert-butyl 4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidine-
1-carboxylate. 
A solution of tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was stirred for further 5.0 minutes. To this 
solution 1-benzothiophen-3-yl-3-boronic acid (0.594 g, 0.0044 mol) and isopropyl 
alcohol (20 ml) was added at room temperature. To this content a solution of K2CO3 (10 
ml, 0.02 mol) in water was added drop wise under nitrogen atmosphere and stirred for 5.0 
minutes. Tetrakis(triphenylphosphine)palladium(0) (0.231 g, 0.0002 mol) was added in to 
the above reaction mixture and the reaction mixture was heated to reflux for 5 hours 
(monitored by TLC). The reaction mixture was added in to the water under stirring. The 
aqueous layer was extracted with ethyl acetate (100 ml × 3), and the combined organic 
layers were washed with water followed by brine and dried over anhydrous Na2SO4. The 
solvent was evaporated under vacuum to give crude product. The crude product was used 
in the next step without further purification. 
 
[C] Preparation of 2-(piperidin-4-ylmethoxy)-5-(m-tolyl)pyrazine. 
A mixture of HCl(g) in dioxane (10 ml) and tert-butyl 4-(((5-(m-tolyl)pyrazin-2-yl) 
oxy)methyl)piperidine-1-carboxylate was stirred at room temperature for over-night 
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(monitored by TLC), and the solvent was removed in vacuo. Water and ethyl acetate were 
added in to the crude product and stirred well. The organic layer was separated and the 
major impurities were removed in the organic layer. The aqueous layer was basified using 
sodium hydroxide solution and the product was extracted with DCM (100 ml × 3). The 
combine organic layers were washed with water followed by brine and dried over 
anhydrous Na2SO4. The solvent was evaporated under vacuum to give pure product. 
Yield: 69 %, mp 87-88oC. 
 
[D] General procedure for the preparation of Aryl(4-(((5-(m-tolyl)pyrazin-2-
yl)oxy)methyl)piperidin-1-yl)methanones. 
To a cooled mixture of 2-(piperidin-4-ylmethoxy)-5-(m-tolyl)pyrazine (0.2 g, 
0.700 mmol) and aryl acid (0.700 mmol) in dry DMF (3 ml), HBTU [2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate] (0.318 g, 0.840 
mmol), DIPEA[di isopropyl ethyl amine], (0.108 g ≅ 0.142 ml,0.840 mmol) and TEA 
(0.21 ml, 1.05 mmol)  was added  to basify the content at 0oC. The reaction mixture was 
stirred for 10 hours at room temperature (monitored by TLC).The reaction mixture was 
poured onto crushed ice, thus the precipitate separated was filtered and washed with water 
to give pure product. The physical constants of the products are recorded in Table-4a. 
 
[E] Biological evaluation of Aryl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl) 
piperidine -1-yl)methanones.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-4b. 
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Table-4a: Physical constants of Aryl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-yl)methanones.  
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
4a CH3
 
 
C25H27N3O2 
 
 
401.50 
 
74 0.54 
4b 
CH3
 
 
C25H27N3O2 
 
 
401.50 
 
69 0.52 
4c N
 
 
C23H24N4O2 
 
488.46 74 0.44 
4d 
N
 
 
C23H24N4O2 
 
488.46 71 0.42 
4e 
OCH3
C25H27N3O3 
 
417.50 
 
80 0.45 
4f 
 
 
C24H25N3O2 
 
 
387.47 
 
59 0.49 
4g 
NH
O
CH3
 
C26H28N4O3 
 
 
444.52 
 
 
64 
 
0.31 
4h 
Br 
 
C25H26BrN3O2 
 
480.39 76 0.42 
4i 
NH2
Br 
 
C24H25BrN4O2 
 
481.38 78 0.36 
 
4j 
 
Cl
 
 
C24H24ClN3O2 
 
 
421.91 
 
84 0.44 
               TLC solvent system:- E.A. : Hexane = 5 : 5 
N
N
O
N
O
R
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ANALYTICAL DATA 
P-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone(4a).mp 124 
-126oC; IR (DRS): 3083, 3049, 2953, 2848, 1678, 1531, 1444, 1329, 1176, 1016, 854, 
792, 748, 701 cm-1; MS: m/z = 401 [M]+; Anal. Calcd for C25H27N3O2: C, 74.79; H, 6.78; 
N, 10.47. Found: C, 74.11; H, 6.72; N, 10.40%. 
 
O-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone(4b).mp 
118-120 oC; IR (DRS): 3049(Ar, C-H Str..), 2914 (C-H Str..), 2860 (C-H Str..),1631 
(amide,C=O Str..), 1599 (Ar, C=C Str..) ,1535 (Ar, C=C Str..),1444 (Ar, C=C Str..), 1340 
(C-H ben), 1201 (C-N Str..), 1168 (C-N Str..), 1006 (C-O-C Str..),  900 (C-H o,p, ben), 
767 (C-H o,p, ben); 1H NMR(400 MHz (DMSO): δ ppm 1.17-1.39(m, 2H, CH), 1.71-
1.79(m, 1H, CH), 1.94-1.97(m, 1H, CH), 2.11-2.13(m, 1H, CH), 2.40(s, 3H, CH3), 2.78-
2.81(m, 1H, CH), 2.98-3.05(m, 1H, CH), 3.42-3.43(d, J=6.4 Hz, 1H, CH), 4.23-4.24(d, 
J=6.4 Hz, 2H, 2CH), 4.69-4.72(d, J=13.04 Hz, 1H, CH), 7.08-7.10(d, J= 7.0 Hz, 1H, 
ArH), 7.16-7.29(m, 5H, ArH), 7.32-7.35(t, 1H, ArH), 7.72-7.77(t, 1H, ArH), 8.26(s, 1H, 
ArH), 8.60(s, 1H, ArH). 13C NMR (100 MHz, DMSO): δ ppm, 18.46, 18.65, 21.12, 
28.22, 28.73, 29.34, 35.15, 35.27, 45.75, 46.30, 69.79, 122.80, 125.13, 125.24, 125.47, 
125.56, 126.30, 128.30, 128.46, 129.02, 129.89, 130.03, 133.30, 133.54, 133.99, 135.86, 
136.44, 137.09, 137.83, 144.40, 158.73, 168.62.; MS: m/z = 401 [M]+; Anal. Calcd for 
C25H27N3O2: C, 74.79; H, 6.78; N, 10.47. Found: C, 74.19; H, 6.64; N, 10.36% 
 
Pyridin-4-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone (4c). 
mp 84-86 oC; IR (DRS): 3049 , 2912 , 2852, 1631, 1533, 1464, 1338, 1278, 1168, 1018 , 
798, 727 cm-1. 1H NMR (400 MHz CDCl3): δ ppm 1.21-1.28(m, 1H, CH), 1.34-1.43(m, 
1H, CH), 1.76-1.79(d, J=12.64 Hz, 1H, CH), 2.0 2.09(m, 1H, CH), 2.35(s, 3H, CH3), 
2.74-2.80(t, 1H, CH), 2.98-3.04(t, 1H, CH), 3.59-3.62(d, J=12.96 Hz, 1H, CH), 4.17-
4.19(d, J=6.0 Hz, 2H, 2CH), 4.69-4.72(d, J=12.2 Hz, 1H, CH), 7.13-7.15(d, J=7.44 Hz, 
1H, ArH), 7.26-7.30(m, 1H, ArH), 7.59-7.70(m, 2H, ArH), 8.20(s, 1H, ArH), 8.40(s, 1H,  
ArH), 8.58-8.63(t, 2H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm, 21.56, 28.48, 29.58, 
29.70, 35.87, 35.90, 41.92, 47.34, 70.01, 70.06, 121.09, 123.23, 123.52, 126.92, 128.84, 
129.54, 132.00, 134.61, 134.94, 136.37, 137.45, 138.68, 143.84, 145.66, 147.80, 150.31, 
150.70, 159.04, 167.71; MS: m/z = 388 [M]+; Anal. Calcd for C23H24N4O2: C, 71.11; H, 
6.23; N, 14.42. Found: C, 71.09; H, 6.10; N, 14.13%. 
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Pyridin-2-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone (4d). 
mp 100-102oC; Purity by HPLC: 88 %; IR (DRS): 3078, 3011, 2933, 2908, 1656, 1533, 
1465, 1344, 1172, 1010, 888, 831, 748, 699 cm-1;; MS: m/z = 489 [M+1]+; Anal. Calcd 
for C23H24N4O2: C, 71.11; H, 6.23; N, 14.42. Found: C, 70.86; H, 6.12; N, 14.36%. 
(3-Methoxyphenyl)(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone (4e). mp 98-99oC; IR (DRS): 3098, 3064, 2954, 2879, 1677, 1556, 1527, 
1440, 1327, 1166, 1014, 848, 799, 747, 699 cm-1; MS: m/z = 417 [M]+; Anal. Calcd for 
C25H27N3O3: C, 71.92; H, 6.52; N, 10.06. Found: C, 71.66; H, 6.40; N, 10.04%.    
 
Phenyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone (4f).mp 
73-75oC; IR (DRS): 3061, 3025, 2958, 2871, 1668, 1548, 1421, 1314, 1151, 1038, 845, 
799, 736 cm-1; MS: m/z = 387 [M]+; Anal. Calcd for C24H25N3O2: C, 74.39; H, 6.50; N, 
10.84. Found: C, 74.16; H, 6.28; N, 10.67%. 
N-(4-(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidine-1-carbonyl)phenyl) 
acetamide (4g). mp 114-116oC; IR (DRS): 3457, 3042, 2946, 2821, 1688, 1556, 1443, 
1331, 1224, 1157, 1032, 842, 805, 796, 748 cm-1; MS: m/z = 445 [M+1]+; Anal. Calcd for 
C26H28N4O3: C, 70.25; H, 6.35; N, 12.60. Found: C, 70.15; H, 6.31; N, 12.44%. 
(4-(Bromomethyl)phenyl)(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone (4h). mp 69-71oC; IR (DRS): 3105, 3048, 2951, 2820, 1676, 1530, 1455, 
1323, 1112, 1041, 834, 769, 698, 621 cm-1; MS: m/z = 481 [M+1]+; Anal. Calcd for 
C25H26BrN3O2: C, 62.50; H, 5.46; N, 8.75. Found: C, 62.39; H, 5.19; N, 8.54%. 
(2-Amino-5-bromophenyl)(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone (4i). mp 160-161oC; IR (DRS): 3483, 3450, 3020, 2940, 2843, 1696, 1542, 
1450, 1320, 1330, 1116, 1018, 856, 788, 716, 631 cm-1; MS: m/z = 482 [M+1]+; Anal. 
Calcd for C24H25BrN4O2: C, 59.88; H, 5.23; N, 11.64. Found: C, 59.84; H, 5.20; N, 
11.09%. 
 (4-Chlorophenyl)(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)methanone 
(4j). mp 106-108oC; IR (DRS): 3125, 3083, 2910, 2830, 1629, 1515, 1443, 1334, 1241, 
1118, 1019, 821, 788, 731, 670 cm-1; MS: m/z = 422 [M+1]+; Anal. Calcd for 
C24H24ClN3O2: C, 68.32; H, 5.73; N, 9.96. Found: C, 68.10; H, 5.70; N, 9.59%.   
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of O-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone(4b).
 
IR Spectrum of Pyridin-4-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)methanone(4c). 
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Mass spectrum of O-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone(4b). 
 
Mass spectrum of Pyridin-4-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)methanone(4c). 
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1H NMR spectrum of O-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone(4b). 
 
Expanded spectrum of O-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl) methanone(4b). 
 
N
N
O
N
O
Studies on nitrogen containing heterocyclic… 
2-(Piperidin-4-ylmethoxy)pyrazine derivatives…                                                                       87 
Expanded spectrum of O-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl) methanone(4b). 
 
1H NMR spectrum of Pyridin-4-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)methanone(4c). 
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Expanded spectrum of Pyridin-4-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)methanone(4c). 
 
Expanded spectrum of Pyridin-4-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)methanone(4c). 
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13C NMR spectrum of O-tolyl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl) methanone(4b). 
 
13C NMR spectrum of Pyridin-4-yl(4-(((5-(m-tolyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)methanone(4c). 
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Table-4b: Antimicrobial activity of Aryl(4-(((5-(m-tolyl)pyrazin-2-yl) oxy) methyl) 
piperidin-1-yl)methanones.  
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
4a 125 200 200 100 >1000 >1000 >1000 
4b 100 200 125 250 250 500 1000 
4c 200 125 125 100 500 500 500 
4d 250 250 250 250 500 1000 1000 
4e 100 100 250 125 250 1000 1000 
4f 62.5 125 200 100 >1000 500 500 
4g 250 100 125 125 1000 250 1000 
4h 500 500 250 250 500 500 500 
4i 250 125 62.5 200 1000 1000 200 
4j 125 500 500 500 200 250 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
 
 
 
 
 
 
 
 
 
 
Part – A 
[Part – I (Section-v)] 
 
Synthesis and biological evaluation of (4-
(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy) 
methyl)piperidin-1-yl)(aryl)methanones 
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SECTION-V 
SYNTHESIS AND BIOLOGICAL EVALUATION OF (4-(((5-(2-METHOXY 
PHENYL)PYRAZIN-2-YL)OXY)METHYL)PIPERIDIN-1-YL)(ARYL)    
METHANONES 
 
Pyrazine plays an important role as intermediates for perfumes, pharmaceuticals, 
agricultural chemicals and food spices. In view of these reports, we have synthesize 2-
(piperidin-4-ylmethoxy)pyrazines derivatives by the condensation of 2-(2-methoxy-
phenyl)-5-(piperidin-4-ylmethoxy)pyrazine with various aromatic acids in the presence of 
TEA. 
 
REACTION SCHEME 
 
 
Pd(PPh3)4, K2CO3 
   
toluene, IPA
N
N
O
N
O
Br O +
deprotection
HBTU, Et3N, DMF
R-COOH
B
OH
OHO N
N
O
N
O
O
O
N
N
O
NH
ON
N
O
N
O
R
O
DIPEA,
HCl(g) in dioxane
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 solution on a Bruker 
AC 400 MHz spectrometer. Elemental analysis of the all the synthesized compounds 
were carried out on Euro EA 3000 elemental analyzer and the results are in agreements 
with the structures assigned.  
 
[A] Preparation of   tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate. 
See, Part-A, Part-1, Section-I Experimental Section [D]. 
 
[B] Preparation of tert-butyl 4-(((5-(2-methoxyphenyl)pyrazin-2-yl) oxy) methyl) 
piperidine-1-carboxilate. 
A solution of tert-butyl 4-(((5-bromopyrazin-2-yl)oxy)methyl)piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was stirred for further 5.0 minutes. To this 
solution (2-methoxyphenyl)boronic acid(0.664 g, 0.0044 mol) and isopropyl alcohol (20 
ml) was added at room temperature. To this content a solution of K2CO3 (10 ml, 0.02 
mol) in water was added dropwise under nitrogen atmosphere and stirred for 5.0 minutes. 
Tetrakis(triphenylphosphine)palladium(0) (0.231 g, 0.0002 mol) was added in to the 
above reaction mixture and the reaction mixture was heated to reflux for 5 hours 
(monitored by TLC). The reaction mixture was added in to the water under stirring. The 
aqueous layer was extracted with ethyl acetate (100 ml × 3), and the combined organic 
layers were washed with water followed by brine and dried over anhydrous Na2SO4. The 
solvent was evaporated under vacuum to give crude product. The crude product was used 
in the next step without further purification. 
 
[C] Preparation of 2-(2-methoxyphenyl)-5-(piperidin-4-ylmethoxy)pyrazine. 
A mixture of HCl(g) in dioxane (10 ml) and tert-butyl 4-(((5-(2-methoxy phenyl) 
pyrazin-2-yl)oxy)methyl)piperidine-1-carboxilate was stirred at room temperature for 
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overnight (monitored by TLC), and the solvent was removed in vacuo. Water and ethyl 
acetate were added in to the crude product and stirred well. The organic layer was 
separated and the major impurities were removed in the organic layer. The aqueous layer 
was basified using sodium hydroxide solution and the product was extracted with DCM 
(100 ml × 3). The combine organic layers were washed with water followed by brine and 
dried over anhydrous Na2SO4. The solvent was evaporated under vacuum to give pure 
product. Yield: 62 %, mp 71-72 oC.    
 
[D] General procedure for the preparation of (4-(((5-(2-methoxyphenyl)pyrazin-
2-yl)oxy)methyl)piperidin-1-yl)(aryl)methanones. 
To a cooled mixture of 2-(2-methoxyphenyl)-5-(piperidin-4-ylmethoxy)pyrazine 
(0.2 g, 0.700 mmol) and aryl acid (0.700 mmol) in dry DMF (3 ml), HBTU[2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate](0.318 g, 0.840 
mmol), DIPEA[di isopropyl ethyl amine] (0.108 g ≅ 0.142 ml,0.840 mmol) and TEA 
(0.21 ml, 1.05 mmol)  was added to basify the content at 0oC. The reaction mixture was 
stirred for 10 hour at room temperature (monitored by TLC). The reaction mixture was 
poured onto crushed ice, thus the precipitate separated was filtered and washed with water 
to give pure product. The physical constants of the products are recorded in Table-5a. 
 
[E] Biological evaluation of (4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy) methyl) 
piperidin-1-yl)(aryl)methanones.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-5b. 
 
 
 
 
 
 
 
 
 
Studies on nitrogen containing heterocyclic… 
2-(Piperidin-4-ylmethoxy)pyrazine derivatives…                                                                       94 
Table-5a: Physical constants of (4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy) 
methyl)piperidin-1-yl)(aryl)methanones. 
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
5a CH3
 
 
C25H27N3O3 
 
 
417.50 
 
73 0.53 
5b 
CH3
 
 
C25H27N3O3 
 
 
417.50 
 
70 0.51 
5c N
 
 
C23H24N4O3 
 
404.46 71 0.48 
5d 
N
 
 
C23H24N4O3 
 
404.46 68 0.44 
5e 
OCH3
C25H27N3O4 
 
433.49 
 
84 0.45 
5f 
 
 
C24H25N3O3 
 
 
403.47 
 
59 0.49 
5g 
NH
O
CH3
 
C26H28N4O4 
 
 
460.52 
 
 
63 
 
0.30 
5h 
Br 
 
C25H26BrN3O3 
 
496.39 75 0.40 
5i 
NH2
Br 
 
C25H27BrN4O2 
 
495.41 78 0.35 
 
5j 
 
Cl C25H26ClN3O2 
 
435.94 
 
      84 0.46 
    TLC solvent system:- E.A. : Hexane = 6 : 4 
 
N
N
O
N
O
R
O
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ANALYTICAL DATA 
(4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(p-tolyl)  
methanone (5a). mp 102-104oC; IR (DRS): 3089, 3039, 2933, 2858, 1618, 1531, 1444, 
1329, 1211,1176, 1016, 854, 788, 699 cm-1; MS: m/z = 417 [M]+; Anal. Calcd for 
C25H27N3O3: C, 71.92; H, 6.52; N, 10.06. Found: C, 71.11; H, 6.41; N, 10.01%.    
(4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(o-tolyl) 
methanone (5b). mp 147-149oC; IR (DRS): 2989, 2920, 2854, 1631, 1531, 1446, 1340, 
1257, 1168, 1097, 1008, 983, 875, 842, 754, 597 cm-1; 1H NMR (400 MHz, DMSO): δ 
ppm 1.18-1.40(m, 2H, CH), 1.74-1.77(d, J=12.12 Hz, 1H, CH), 1.96-1.99(d, J=12.12 Hz, 
1H, CH), 2.12-2.15(m, 1H, CH), 2.23(s, 3H, CH3), 2.82(t, 1H, CH), 3.0-3.06(t, 1H, CH), 
3.44-3.46(d, J=7.2 Hz, 1H, CH), 3.88(s, 3H, OCH3), 4.24-4.25(d, J= 5.92 Hz, 2H , 2CH ), 
4.71-4.74(d, J= 12.92 Hz, 1H ,CH), 7.03-7.10(m, 2H, ArH), 7.19-7.29(m, 4H, ArH), 
7.34-7.38(t, 1H ,ArH), 7.74-7.76(d, J=7.32 Hz, 1H, ArH), 8.27 (s, 1H, ArH), 8. 65(s, 1H, 
ArH). 13C NMR (100 MHz, DMSO): δ ppm,18.46, 18.63, 28.22, 28.73, 29.33, 35.29, 
45.77, 55.23, 69.67, 111.19, 120.55, 125.01, 125.53, 128.28, 129.60, 129.87, 130.02, 
133.82, 136.34, 141.07, 142.80, 156.26, 158.03, 168.75.MS: m/z = 418 [M+1]+; Anal. 
Calcd for C25H27N3O3: C, 71.92; H, 6.52; N, 10.06. Found: C, 71.90; H, 6.30; N, 9.88% 
(4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(piridin-4-yl) 
methanone (5c). mp 63-65oC; Purity by HPLC: 89 %; IR (DRS): 3078, 2958, 2858, 
1634, 1525, 1478, 1278, 1054, 888, 841, 754, 703 cm-1; MS: m/z = 404 [M]+; Anal. Calcd 
for C23H24N4O3: C, 68.30; H, 5.98; N, 13.85. Found: C, 68.10; H, 5.90; N, 13.73%. 
(4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(pyridin-2-yl) 
methanone (5d). mp 111-112oC; Purity by HPLC: 88 %; IR (DRS): 3081, 3054, 2933, 
2908, 1626, 1533, 1465, 1344, 1172, 1010, 878, 831, 748, 699 cm-1; MS: m/z = 405  
[M+1]+; Anal. Calcd for C23H24N4O3: C, 68.30; H, 5.98; N, 13.85. Found: C, 68.27; H, 
5.88; N, 13.72%. 
(3-Methoxyphenyl)(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone (5e). mp 116-118oC IR (DRS): 3108, 3064, 3015, 2924, 2879, 1627, 1556, 
1527, 1440, 1327, 1166, 1014, 831, 798, 727, 676 cm1; MS: m/z = 433 [M]+; Anal. Calcd 
for C25H27N3O4: C, 69.27; H, 6.28; N, 9.69. Found: C, 69.20; H, 6.23; N, 9.50%. 
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(4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(phenyl) 
methanone (5f). mp 173-175oC; IR (DRS): 3085, 3047, 2938, 2871, 1636, 1548, 1421, 
1314, 1151, 1018, 888, 834, 746, 703 cm-1; MS: m/z = 403 [M]+; Anal. Calcd for 
C24H25N3O3: C, 71.44; H, 6.25; N, 10.41. Found: C, 71.40; H, 6.18; N, 10.37%.   
N-(4-(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-carbonyl) 
phenyl)acetamide (5g). mp 129-131oC; IR (DRS): 3416(N-H str.), 3173(Ar, C-H str.), 
3097(Ar, C-H str.), 3043(Ar, C-H str.), 2937(C-H str.), 2854(C-H str.), 1691(amide, C=O 
str.), 1599(Ar, C=C str.), 1531(Ar, C=C str.), 1496(Ar, C=C str.),  1338(C-H ben), 
1257(C-H ben), 1172(C-N str.), 1020(C-O-C str.),  758(C-H o,p, ben)cm-1; 1H NMR (400 
MHz, DMSO): δ ppm 1.24-1.36(m, 2H, CH), 1.86-1.92(m, 2H, CH), 2.08(s, 3H, OCH3), 
2.11-2.16(m, 1H, CH), 2.85-3.08(m, 2H, CH), 3.83-3.93(m, 4H, OCH3, CH), 4.24-4.26(d, 
J=6.4 Hz, 2H, 2CH), 4.55-4.58(d, J=13.0 Hz, 1H, CH), 7.03-7.09(m, 2H, ArH), 7.30-
7.39(m, 3H, ArH), 7.74-7.76(d,d J= 1.56 Hz, 1.48 Hz, 1H, ArH), 8.28-8.29(d, J=1.08 Hz, 
1H, ArH), 8.65-8.66(d, J= 1.16 Hz, 1H, ArH), 10.0(s, 1H, NH). 13C NMR (100 MHz, 
DMSO): δ ppm, 22.17, 23.92, 35.29, 55.29, 69.75, 111.29, 118.37, 120.57, 125.03, 
127.41, 129.64, 130.04, 130.26, 133.87, 140.30, 141.08, 142.79, 156.30, 158.09, 168.38, 
169.06. MS: m/z = 460 [M]+; Anal. Calcd for C26H28N4O4: C, 67.81; H, 6.13; N, 12.17. 
Found: C, 67.76; H, 6.02; N, 12.04%. 
(4-(Bromomethyl)phenyl)(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-yl)methanone (5h). mp 90-92oC; IR (DRS): 3048, 2951, 2820, 1636, 1530, 
1455, 1323, 1112, 1041, 824, 621 cm-1; MS: m/z = 497 [M+1]+; Anal. Calcd for 
C25H26BrN3O3: C, 60.49; H, 5.28; N, 8.47. Found: C, 60.39; H, 5.19; N, 8.42%. 
(2-Amino-5-bromophenyl)(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl) 
piperidine-1-yl)methanone (5i). mp 239-241oC; IR (DRS): 3483, 3410, 3083, 3043, 
2940, 2843, 1616, 1542, 1450, 1320, 1330, 1116, 1018, 780, 703, 631 cm-1; MS: m/z = 
498 [M+1]+; Anal. Calcd for C25H27BrN4O2: C, 57.95; H, 5.07; N, 11.26. Found: C, 
57.02; H, 5.02; N, 11.22%. 
(4-Chlorophenyl)(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl) 
methanone (5j). mp 167-169oC; IR (DRS): 3083, 3010, 2954, 2830, 1629, 1515, 1443, 
1334, 1241, 1118, 1019, 841, 768,  690 cm-1; MS: m/z = 464 [M+1]+; Anal. Calcd for 
C25H26ClN3O2: C, 65.82; H, 5.52; N, 9.60. Found: C, 65.50; H, 5.46; N, 9.59%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of (4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-yl)(o-
tolyl)methanone(5b).
 
IR Spectrum of N-(4-(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
carbonyl)phenyl)acetamide(5g).
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Mass spectrum of (4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-1-
yl)(o-tolyl) methanone (5b). 
 
 Mass spectrum of N-(4-(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-carbonyl) phenyl)acetamide (5g). 
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 1H NMR spectrum of (4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-
1-yl)(o-tolyl) methanone (5b). 
 
Expanded spectrum of (4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-
1-yl)(o-tolyl)methanone(5b). 
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Expanded spectrum of (4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-
1-yl)(o-tolyl)methanone(5b).
 
1H NMR spectrum of N-(4-(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-carbonyl)phenyl)acetamide(5g).
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Expanded spectrum of N-(4-(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-carbonyl)phenyl)acetamide(5g). 
 
Expanded spectrum of N-(4-(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-carbonyl)phenyl)acetamide(5g). 
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13C NMR spectrum of (4-(((5-(2-Methoxyphenyl)pyrazin-2-yl)oxy)methyl)piperidin-
1-yl)(o-tolyl)methanone(5b).
 
13C NMR spectrum of N-(4-(4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)methyl) 
piperidin-1-carbonyl) phenyl)acetamide (5g). 
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Table-5b: Antimicrobial activity of (4-(((5-(2-methoxyphenyl)pyrazin-2-yl)oxy)       
methyl) piperidin-1-yl)(aryl)methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
4a 100 200 200 200 1000 500 500 
4b 62.5 100 500 500 500 1000 1000 
4c 250 250 250 500 250 1000 1000 
4d 200 200 200 62.5 >1000 >1000 >1000 
4e 100 100 100 125 250 500 500 
4f 125 100 200 125 200 500 250 
4g 200 500 125 500 500 200 200 
4h 250 250 250 200 250 500 500 
4i 500 125 125 100 500 1000 1000 
4j 500 200 500 250 1000 250 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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INTRODUCTION 
 
Although chroman was first prepared in 1905, little interest was shown in the 
compound until studies on the tocopherols (Vitamin-E) began to indicate that they were 
derivatives of chroman. Same as many derivatives of chroman were prepared like a 
nebivolol acid and nebivolol drug. The monoalkyl chromans can be divided into two 
groups-one with the alkyl substituted attacked to the benzene ring and the second with 
attacked to the heterocyclic ring. The former can be obtained from appropriate derivatives 
of benzene similar to those used for the preparation of chroman. Chroman is stable to 
acids and oxidizing agents. It is soluble in common organic solvents1. 
Chroman is an aromatic heterocyclic organic compound. It is a bicyclic structure, 
consisting of a six-membered benzene ring fused to a six-membered oxygen hetero 
atom(benzopyrane).  
 
O
1
2
3
456
7
8  
 
6-Fluorochroman-2-carboxylic acid is a solid at room temperature. And it is a 
derivative of nebivolol drug. And it is also known as nebivolol acid .Nebivolol is an 
antihypertensive compound. Nebivolol has been studied in over 3000 patients with 
hypertension. The use of nebivolol is contraindicated in patients with, cardiogenic shock, 
uncontrolled heart failure, Sick sinus syndrome, Second and third degree heart block, 
Asthma, Hypotension, and Pregnancy.etc.  
 
O
F
O
OH
 
 
6-FLUOROCHROMAN-2-CARBOXYLIC ACID ( NEBIVOLOL ACID) 
 
O N O
F
OH OH
F
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NEBIVOLOL [2,2’-azanediylbis(1-(6-fluorochroman-2-yl)ethanol)] 
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Vitamin E refers to a family of eight molecules having a chromanol ring (chroman 
ring with an alcoholic hydroxyl group) and a 12-carbon aliphatic side chain containing 
two methyl groups in the middle and two more methyl groups at the end. Tocotrienols 
(found in high concentrations in palm oil) are many times more potent as anti-oxidants 
than are tocopherols, but they are poorly assimilated by digestion, are poorly distributed 
to tissues in blood and are rapidly metabolized and eliminated from the body. But 
tocotrienols are well-absorbed by the skin and thus are well suited for use as a Vitamin E 
cream. 
 
SYNTHETIC ASPECT 
 
1. K. J. Hodgetts2 has developed a new method for 2-substituted chroman by 
intermolecular Mitsunobu reaction of a homochiral halopropanol and 2-
bromophenol. 
 
+
Br
OH Ph
OH Cl
O Ph
THF
BuLi
 
 
2.  C. Lherbet et al .3 have synthesized isochroman in the one pot-reaction by using 
different benzaldehydes and phenylethanethiol or phenyl ethanol in presence of 
bismuth triflate as a catalyst. 
 
XH R-CHO, Bi(OTf)3
Toluene
X
R
X= O,S
 
 
3. C. S. López et al. 4 have developed a mild and convenient one-pot photochemical 
synthesis of chroman-4-one derivatives. 
 
 
hv
O
O O
O  
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4.  H. Hamamoto et al.5 synthesized chroman by direct aromatic carbon–oxygen 
bond-formation reaction involving aromatic cation radical intermediates using the 
hypervalent iodine (III) reagent, phenyl iodine (III) bis(trifluoroacetate) (PIFA). 
 
 
CatalystOH
MeO
MeO O
MeO
MeO   
 
5.  S. Emami et al.6 have synthesized azolyl chroman derivatives prepared as 
conformationally constrained analogs of (aryl alkyl) azoles. 
 
TriethylorthoformateN
O
OH
N
N
O
O
N N
N
 
 
6.  M.Venkati et al.7 have synthesized chroman from substituted o-hydroxy aceto -
phenone and substituted benzaldehyde in 60% KOH. 
 
+
60 % KOH
R1 = CH3, Ph
R2 = H, CH3, OCH3, Cl
O
OHH3CO O
O
H3CO
CHO
 
7.  R. R. Karimi et al.8 have developed simple, clean and benign route for synthesis 
of 2H-chromen-2-ones derivatives through one-pot condensation of β-ketoesters 
and substituted phenols in the presence of 1-chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2]octane. Bistetrafluoroborate is (SelectfluorTMF-TEDA-
BF4) was used as catalyst under solvent free reaction conditions. 
 
+ +
Selectfluor 10 mol %
OH
CN
CN
O NH2
CN
R
RCHO
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8. S. R. Sarda et al.9 have synthesized 2,4-diphenyl-4H-chromen-5-one  from α, β-
unsaturated carbonyl compounds and 1,3-cyclohexanedione under  microwave 
irradiation in the presence ZnCl2/montmorillonite K-10. 
+ K-10/ZnCl2
O O
O
O
O
MW
 
 
9.  D. P. Kardile et al.10 have synthesized 7-hydroxy-4-methylcoumarin from 
various phenols like resorcinol, m-cresol etc. condensed with ethylacetoacetate 
(II) in presence of concentrated sulphuric acid by Pechmann reaction. 
 
Conc. H2SO4+
OH
OH
OOH O
O
H5C2O
O  
 
10. R. Suthunuru et al.11 have developed highly effective, facile, one-pot 
regioselective synthesis of a series of 4,7-dihydroxy-4-phenyl-chroman-2-ones 
involves a die none-phenol rearrangement followed by a Michael type reaction. 
 
+
TFA, NaOAc
R = H, Me, Cl
OHOH
R
OOH
R
O
OH
OH
O
OH
 
 
11.  H. Lee et al.12 have synthesized 6-hydroxy-7-methoxy-4-chromanone using 
aluminum chloride as catalyst. 
 
+
OH
OH
MeO
O
O
O
OH
MeO
OH
O
O
O
AlCl3
CH2Cl2
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12.  Q. Wang et al.13 have synthesized 6-hydroxy chroman from condensation of 2-
methyl-3-butene-2-ol and substituted phenol in the presence of formic acid. 
 
+
OH
OH
O
OH
OH
HCOOH
 
 
13.  X. Meng et al.14 have developed a  novel domino reaction catalyzed by 
triphenylphosphine for synthesis of the highly functionalized chroman 
derivatives. 
 
+
PPh3 (30 MOl %)
R = Et, Me
OH
NP(S)Ph2
COOR
O
NHP(S)Ph2
COORCH2Cl2
 
 
14. D.Lu et al.15 have developed symmetric tandem Michael addition hemi-
acetalization between aliphatic aldehydes and (E)-2-(2-nitrovinyl)phenols for 
constructing chroman backbones 
 
+
Prolylprolinols
R = Me, Et, Ph
O OH
R
NO2
OH
NO2 CHO
R
 
 
15.  M.Yoshida et al.16 have synthesized chroman in the presence of 5 mol % 
Pd2(dba)3·CHCl3 and 20 mol % 1,1′-bis(diphenylphosphino)-ferrocene (DPPF) 
in dioxane at 120 °C for 5 min. 
 
+
OH
COOR
Ar
Ar
OCO2Me
O
Ar
COOR
Ar
Pd (O)
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16.  C. Selenski et al.17 have synthesized chroman derivatives as like natural 
molecule of (+)-mimosifoliol. 
OcoB
HO
O R
OR
 
 
17.  J. Barluenga et al.18 have synthesized chroman derivatives by the reaction of 
different ally phenyl ethers with Ipy2BF4. 
 
Ipy2BF4
O
Ph
I
O
Ph  
 
18. M. M. Biddle et al.19 have synthesized flavanones and chromanone using 
bifunctional thiourea catalysts promote an asymmetric oxo-conjugate 
addition to a β-ketoester alkylidene. 
 
Chiral thiourea catalyst
O R
O
COOt-Bu
O ROH
 
 
REACTION MECHANISM 
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THERAPEUTIC IMPORTANCE 
The chroman ring system represents a privileged structure in drug discovery. 
The number of bioactive compounds containing this ring system is so vast that the 
complete range of their biological activities can be hardly classified20-22 
1. Antifungal23                     9.Antiallergic34 
2. Antibacterial24,25   10.Anti-inflammatory35 
3. Antioxidant 26    11.Antitumor36 
4. Anti HIV27    12.Antitubercular37 
5. Antiarrythmic28   13.Antidiabetic38 
6. antiepileptic agents29-31  14.Hepatoprotective agents39 
7. antihypertensive32   15.Antiulcer activity40 
8. Antiviral33 
M.C.Patel et al.41 have synthesized some novel chroman derivative  and 
studied  their  antibacterial  and antifungal activities, using the E. coli, P.aeruginosa, S. 
aureus, and S.Pyogenus and Candida albicans. 
 
O
O O
NH
N
 
 
G. Hua et al.42 have synthesized chroman- and 2,3-dihydrobenzofuran-based 
constraints as a potent and highly selective kappa opioid receptor agonists 
 
O
O
N
N OH
 
 
B. S. Priya et al.43 have synthesized 6-fluoro-chroman-2-carboxamides by 
using nebulic acid chloride with different amines in presence of triethylamine as acid 
scavenger and dichloroethane as solvent. These molecules were evaluated for their 
efficacy as antimicrobials invitro by disc diffusion and microdilution method against 
pathogenic strains such as Bacillus substilis, Escherichia coli, Pseudomonas fluorescens, 
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Xanthomonas campestris pvs, X. oryzae, Aspergillus niger, A. flavus, Fusarium 
oxysporum, Trichoderma species, F. monaliforme, and Penicillum species. 
 
O
O
NH
F
CF3
Cl
 
 
P.V.Kumar et al.44 have synthesized 3-indolizin-2-yl-chromen-2-one as a 
antitubercular, antiviral and anticancer activities 
 
O O
NN
OCH3  
 
Z. Nazarian et al.45 have synthesized a chalconoids containing a 6-chloro-
2H-chromen-3-yl group and showed cytotoxicity assessment against mouse peritoneal 
macrophage cells.It showed that these compound display antileishmanial activity at non-
cytotoxic concentrations. 
 
O
Cl
O
 
 
S. Gowrisankar et al.46 have synthesized 4-substituted 3-exo-
methylenechroman derivatives and evaluated as a antimicrobial agents. 
 
O
EtOOC
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J. G. Kanga et al.47 have isolated 2-hydroxymethyl-chroman-4-one which 
exhibited good activities against phytopathogen such as Pythium ultimum, Phytophthora 
capsici and Sclerotinia sclerotiorum 
 
O
OH
O
 
 
K.Hatzade et al.48 have synthesized 7-hydroxy-3-pyrazolyl chromones and 
evaluated for their in vitro antimicrobial and anti-oxidant activity. 
 
O
O
N
H
N
Cl
Cl OH
 
 
 
M. Koufaki et al.49 have synthesized 5-substituted chroman and evaluated as 
a their activity against oxidative Stress Induced Cellular Damage. 
 
O
OH
NH
O
OH
OH
 
 
D. T. Witiak et al.50 have synthesized ethyl 6-substituted-chroman and 
evaluated as anti-hyperlipidemic agent. 
 
OH5C6
O
COOH
 
 
K. A. Reddy et al.51 have synthesized benzyloxy containing chroman 
derivatives and evaluated for their euglycemic and hypolipidemic activities. 
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O
N
O
S
NH
O
O  
 
U. Gerlach et al.52 have synthesized various ethanesulfonamide containing 
chroman for development as an antiarrhythmic drug 
 
O
Cl
N
S
O
O
OH
 
 
N. T. Hatzenbuhler et al.53 have worked on combining a 5-HT1A moiety (3-
aminochroman scaffold) and a 5-HT transporter (indole analogues) linked through a 
common basic nitrogen via an alkyl chain attached at the 1- or 3-position of the indole  
evaluated for dual affinity at both the 5-HT reuptake site and the 5-HT1A receptor. 
 
O
NH2O
F
N
N
H
F
 
 
P. Holmberg et al.54 have synthesized novel 2-aminotetralin and 3-
aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists. 
 
O
N
OMeMeO
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PART I-
STUDIES ON 1,3,4- THIADIAZOLE  
DERIVATIVES.
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INTRODUCTION 
Thiadiazole derivatives have played an important role in pharmaceutical 
industries and exhibited various biological activities due to the presence of – 
N=C-S group.
1   In thiadiazole ring system one sulphur and two nitrogen atoms are 
present in a five membered ring. According to their position, thiadiazole systems 
are classified as 1,2,3-thiadiazole (I), 1,2,4-thiadiazole (II), 1,3,4-
thiadiazoles(III)  and 1,2,5-thiadiazoles(IV). 
 
 
S
N
N
S
N
N
S
N N S
N
N
(i) (ii) (iii) (iv)  
 
Among these four types of thiadiazoles,1,3,4-thiadiazole is well known. Fischer 
has described the first 1,3,4-thiadiazole in 1882 and further developed by Buch and co-
workers. 
 
SYNTHETIC ASPECT 
 
Literature survey reveals that several publications and patents
2  
 
described the synthesis of 1,3,4-thiadiazole as under. 
1.  Li-xue Zhang et al.
3 have synthesized 1,3,4-thiadiazoles by the cyclization of 
     aromatic acid with triazole in presence of POCl3. 
 
O
N
N NNH2
SH
Ar -COOH
POCl3
O
N
N N
N
S
Ar  
 
  2.   J.Mohan et al.
4 have prepared thiadiazole derivatives by the cyclization of  amino    
mercapto triazole and aryl aldehyde in presence of p-Ts-OH 
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N
N
N
R
NH2
Ar-CHO
P-Ts-OH
N
N
N NH
S
R
 
 
 3.   Microwave irradiation used for the preparation of thiadiazole using DMF as an  
energy transfer medium was reported by K. Mazaahir et al.
5 
4.     Zhong-Yi et al.
6 have   been  prepared  thiadiazole  derivatives from amino  
           mercapto triazole and aryl aldehyde in presence of L-(+)-tartaric acid. 
 
N
N N
SH
NH2
R
R-CHO
L-(+)- tartaric acid N
N N
R
N
H
S
R 
5.  Q.Bano and co-workers
7 have been prepared 6-phenyl amino-1,3,4-thiadiazole 
by reacting triazole with amino acid. 
 
O N
N
NR
NH2
SH
O N
N N
R
N
S
NH
 
 
6.  A.A.Hassan et al.
8 have prepared 1,3,4-thiadiazoles by the cyclization  
   of  tetracyanoethene and 4-phenyl thiosemicarbazides. 
 
+R
NH
S
NH
NH2
NC
NC
CN
CN S
NN
NHR CN
CN  
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7.   K. Zamani et al.
9
 have prepared thiadiazole from the thiosemicarbazide   
            by   the  cyclization in sulphuric acid. 
 
N
O
NH
NH S
NH
Con. H2SO4
N
N
S
N
NH
 
 
8.   J. Sun et al.
10 have synthesized a series of 1,3,4-thiadiazole derivatives from2,3-   
          dihydro benzo[b][1,4] dioxine-6-carboxylic acid on treatment with     
thiosemicarbazide in  presence of phosphoryl chloride. 
 
 
+
O
O
OH
O
NH2
NH NH2
S
NN
S
NH2O
O
POCl3
 
 
 
9.     F. Aryanasab et al.11 have synthesized a series of 2-amino-1,3,4-thiadiazoles in 
water. 
 
+
Et3N,  H2O
reflexNH S
S
NH
NH2
O N
S
N
NH  
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REACTION MECHANISM 
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THERAPEUTIC IMPORTANCE  
Literature survey revealed that various thiadiazoles have resulted in many 
potential drugs and are known to exhibit a broad spectrum of pharmacological 
properties. The specific pharmacological activities associated are as under. 
 
1. Antitumor
12
   8.Antinelmintic19 
2. Antiviral
13
    9.CNS depressant20 
3. Antibacterial
14
                   10.Antischistosomal21 
       
4. Amoebicidal
15
            11.Herbicidal22 
5. Antagonist agent 
16 
                  12.Insecticidal23 
6. Antitubercular 
17
                   13.Pesticidal24 
7. Antipyretic 
18
                   14.Hypogycemic25 
 
V. Fabrice et al.
26 
have synthesized 1,3,4-thiadiazole derivatives  and 
screened for their antiinflammatory, anticancer and anti-HIV activity. U.V. Laddi 
et al.
27 
have discovered thiadiazoles possessing antimicrobial and antituberculosis 
activity. B.G.Ronald et al.
28
 have reported thiadiazoles as antiinflammatory 
agents. A.Mobinikhaledi et al.
29
have investigated 1,3,4-thiadiazoles and tested for 
insecticidal activity. Che Chao et al.
30 have prepared thiadiazole derivatives 
showed antifungal and plant growth regulating effect. 
 
S
O
O
NH2
Cl
N
S
N
N
 
 
 
      C.Chazalete et al.31 have synthesized acetazolamide possessing 
diuretics and antiglaucoma activity. A.Varvareso et al.32 suggested thiadiazoles and 
reported them as antidepressant. P.Mishra et al.33 have screened 1,3,4- 
thiadiazoles for their potent spasmolytic activity and anti-inflammatory activity. B. 
Masercel et al.34  have synthesized 1,3,4-thiadiazoles possessing potent 
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carbonic anhydrase inhibitor properties and also prepared 5-valproyl amino 1,3,4-
thiadiazole-2-sulphonamide (XIII)  as str.ong anticonvulsant. 
 
S
NNO
NH S
O
O
NH2
S
N
N
S
O
O
NH2
NH
O
 
 
 
              C. T. Supuran and Andrea Scozzafava35 have reported 1,3,4-thiadiazole 
derivatives  as  carbonic  anhydrase  inhibitors  and  antitumor.  E.  Palaska  et  al. 36 
synthesized thiadiazoles containing anti-inflammatory activity. J. M. Colacino et 
al.37 have documented anti-influenza virus activity of thiadiazoles. 
   L.M.Thomasco et al.
38 have prepared 1,3,4-thiadiazole  possessing 
potent antibacterial activity against Gram positive and Gram negative organisms. 
S. A. Carvalho and co-workers
39 have documented antitrypanosomal profile of 1,3,4- 
thiadiazole derivatives, Z. Kiani et al.
40 have discovered thiadiazoles as 
antituberculosis agent 
 
S
N N
R
F
N
O
O
NH
O  
 
N
N
N
+
O
-
O
N
S
N
NH
N
OH
OH  
 
A. faroumadi et al.
41 
have synthesized 1,3,4-thiadiazoles (XVI) and studied 
their leishmanicidal activity. H.N. Dogan et al.
42 have prepared 2,5-disubstituted-
1,3,4- thiadiazolo derivatives as anticonvulsant and antimicrobial agent. N. Terzioglv 
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and A. Gursoy
43 have discovered thiadiazoles and studied their anticancer activity. A. 
Foroumadi and co-workers
44 
have documented antituberculosis activity and 
cytotoxicityof 1,3,4-thiadiazoles. 
 
XN
+O
-
O
N
S
N
N
X
X= O,S
Y=CH2,O,NR
 
 
Recently S. Karakus and S. Rollas
45
 have screened thiadiazoles for 
their antituberculosis activity. Jui-Yi Chou et al.46 have synthesized thiadiazoles and 
reported them as anticancer agents. 
A. R. Bhat et al.47 have synthesized new series of thiadiazoles evaluated on in 
vitro growth of microorganisms causing microbial infection. 
 
N
S
NN
N
O
O
Cl
Cl
 
 
V. Jatav et al.48 have synthesized a series of 3-[5-substitutedphenyl-1,3,4-
thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones and evaluated for anticonvulsant,  
sedative-hypnotic and CNS depression activities. 
 
N
N S
NNO
 
F. Poorrajab et al.49 have synthesized 1,3,4-thiadiazole derivatives and 
evaluated in vitro against Leishmania major. 
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N
N
NN
S
N
N
O2N O
R  
 
H. Rajak et al.50 have synthesised 2,5-disubstituted-1,3,4-thiadiazole and tested 
for antitumor activity against Ehrlich ascites carcinoma cells in Swiss albino mice. 
 
R = 4-Cl, 4-NO2, 4-OH, 2-Cl, 3-Cl
S
NN
NH N
N
O
NH
O O
R
 
 
Work done from our laboratory 
K.M.Thaker51 have synthesized 2-(3’5’-dichlorobenzo[b]thiophen-2’-yl)-5-
arylamino-1,3,4-thiadiazoles from triazole. S.L.Vasoya52 have synthesized some new 
thiosemicarbazide and 1,3,4-thiadiazole heterocycles bearing the benzo[b]thiophene 
nucleus as potent antituberculer and antimicrobial agents.  
In light of wide varieties of therapeutic activities exhibited by thiadiazole, we 
have embarked upon the synthesis of some new thiadiazole derivatives which have 
been described in following sections. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-(6-  
FLUOROCHROMAN-2-YL)-6-ARYL[1,2,4]TRIAZOLO 
[3,4-b] [1,3,4]THIADIAZOLES.     
 
 
 
 
 
 
 
Part – B 
[Part – I (Section-i)] 
 
Synthesis and biological evaluation of 3-
(6-fluorochroman-2-yl)-6-aryl-[1,2,4] 
triazolo[3,4-b][1,3,4]thiadiazoles. 
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   SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(6-FLUORO 
CHROMAN-2-YL)-6-ARYL-[1,2,4]TRIAZOLO[3,4-b][1,3,4] 
THIADIAZOLES. 
Thiadiazole derivatives are associated with broad spectrum of biological 
activities. In view of these finding it appeared of interest to synthesize some newer 
thiadiazole derivatives, with better potency. Thiadiazoles of type (I) have been 
prepared by cyclocondensation of 4-amino-5-(6-fluorochroman-2-yl)-4H-1,2,4-
triazole-3-thiol with different aromatic acids in presence of phosphorous 
oxychloride, as shown in reaction scheme. 
 
 REACTION SCHEME 
 
 
O
F
O
OH
CH3OH
Con. H2SO4 Hydrazine HydrateO
F
O
O
Ethanol
O
F
O
NH
NH2
CS2/KOHMethanol
O
F
O
NH
NH
S
S K
Hydrazine Hydrate
O
F
N
N
N
NH2 SH
R--COOHPOCl3
O
F
N
N
N
N S
R
(Type I ) R=Aryl
- +-
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The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further 
supported by mass spectroscopy. Purity of all the compounds has been checked on thin 
layer chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 and DMSO solution 
on a Bruker AC 300 MHz, 400 MHz and 100MHz spectrometer. Elemental analysis of 
the all the synthesized compounds were carried out on Euro EA 3000 elemental analyzer 
and the results are in agreements with the structures assigned.  
 
[A]     Synthesis of  Methyl 6-fluorochroman-2-carboxylate. 
         6-Fluorochroman-2-carboxylic acid (2.0 gm, 0.01 mol ) in methanol (10 ml) was 
stirred at room temperature  for  5 minutes then add concentrated H2SO4 (0.5 ml, 0.01 
mol) and stir the reaction mixture at room temperature for 10 hours.After the completion 
of the reaction checked by TLC, methanol was removed in vacuo and then add methelene 
dichloride(40 ml) and stir it further for 10 minutes.The resultant mixture was treated with 
saturatured sodium bicarbonate until pH become neutral. The neutral solution was treated 
with sodium sulphate and then organic layer was removed in vacuo. Collect the crude 
product and there is no need to purification, the crude ester directly used for further 
reaction. 
 
[B]    Synthesis of 6-Fluorochroman-2-carbohydrazide. 
         Methyl 6-fluorochroman-2-carboxylate (2.0 g, 0.01 mol) in absolute ethanol (25 
ml) was cooled at 0-(-5)0c.To the cooled solution add hydrazine hydrate (4.0 ml, 0.08 
mol) and stir the reaction mixture at 0-(-5)0c for 10 hours. After the completion of the 
reaction (monitored by TLC). The white color solid separated was filtered and washed 
with cold ethanol and crystallized from ethanol. 
 
[C]   Preparation of Potassium 2-[(6-fluorochroman-2-yl)carbonyl] hydrazine     
carbodithioate. 
To a mixture of potassium hydroxide (8.40g, 0.15 mol) and 6- fluorochroman -2-
carbohydrazide (17.0 g, 0.1 mol) in methanol (50 ml), carbon disulphide (11.4g, 0.15 
mol) was added. This mixture was stirred for 22-24 hours at room temperature. Thus the 
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solid obtained was filtered and washed with diethyl ether and dried. There is no need to 
purify the salt for further reaction. 
 
[D]  Preparation of 4-Amino-5-(6-fluorochroman-2-yl)-4H- 
1,2,4-triazole-3-thiol. 
 A suspension of the potassium salt (24.5g, 0.1 mol), hydrazine hydrate (15 ml, 
0.3 mol) and water (5 ml) was refluxed with stirring for 30 hours. The color of the 
reaction mixture changed to green, hydrogen sulfide was evolved (lead acetate paper 
and odour) and a homogeneous solution was resulted. Dilute the solution with of cold 
water (100 ml) and neutralized with glacial acetic acid. Thus the white solid precipitates 
were formed. The product was filtered, washed with cold water and crystallized from 
dioxane yield 50%,  m.p.173 oC. 
 
[E] General procedure for the preparation of 3-(6-Fluorochroman-2-yl)-6-  
aryl-[1,2,4] triazolo [3,4-b][1,3,4]thiadiazoles. 
            A mixture of 4-amino-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-
thiol(2.26g,  0.01  mol) and different aryl acids (0.01 mol) in phosphorous oxychloride 
(15 ml) was refluxed with continuous stirring. After completion the reaction (15-16 hours 
monitoring by TLC), the content was cooled to room temperature then add ice cooled 
water and thus solid separated out was filtered, washed with water and neutralized 
with sodium bicarbonate solution.Crude product was purified by column 
chromatography to give the analytical pure compounds. The physical constants of the 
products are recorded in Table-6a. 
 
[F]  Biological evaluation of 3-(6-Fluorochroman-2-yl)-6-aryl-[1,2,4] 
triazolo [3,4-b][1,3,4]thiadiazoles. 
   Antimicrobial testing was carried out as described in Part-B, Part-I, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-6b. 
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Table-6a: Physical constant of 3-(6-Fluorochroman-2-yl)-6-aryl-[1,2,4] triazolo 
                 [3,4-b][1,3,4]thiadiazoles. 
 
O
F
N
N
N
N S
R  
 
Sr. 
No Substitution R M. F. M. W. Yield (%) Rf  value 
6a 
Cl
 
 
C18H12ClFN4OS
 
386.83 95 0.49 
6b 
O
O
 
 
C20H17FN4O3S 
 
412.43 79 0.31 
6c NH2
 
 
C18H14FN5OS 
 
367.40 87 0.59 
 
6d N
+
O
-
O
 
 
C18H12FN5O3S 
 
397.38 94 0.38 
6e 
NH2
 
 
C18H14FN5OS 
 
367.40 82 0.54 
 
6f Cl
 
 
C18H12ClFN4OS
 
386.83  81 
 
0.61 
6g 
Cl
 
 
C18H12ClFN4OS
 
386.83 74 0.51 
6h 
 
 
C19H15FN4OS 
 
366.41 72 0.41 
 
6i 
NH2
 
 
C18H14FN5OS 
 
367.40 86 0.68 
6j O
 
 
C19H15FN4O2S 
 
382.41 83 0.63 
                TLC solvent system:- E.A. : Hexane = 9 : 1 
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ANALYTICAL DATA 
6-(3-Chlorophenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
(6a). mp 150-154 °C; IR (DRS): 3073, 3031, 2957, 2847, 1625, 1462, 1442, 1325, 1258, 
1140, 1065, 1018, 825, 748, 701, 685 cm-1; 1H NMR (300 MHz, CDCl3): δ ppm 2.44-
2.48(m, 1H, 2CH), 2.74-2.76(m, 1H, 2CH), 3.04(m, 2H, 2CH), 5.66-5.68(m, 1H, CH), 
6.82-6.84(m, 3H, ArH), 7.48-7.50(d, J= 5.79 Hz, 1H, ArH), 7.56(m, 1H, ArH), 7.73-
7.75(d, J= 6.69 Hz, 1H, ArH), 7.90(s, 1H, ArH). 13C NMR (100 MHz, DMSO): δ ppm 
23.47, 23.83, 38.97, 68.33, 102.68, 107.14, 113.57, 113.80, 115.01, 115.24, 117.38, 
117.46, 122.81, 125.55, 126.44, 130.52, 130.92, 134.66, 146.13, 149.45, 161.22, 165.22, 
175.36; MS: m/z = 386 [M]+; Anal. Calcd for C18H12ClFN4OS: C, 55.89; H, 3.13; N, 
14.48. Found: C, 55.83; H, 3.04; N, 14.08%. 
6-(3,4-Dimethoxyphenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4] 
thiadiazole (6b). mp 119-121°C; IR (DRS): 3090(Ar, C-H str.), 3020(Ar, C-H str.), 
2935(C-H str.), 2839(C-H str.), 1637(Ar, C=C str.), 1492(Ar, C=C str.), 1440(C-H ben), 
1363(C-H ben), 1138(C-F str.), 1058(C-N str.), 1020(C-O-C str.), 810(C-H o,p, ben), 
756(C-H o,p, ben), 705(C-C o,p, ben), 680(C-C o,p, ben) cm-1; 1H NMR (400 MHz, 
DMSO): δ ppm 2.41-2.44(m, 1H, 2CH), 2.58-2.65(m, 1H, 2CH), 3.02-3.19(m, 2H, 2CH), 
3.90(s, 6H, OCH3, OCH3), 5.70-5.73(d,d, J= 4.4 Hz, 3.4 Hz, 1H, CH), 6.78-6.93(m, 3H, 
ArH), 7.09-7.11(d, J=8.44 Hz, 1H, ArH), 7.39(s, 1H, ArH), 7.49-7.51(d, J= 7.72 Hz, 1H, 
ArH). 13C NMR (100 MHz, DMSO): δ ppm 23.88, 38.92, 55.72, 68.23, 102.47, 108.96, 
111.54, 113.59, 113.81, 115.04,115.31, 117.47, 121.19, 122.98, 130.42, 130.80, 147.17, 
149.14, 152.65, 161.11, 166.12, 166.55, 175.12; MS: m/z = 412 [M]+; Anal. Calcd for 
C20H17FN4O3S: C, 58.24; H, 4.15; N, 13.58. Found: C, 58.18; H, 3.99; N, 13.49%. 
4-(3-(6-Fluorochroman-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazol-6-yl)aniline (6c). 
mp 168-170 °C; IR (DRS): 3422, 3378, 3030, 2964, 2853, 1642, 1612,  1581, 1471, 1368, 
1247, 1156, 1057, 1014, 819, 744, 710, 678 cm-1; MS: m/z = 367 [M]+; Anal. Calcd for 
C18H14FN5OS: C, 58.84; H, 3.84; N, 19.06. Found: C, 58.69; H, 3.78; N, 18.90%. 
3-(6-Fluorochroman-2-yl)-6-(4-nitrophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
(6d). mp 158-160°C; IR (DRS): 3074, 2987, 2851, 1645, 1612, 1585, 1468, 1345, 1184, 
1250, 1061, 1023, 820, 780, 744, 695, 566 cm-1; MS: m/z = 397 [M]+; Anal. Calcd for 
C18H12FN5O3S: C, 54.40; H, 3.04; N, 17.62. Found: C, 54.28; H, 2.93; N, 17.44%. 
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2-(3-(6-Fluorochroman-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)aniline (6e). 
mp 147-149 °C; IR (DRS): 3442, 3091, 3081, 2975, 2844, 1641, 1579, 1556, 1464, 1357, 
1242, 1145, 1088, 1017, 832, 750, 687 cm-1; MS: m/z = 367 [M]+; Anal. Calcd for 
C18H14FN5OS: C, 58.84; H, 3.84; N, 19.06. Found: C, 58.41; H, 3.78; N, 18.99%.   
6-(4-Chlorophenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
(6f). mp 116-118°C; IR (DRS): 3080, 2983, 2867, 1629, 1572, 1525, 1462, 1381, 1245, 
1196, 1046, 1011, 830, 778, 701, 665, 578 cm-1; MS: m/z = 386 [M]+; Anal. Calcd for 
C18H12ClFN4OS: C, 55.89; H, 3.13; N, 14.48. Found: C, 55.84; H, 2.97; N, 14.17%. 
6-(2-Chlorophenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 
(6g). mp 183-185 °C; IR (DRS): 3077, 2978, 2863, 1625, 1609, 1563, 1464, 1331, 1238, 
1142, 1038, 1014, 870, 832, 778, 668, 514 cm-1; MS: m/z = 386 [M]+; Anal. Calcd 
C18H12ClFN4OS: C, 55.89; H, 3.13; N, 14.48. Found: C, 55.67; H, 3.01; N, 14.21%. 
3-(6-Fluorochroman-2-yl)-6-(o-tolyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole (6h). mp 
160-162°C; IR (DRS): 3063, 2962, 2854, 1603, 1545, 1542, 1452, 1325, 1260, 1146, 
1060, 1023, 812, 754, 662, 518 cm-1; MS: m/z = 366 [M]+; Anal. Calcd for C19H15FN4OS: 
C, 62.28; H, 4.13; N, 15.29. Found: C, 62.19; H, 3.97; N, 15.24%. 
3-(3-(6-Fluorochroman-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)aniline (6i). 
mp 109-111°C; IR (DRS): 3428, 3392, 3075, 2964, 2853, 1721, 1601, 1581, 1423, 1371, 
1241, 1149, 1054, 1026, 888, 848, 766, 720, 665, 578 cm-1; MS: m/z = 367 [M]+; Anal. 
Calcd for C18H14FN5OS: C, 58.84; H, 3.84; N, 19.06. Found: C, 58.53; H, 3.71; N, 
18.90%. 
3-(6-Fluorochroman-2-yl)-6-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4] 
thiadiazole (6j). mp 224-226°C; IR (DRS): 3061, 2951, 2872, 1689, 1589, 1579, 1462, 
1354, 1208, 1135, 1099, 1003, 819, 755, 688 cm-1; MS: m/z = 382 [M]+; Anal. Calcd for 
C19H15FN4O2S: C, 59.67; H, 3.95; N, 14.65. Found: C, 59.08; H, 3.88; N, 14.62%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of 6-(3,4-Dimethoxyphenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo 
[3,4-b][1,3,4]thiadiazole(6b).
 
Mass spectrum of 6-(3-Chlorophenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazole(6a).
 
500750100012501500175020002500300035004000
1/cm
60
65
70
75
80
85
90
95
100
%T
30
90
.0
7
30
20
.6
3
29
35
.7
6
28
39
.3
1
17
24
.4
2
16
37
.6
2
16
18
.3
3
14
92
.9
5
14
65
.9
5
14
44
.7
3
13
63
.7
2
12
74
.9
9
11
38
.0
4
10
89
.8
2
10
58
.9
6
10
39
.6
7
10
20
.3
8
91
4.
29
81
0.
13
75
6.
12 7
05
.9
7
68
0.
89
4
PBV-103
m/z=386
O
F
N
N
N
N S
Cl
O
F
N
N
N
N S
O
O
 Studies on nitrogen containing heterocyclic…                
Thiadiazole derivatives...                                                                                                  138 
Mass spectrum of 6-(3,4-Dimethoxyphenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo 
[3,4-b][1,3,4]thiadiazole(6b). 
 
1H NMR spectrum of 6-(3-Chlorophenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo 
[3,4-b][1,3,4]thiadiazole(6a). 
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Expanded spectrum of 6-(3-Chlorophenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo 
[3,4-b][1,3,4]thiadiazole(6a).
 
1H NMR spectrum of 6-(3,4-Dimethoxyphenyl)-3-(6-fluorochroman-2-yl)-
[1,2,4]triazolo [3,4-b][1,3,4]thiadiazole(6b). 
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Expanded spectrum of 6-(3,4-Dimethoxyphenyl)-3-(6-fluorochroman-2-yl)-
[1,2,4]triazolo [3,4-b][1,3,4]thiadiazole(6b). 
 
Expanded spectrum of 6-(3,4-Dimethoxyphenyl)-3-(6-fluorochroman-2-yl)-
[1,2,4]triazolo [3,4-b][1,3,4]thiadiazole(6b). 
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13C NMR spectrum of 6-(3-Chlorophenyl)-3-(6-fluorochroman-2-yl)-[1,2,4]triazolo 
[3,4-b][1,3,4]thiadiazole(6a).
 
13C NMR spectrum of 6-(3,4-Dimethoxyphenyl)-3-(6-fluorochroman-2-yl)-
[1,2,4]triazolo [3,4-b][1,3,4]thiadiazole(6b). 
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ANTIMICROBIAL ACTIVITY 
Biological evaluation of 3-(6-fluorochroman-2-yl)-6-aryl-[1,2,4]  triazolo [3,4-
b][1,3,4]thiadiazoles. 
 All of the synthesized compounds (6a-j) were tested for their antibacterial and 
antifungal activity (MIC) in vitro by broth dilution method with two Gram-positive 
bacteria Staphylococcus aureus MTCC-96 and Streptococcus pyogenes MTCC 442, two 
Gram-negative bacteria Escherichia coli MTCC 443 and Pseudomonas aeruginosa 
MTCC 441 and three fungal strains Candida albicans MTCC 227, Aspergillus Niger 
MTCC 282 and Aspergillus clavatus MTCC 1323 taking gentamycin, ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin and greseofulvin as standard drugs. 
The standard strains were procured from the Microbial Type Culture Collection (MTCC), 
Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly synthesized 
compounds, defined as the lowest concentration of the compound preventing the visible 
growth, were determined by using micro dilution broth method according to NCCLS 
standards.38 
 
Minimal Inhibition Concentration [MIC] 
The main advantage of the Broth Dilution Method for MIC determination lies in 
the fact that it can readily be converted to determine the MIC as well. 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately subcultured (before 
inoculation) by spreading a loopful evenly over a quarter of plate of medium 
suitable for the growth of the test organism and put for incubation at 37 0C 
overnight.  
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
5. The amount of growth from the control tube before incubation (which represents 
the original inoculums) is compared.  
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Methods used for primary and secondary screening 
Each synthesized compounds were diluted in DMSO to obtain 2000 μg mL-1 
concentration, as a stock solution. Inoculum size for test str.ain was adjusted to 108 cfu 
(colony forming unit) per milliliter by comparing the turbidity. 
 
Primary screen: In primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 
concentrations of the synthesized compounds were taken. The active synthesized drugs 
found in this primary screening were further tested in a second set of dilution against all 
microorganisms.  
 
Secondary screen: The compounds found active in primary screening were similarly 
diluted to obtain 200 μg mL-1, 100 μg mL-1, 50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 
6.250 μg mL-1 concentrations.  
 
Reading Result: The highest dilution showing at least 99 % inhibition zone is taken as 
MIC. The result of this is much affected by the size of the inoculums. The test mixture 
should contain 108 organism/mL.     
 
                The results obtained from antimicrobial susceptibility testing are depicted in 
Table 6b. 
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Table-6b: Antimicrobial activity of 3-(6-Fluorochroman-2-yl)-6-aryl-[1,2,4]  
triazolo [3,4-b][1,3,4]thiadiazoles. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
6a 100 62.5 250 250 1000 >1000 >1000 
6b 250 250 250 200 >1000 >1000 >1000 
6c 125 100 250 100 >1000 >1000 >1000 
6d 200 200 100 200 1000 >1000 >1000 
6e 62.5 125 62.5 100 500 1000 1000 
6f 125 200 100 125 >1000 250 500 
6g 500 500 250 200 500 1000 1000 
6h 500 250 200 100 >1000 >1000 >1000 
6i 500 500 100 100 1000 250 250 
6j 250 500 250 250 500 500 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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STUDIES ON 1,3,4-OXADIAZOLE 
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INTRODUCTION  
Oxadiazoles belong to an important group of heterocyclic compounds 
having –N=C-O- linkage. It is well documented that oxadiazole system contains 
the following members which are numbered by designating the hetero atoms at 
particular position. 
 
N
N
O
N
O
N
N
O
N
N
O
N
(1) (2) (3) (4)  
 
1,3,4-Oxadiazole is a heterocyclic molecule with oxygen atom at 1 and two 
nitrogen atoms at 3 and 4 position. 1,3,4-Oxadiazole is a thermally stable aromatic 
molecule.1 They have been known for about 80 years it is only in the last decade 
that investigations in this field have been intensified. This is because of large number 
of applications of 1,3,4-oxadiazoles in the most diverse areas viz. drug 
synthesis, dye stuff industry, heat resistant materials, heat resistant polymers and 
scintillators. Reviews of the relevant literature prior to 1965 are available.2 
 
SYNTHETIC ASPECT 
Most 1,3,4-oxadiazoles are best obtained by synthesis from acyclic precursors. 
Such reactions are ‘one bond’ or ‘two bond’ cyclization. Different methods for the 
synthesis have been cited in literature.3-8  
1. B. Chandrakantha et al.9 have synthesized oxadiazoles by the reaction of hydrazide 
and aromatic acid in presence of POCl3. 
 
O
NH
O
NH2
F
O
F N
O
N
RPOCl3 + R-COOH
110 
o
C
 
 
2. D. Ramesh and B. Sreenivasan10 have synthesized 1,3,4-oxadiazoles  from 
semicarbazide in presense of POCl3. 
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NH N
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N
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3. K. Mogilaiah and B. Sakram11 have prepared 1,3,4-oxadiazoles from 
acetophenone-2-trifluoromethyl-1,8-naphthyridine-3-carbonyl hydrazone in 
presence of acetic anhydride. 
 
N N
NH
O
CF3
N
Ar
AC2O
N N CF3
N
O
N
O
Ar
 
 
4. Yu Yuve have reported microwave-assisted synthesis protocol of oxadiazoles with 91 
% of the yield.12 
 
R NH
O
NH2
R
1
O
OH O
N N
R R
1
POCl3
MW, 12 min
+
 
 
 
5. L. Somogyi13 have been synthesized 1,3,4-oxadiazoles  from several steps, from aryl 
hydrazides and aryl aldehydes. 
 
R
NH
O
NH2
R
1
O
Ac Cl
O
N N
R R
1+ +
 
 
 
6. Silica sulfuric acid catalyst used for the rapid and ecofriendly synthesis of 1,3,4-
oxadiazoles at ambient temperature reported by M. Dabiri et al.14 
 
R C(OEt)3 R
1
NH
O
NH2
O
N N
R R
1
Silica, H2SO4
MW,10min
+
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7. Green chemistry and one-pot, solvent-free using microwave mediated synthesis of 
1,3,4-oxadiazoles  were reported by V. Polshettiwar.15 
 
R C(OEt)3 R
1
NH
O
NH2 O
N N
R R
1
MW
80 
o
C, 10 min
+
 
 
8. A mild, general, convenient, and efficient one-pot synthesis of 2-phenyl-5-substituted-
1,3,4-oxadiazoles were reported by P. Stabile.16 
 
N
H
H
N
O
O
N N
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acetone, 400C
 
 
 
REACTION MECHANISM 
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THERAPEUTIC IMPORTANCE 
2,5-Disubstituted-1,3,4-oxadiazole derivatives have been tested for various 
pharmacological activities, which have been summarized as under. 
1. Antibacterial17   8.Antifungal24 
2. Antiinflammatory18   9.Cardiovacular25 
3. Analgesic19               10.Herbicidal26 
4. Antiviral and anticancer20             11.Hypoglycemic27 
5. Antihypertensive21              12.Hypnotic and Sedative28 
6. Anticonvulsant22              13.MAO inhibitor29 
7. Antiproliferative23              14.Insecticidal30 
 
 
 S. R. Bishnoi et al.31 have screened oxadiazoles for their antimicrobial activity. 
A. El-Azzouny et al.32 have synthesized 1,3,4-oxadiazole derivatives and evaluated for 
their analgesic, anti-inflammatory, ulcerogenic effects and inhibitory activity on 
plasma prostaglandin E2  (PGE2) Level. 
 S. V. Bhandari et al.33 have reported 1,3,4-oxadiazoles for their anti-
inflammatory activity. Song Cao et al.34 have investigated some oxadiazoles possessing 
insecticidal activity. G. V. Suresh Kumar et al.35 have discovered oxadiazole derivatives 
and reported their antimycobacterial activity. Ali Almasired et al.36 have prepared 1,3,4- 
oxadiazoles of type as anticonvulsant agent. Meria Grazia Mamolo et al.37 have 
synthesized 3-substituted-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-ones of type and 
studied their antimycobacterial activity. 
 
 
 
 
 
Krishna Kant Jha et al.38 have reported antimicrobial activity of oxadiazole 
derivatives. J. A. Christopher et al.39 have documented human immunodeficiency virus 
O
N N
O
NH2
F
N
O
N N
X
O
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(HIV) infection of 1,3,4-oxadiazole derivatives. S. J. Gilani et al.40 have synthesized 
some oxadiazoles as anti-inflammatory and analgesic agents. K. Subrahmanya Bhat et 
al.41 have prepared new fluorine containing 1,3,4-oxadiazoles  and reported them as 
potential antibacterial and anticancer agents. T. P. Mohan et al.42 have synthesized 
2,5-disubstituted-1,3,4-oxadiazole derivatives and screened for their insecticidal 
activity. 
 
O
CH3 CH2
O
N N
R
N
O
N
ClCl
F R
 
 
 Ronald Kim et al.43 have discovered oxadiazole derivatives useful as protease 
inhibitors. Mohd Amir and Kumar Shikha44  have documented anti-inflammatory, 
analgesic and ulcerogenic activity of some newly synthesized oxadiazoles. A. Ali et 
al.45 have investigated some oxadiazole derivatives possessing antimicrobial and 
anti-HIV-1 activity. A. Sherif et al.46 have reported oxadiazoles as potential 
antitumor and anti-HIV agents. A. Zarghi et al.47 have synthesized R-substituted-5-
(2-benzyloxyphenyl)-1,3,4-oxadiazoles possessing anticonvulsant activity. M. Tareq et 
al.48 have synthesized 2,5-disubstituted-1,3,4-oxadiazoles useful as tyrosinase 
inhibitors.  
 
N
O
N
NH2
O
F
N
O
N
Br
N
 
 
Kiselyov et al.49 have synthesized novel derivatives of 1,3,4-oxadiazoles as potent 
mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin 
embryo and cell culture assays. 
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Work done from our laboratory 
K. M. Thaker50 have synthesized 2-(3',5'-dichlorobenzo[b]thiophen-2'-yl)-5-
aryl-1,3,4-oxadiazoles in the presence of aromatic acid. S. L. Vasoya51 reported facile 
synthesis of some new acetyl oxadiazoles bearing benzo[b]thiophene nucleus as a 
potent biological active agent. Preparation and antimicrobial activity of 2-aryl-5-(5',7'-
diiodo-8'-quinolinoxy)-1,3,4-oxadiazoles have been reported by H. S. Joshi.52  
Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
under taken the synthesis of several oxadiazoles which has been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF  
                     2-(6-FLUOROCHROMAN-2-YL)-5-ARYL-1,3,4-OXADIAZOLES. 
 
 
 
 
 
 
 
 
 
 
 
 
Part – B 
[Part – II (Section-i)] 
 
Synthesis and biological evaluation of 2-
(6-fluorochroman-2-yl)-5-aryl-1,3,4-
oxadiazoles. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-(6-FLUORO-
CHROMAN-2-YL)-5-ARYL-1,3,4-OXADIAZOLES. 
Synthesis of 1,3,4-oxadiazole derivatives has attracted considerable attention 
in view of therapeutic applications. Looking to this, the synthesis of 1,3,4-
oxadiazoles was undertaken by the condensation of different aromatic acid with 6-
fluorochroman-2-carbohydrazide in presence of phosphorous oxychloride, as shown 
in reaction scheme.    
 
REACTION SCHEME 
 
O
F
O
NH
NH2
R-COOH
POCl3
OF
N
O
N
R(Type II) R=Aryl  
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 solution on a Bruker 
AC 400 MHz and 100 MHz spectrometer. Elemental analysis of the all the synthesized 
compounds were carried out on Euro EA 3000 elemental analyzer and the results are in 
agreements with the structures assigned.  
 
[A]       Synthesis of   6-Fluorochroman-2-carbohydrazide. 
 See PART-B, part-I, section-I [B]. 
 
[B]  General procedure for the preparation of 2-(6-Fluorochroman-2-yl)-5-aryl-
1,3,4-oxadiazoles. 
A mixture of 6-fluorochroman-2-carbohydrazide (2.0 g, 0.01mol) and different 
aryl acids (0.01mol) in phosphorous oxychloride (10 ml) was refluxed with continuous 
stirring. After completion of the reaction (13-15 hours monitoring by TLC), the content 
was cooled to room temperature then add ice cooled water and neutralized with sodium 
bicarbonate solution. Then the mixture was by extracted into ethyl acetate. The organic 
extracts was washed with water (2 x 10 ml), dried with Na2SO4, solvent was removed in 
vacuo and the resulting crude product was purified by column chromatography to give the 
analytical pure compound. The physical constants of the products are recorded in Table-
7a. 
 
[C]      Biological evaluation of 2-(6-Fluorochroman-2-yl)-5-aryl-1,3,4-oxadiazoles. 
           Antimicrobial testing was carried out as described in Part-B, Part-II, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-7b. 
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Table-7a: Physical constant of 2-(6-Fluorochroman-2-yl)-5-aryl-1,3,4-oxadiazoles. 
 
O
F
N
O
N
R  
 
Sr. 
No Substitution R M. F. M. W. Yield (%) Rf  value 
7a O
 
 
C18H15FN2O3 
 
326.32 94 0.47 
7b 
 
 
C18H15FN2O2 
 
310.32 88 0.39 
7c NH2
 
 
C17H14FN3O2 
 
311.31 77 0.52 
 
7d 
 
 
C18H15FN2O2 
 
310.32 91 0.42 
7e 
NH2
 
 
C17H14FN3O2 
 
311.31 89 0.50 
 
7f Cl
 
 
C17H12ClFN2O2
 
330.74  72 
 
0.59 
7g N
+
O
-
O
 
 
C17H12FN3O4 
 
341.29 76 0.41 
7h 
Cl
 
 
C17H12ClFN2O2
 
330.74 78 0.38 
 
7i 
NH2
 
 
C17H14FN3O2 
 
311.31 83 0.67 
7j 
Cl
 
 
C17H12ClFN2O2
 
330.74 79 0.62 
 
              TLC solvent system:- E.A. : Hexane = 7 : 3 
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ANALYTICAL DATA 
2-(6-Fluorochroman-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole (7a). mp 140-142 
°C; IR (DRS): 3028, 2974, 2943, 2841, 1616, 1558, 1425, 1303, 1259, 1174,1080,1024, 
873, 819, 798, 736, 636, 570 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 2.42-2.51(m, 2H, 
2CH), 2.96-2.99(t, 2H, 2CH), 3.88(s, 3H, OCH3), 5.39-5.42(d,d, J=3.76 Hz, 3.68 Hz, 1H, 
CH), 6.79-6.87(m, 3H, ArH), 6.99-7.01(d, J=8.8 Hz, 2H, ArH), 7.99-8.01(d, J=8.76 Hz, 
2H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 23.59, 24.86, 44.20, 55.49, 68.80, 114.34, 
114.50, 114.57, 115.36, 115.58, 116.06, 117.96, 118.04, 122.35, 122.43, 128.90, 149.31, 
149.33,156.08, 158.46, 162.53, 164.06, 165.46; MS: m/z = 326 [M]+; Anal. Calcd for 
C18H15FN2O3: C, 66.25; H, 4.63; N, 8.58. Found: C, 66.10; H, 4.56; N, 8.30%. 
2-(6-Fluorochroman-2-yl)-5-(p-tolyl)- 1,3,4-oxadiazole (7b). mp 110-112°C; IR (DRS): 
3036(Ar, C-H str.), 2955(C-H str.), 2922(C-H str.), 2852(C-H str.), 1616(Ar, C=C str.), 
1570(Ar, C=C str.), 1496(Ar, C=C str.), 1390(C-H ben), 1263(C-H ben), 1178(C-F str.), 
1139(C-F str.), 1080(C-N str.), 1016(C-O-C str.), 821(C-H o,p, ben), 767(C-H o,p, ben), 
729(C-H o,p, ben), 700(C-C o,p, ben), 561(C-C o,p, ben) cm-1; 1H NMR (400 MHz, 
CDCl3): δ ppm 2.35-2.44(m, 5H, 2CH, 3CH), 2.88-2.91(t, 2H, 2CH), 5.32-5.35(d,d,  
J=3.76 Hz, 3.72 Hz, 1H, CH), 6.72-6.80(m, 3H, ArH), 7.22-7.24(d, J=7.96 Hz, 2H, ArH), 
7.86-7.88(d, J= 8.08 Hz, 2H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 14.15, 21.68, 
22.71, 23.58, 24.87, 29.38, 29.68, 29.72, 31.95, 44.20, 68.80, 114.34, 114.58, 115.36, 
115.58, 117.97, 118.05, 120.80, 122.34, 122.42, 127.07, 129.79, 142.61, 149.29, 149.31, 
156.09, 158.46, 164.30, 165.66; MS: m/z = 310 [M]+; Anal. Calcd for C18H15FN2O2: C, 
69.67; H, 4.87; N, 9.03. Found: C, 69.18; H, 4.80; N, 8.93%. 
4-(5-(6-Fluorochroman-2-yl)-1,3,4-oxadiazol-2-yl)aniline (7c). mp 138-140 °C; IR 
(DRS): 3452, 3403, 3030, 2964, 2853, 1642, 1612, 1581, 1471, 1378, 1245, 1156, 1077, 
1025, 878, 819, 788, 721, 698, 558 cm-1; MS: m/z = 311 [M]+; Anal. Calcd for 
C17H14FN3O2: C, 65.59; H, 4.53; N, 13.50. Found: C, 65.57; H, 4.29; N, 13.44%. 
2-(6-Fluorochroman-2-yl)-5-(O-tolyl)-1,3,4-oxadiazole (7d). mp 114-116 °C; IR 
(DRS): 3074, 2987, 2851, 1645, 1612, 1585, 1468, 1325, 1281, 1184, 1077, 1034,820, 
745, 696, 545 cm-1; MS: m/z = 310 [M]+; Anal. Calcd for C18H15FN2O2: C, 69.67; H, 
4.87; N, 9.03. Found: C, 69.28; H, 4.83; N, 8.98%. 
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2-(5-(6-Fluorochroman-2-yl)-1,3,4-oxadiazol-2-yl)aniline (7e). mp 161-163 °C; IR 
(DRS): 3419, 3371, 3081, 2975, 2844, 1641, 1579, 1556, 1464, 1362, 1232, 1176, 1060, 
1004, 810, 756,  592 cm-1; MS: m/z = 311 [M]+; Anal. Calcd for C17H14FN3O2: C, 65.59; 
H, 4.53; N, 13.50. Found: C, 65.41; H, 4.45; N, 13.39%.       
2-(4-Chlorophenyl)-5-(6-fluorochroman-2-yl)-1,3,4-oxadiazole (7f). mp 105-107°C; 
IR (DRS): 3080, 2983, 2867, 1629, 1572, 1525, 1462, 1245, 1196, 1079, 1017,  830 cm-1; 
MS: m/z = 330 [M]+; Anal. Calcd for C17H12ClFN2O2: C, 61.73; H, 3.66; N, 8.47. Found: 
C, 61.63; H, 3.58; N, 8.43%. 
2-(6-Fluorochroman-2-yl)-5-(4-nitrophenyl)-1,3,4-oxadiazole (7g). mp 133-135 °C; IR 
(DRS): 3077, 2978, 2863, 1625, 1609, 1563, 1464, 1384, 1238, 1142, 1058, 1022, 870, 
798, 732, 687, 603  cm-1; MS: m/z = 341 [M]+; Anal. Calcd C17H12FN3O4: C, 59.83; H, 
3.54; N, 12.31. Found: C, 59.77; H, 3.40; N, 12.21%. 
2-(2-Chlorophenyl)-5-(6-fluorochroman-2-yl)-1,3,4- oxadiazole (7h). mp 173-175°C; 
IR (DRS): 3012, 2962, 2854, 1603, 1545, 1542, 1452, 1345, 1260, 1146, 1082,  1010, 
888, 825, 777, 731, 634, 512 cm-1; MS: m/z = 330 [M]+; Anal. Calcd for C17H12ClFN2O2: 
C, 61.73; H, 3.66; N, 8.47. Found: C, 61.65; H, 3.57; N, 8.34%. 
3-(5-(6-Fluorochroman-2-yl)-1,3,4–oxadiazol-2-yl)aniline (7i). mp 169-171°C; IR 
(DRS): 3443, 3401, 3075, 2964, 2853, 1721, 1601, 1581, 1423, 1392, 1228, 1149, 1054, 
1013, 799, 720, 666 cm-1; MS: m/z = 311 [M]+; Anal. Calcd for C17H14FN3O2: C, 65.59; 
H, 4.53; N, 13.50. Found: C, 65.25; H, 4.47; N, 13.37%. 
2-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-1,3,4-oxadiazole (7j). mp 181-183°C; 
IR (DRS): 3061, 2951, 2872, 1689, 1589, 1579, 1462, 1310, 1288, 1175, 1099, 1012, 
798, 755, 678 cm-1; MS: m/z = 330 [M]+; Anal. Calcd for C17H12ClFN2O2: C, 61.73; H, 
3.66; N, 8.47. Found: C, 61.08; H, 3.61; N, 8.41%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of 2-(6-Fluorochroman-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole 
(7a).
 
IR Spectrum of 2-(6-Fluorochroman-2-yl)-5-(p-tolyl)-1,3,4-oxadiazole(7b).
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Mass spectrum of 2-(6-Fluorochroman-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole 
(7a).
 
Mass spectrum of 2-(6-Fluorochroman-2-yl)-5-(p-tolyl)- 1,3,4-oxadiazole (7b).
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1H NMR spectrum of 2-(6-Fluorochroman-2-yl)-5-(4-methoxyphenyl)-1,3,4-
oxadiazole(7a).
 
Expanded spectrum of 2-(6-Fluorochroman-2-yl)-5-(4-methoxyphenyl)-1,3,4-
oxadiazole(7a). 
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Expanded spectrum of 2-(6-Fluorochroman-2-yl)-5-(4-methoxyphenyl)-1,3,4-
oxadiazole(7a). 
 
1H NMR spectrum of 2-(6-Fluorochroman-2-yl)-5-(p-tolyl)- 1,3,4-oxadiazole (7b).
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Expanded spectrum of 2-(6-Fluorochroman-2-yl)-5-(p-tolyl)- 1,3,4-oxadiazole (7b). 
 
 
Expanded spectrum of 2-(6-Fluorochroman-2-yl)-5-(p-tolyl)- 1,3,4-oxadiazole (7b). 
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13C NMR spectrum of 2-(6-Fluorochroman-2-yl)-5-(4-methoxyphenyl)-1,3,4-
oxadiazole(7a).
 
13C NMR spectrum of 2-(6-Fluorochroman-2-yl)-5-(p-tolyl)- 1,3,4-oxadiazole (7b).
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Table-7b: Antimicrobial activity of 2-(6-Fluorochroman-2-yl)-5-aryl-1,3,4-
oxadiazoles. 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
7a 500 250 62.5 125 500 500 1000 
7b 200 250 125 100 >1000 500 500 
7c 250 500 200 62.5 >1000 250 500 
7d 125 250 100 200 500 1000 >1000 
7e 250 250 250 250 250 500 500 
7f 200 125 200 100 1000 >1000 >1000 
7g 500 250 100 100 500 >1000 >1000 
7h 125 125 200 125 1000 >1000 >1000 
7i 100 100 125 200 1000 >1000 >1000 
7j 200 200 250 250 >1000 500 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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INTRODUCTION 
 
1,2,4-Triazoles have proved to be most useful framework for biological  
activities among nitrogen containing five membered heterocycles. In five membered 
heterocyclic ring system 4-aryl triazole (I) have three nitrogen atoms at 1,2 and 4 
positions, an aryl group at 4-position and free mercapto group at 3-position. 
 
N
N N
SHX
R
1 2
3
4
5
 
 
SYNTHETIC ASPECT 
 
    Several methods have been reported in the literature for the preparation of 4- 
aryl triazoles. 
 
1.  A.R.Katritzky et al.1 have synthesized 4- aryltriazoles by the cyclization of   
semicarbazide. 
 
 
O
NH
N
NHR
N
N N
R
2
R1  
 
2. K. Zamani et al.
2  synthesized 4-aryltriazole from thiosemicarbazide by ring 
        closure reaction with 2N NaOH. 
 
N
O
NH
NH
S
NH
N
2 NaOH N N
N SH
 
 
3. T. Plech et al.3 have synthesized   s-triazoles  by the reaction of 3- chlorobenzoic 
acid hydrazide, arylisothiocyanates and 1-[(3- chrophenyl) carbonyl]-4-sustituted 
thisemicarbazides. The reaction was complete in short time. Which on alkaline 
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cyclization with  2%  solution of  soduim hydroxide afforded the corresponding 5- 
(3- chrophenyl)-4- substituted-2,4- dihydro-3H-1,2,4-triazole-3-thiones. 
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4. S.Shelke et al.4 have synthesized some novel azoles as antimicrobial agents.Thio-
semicarbazides (2) have been prepared from acid hydrazide (1), and fluorinated 
aryl isothiocynates. Thiosemicarbazides (2) in 1% NaOH to gave compounds (3). 
with 72-88% yield under green technique. 
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5. R.J.Singh et al.5 have novel synthesized of some 1,2,4- triazoles as potent 
bacteriocidal agents with the reaction of 4- methyl phenyl amine, carbon 
disulphide and ammonia  in the methanol as a solvent and leadnitrate as a 
catalyst and compound (1) was obtained.Pyridine carboxylic acid 
hydrazides(a-c) were react with 4-methylphenylisotiocyanate in the presence 
of ethanol to give compound (2a-c) which on reaction with 2M sodium 
hydroxide solution to give final compounds (3a-c) with higer yield (75-
85%). 
 
NH2
CS2/NH3/Pb(NO3)2
NCS
+
N
a. 2-pyridil
b. 3-pyridil
c. 4-pyridil
N
NaOHN N
N N
SH
1
(2a-c)(3a-c)
O
NH
NH
S
NH
O
NH
NH2
 
 
6. G. Naganagowda et al.6 have been synthesized 5-substituted-4-aryl-3-mercapto-
4h-1,2,4-triazoles. The compound (1) was treated with hydrazine hydrate to 
obtaine-3-chloro-1-benzothiophene-2-carbohydrazide(2) in good yield.Then 
condensation of carbo hydrazide (2) with  aryl isothiocyanates separately afforded 
thiosemicarbazides (3) in good yields. Then the compounds 3a-b upon heating 
with 4N NaOH in ethanol underwent smooth cyclization through dehydration to 
form 5-substituted-4-aryl-3-mercapto-4H-1,2,4-triazoles (4). 
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7.  I. Khan et al.7 have been synthesized some new 1,2,4- triazoles with 
antioxidant activities and urease inhibition.Substituted aromatic esters 
(2)were synthesized by the reaction of corresponding acids(1) with methanol 
in the presence of catalyitic amount of sulfuric acid. Esters(2) were 
converted to the corresponding acid hydrazides(3)  by refluxing with 
hydrazine (80%) and phenylisothiocyanates(4) in methanol and obtained 
carbothioamides (5). Then compounds (6) were synthesized by 
intramolecular dehydrative cyclization of carbothioamides(5) when refluxed 
in 4N NaOH solution , followed by neutralization with concentrated HCl. 
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REACTION MECHANISM 
 
 
 
 
THERAPEUTIC IMPORTANCE 
4-Aryltriazoles are reported to exhibit a wide variety of biological 
activities such as, 
1.  Antiinflammatory
8
 
2.   Biocides 
9 
3.  Cholesteryl ester transfer protein 
10
 
4.  Antidepressant 11 
 
Chang et al.
12 have synthesized aryltriazoles and reported them as antifungal 
drugs. O. Crisan et al.
13 
have screened antiinflammatory activity of triazoles. 
A.Varvaresou et al.
14 have synthesized triazoles and reported their antimicrobial 
potency and antidepressant activities. Papakonstantinou et al.15 have investigated 
some triazole derivatives possessing significant antiviral activity. T. Konosu and 
co-workers 16   have prepared aryltriazoles as fungicides. 
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N N N
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N.Yasuda et al.
17 have discovered aryltriazoles which have been 
extensively investigated for their antibacterial properties. S.C. Bahel et al.
18 have 
documented anti- fungal activity of aryl triazoles. Athansia varvaresou et al.
19 have 
synthesized aryltriazoles possessing antidepressant activity. Chu. Changhu et al.
20   
have screened 4-aryltriazoles for their antifungal activity. 
 
N
N N N
N
NH
SAr
- O
OH  
 
 
Some aryltriazoles possessing analgesic and diuretic activities have been 
synthesized by Shrivastava S.K. et al.
21 Wang Sheng et al.
22 have reported triazoles 
as herbicidal agents. 
R.F. Lowe and co-workers
23 
have reported aryltriazoles as useful 
antagonists. B.Holla et al.
24 have documented anticancer activity of aryltriazoles. 
Welsh et al. 
25 have discovered aryltriazoles and reported them as analgesic agents. 
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 R.J. Singh et al.
5
 synthesized some novel   1,2,4-Triazoles as potent bacteriocidal 
agents 
 
N N
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G.Naganagowda et al.
6 
have synthesized of some new 3- 
chlorobenzothiophene-2-carbonylchloride derivatives which shown good activities like 
antimicrobial and anthelmintic. 
S
Cl
N
N
N
SH
R1  
 
G. Parameshwarappa et al.
26
 have been synthesized 5- bromo-3-amino 
benzofuran nucleus from 5- bromosalicylonitrile which was the shown a good activities 
of anti-microbial. 
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 A.A. Siddiqui et al.
27
 have designed, synthesized and screened in vivo triazole 
incorporated with pyridazinones as a new class of antihypertensive agents. 
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S. Shelke et al.
4
 have discovered green synthesis of some novel azoles as 
antimicrobial agents. 
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M. D. Grandi et al.
28
 have synthesized 3,4,5- substituted triazoles derivatives as 
inhibitors of HIV RT Ribonuclease H 
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Work done from our laboratory 
S.L.Vasoya
29 have synthesized some new thiosemicarbazide and 1,2,4-
triazoles heterocycles bearing the benzo[b]thiophene nucleus as potent antituberculer 
and antimicrobial agents. 
 In light of wide varieties of therapeutic activities exhibited by aryl triazole, 
we have embarked upon the synthesis of some new aryl triazole derivatives which 
have been described in following sections. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 5-( 6-
FLUOROCHROMAN-2-YL)-4-ARYL-4H -1,2,4 TRIAZOLE-
3- THIOLS. 
 
 
 
 
  
Part – B 
[Part – III (Section-i)] 
 
Synthesis and biological evaluation of 5-
(6-fluorochroman-2-yl)-4-aryl-4H-1,2,4 
- triazole-3-thiols  
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SECTION-I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-(6-FLUORO 
CHROMAN-2-YL)-4-ARYL-4H -1,2,4-TRIAZOLE-3- THIOLS. 
 
4-Aryltriazole derivatives are associated with broad spectrum of 
pharmacological activity. In views of these findings, it appeared of interest to 
synthesize 5-(6-fluorochroman-2-yl)-4-aryl-4H-1,2,4-triazole-3-thiols. The 
synthesis of triazole derivatives of  type (III)  have  been  undertaken  by  
heating dry potassium 2-[(6-fluorochroman-2-yl)carbonyl]hydrazine   carbodithioate  
with different aromatic amines. 
 
REACTION SCHEME 
 
 
O
F
O
NH
NH S
S
K
R-NH2
O
F
N
N
R SH
(Type III) R=Aryl
+
-
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 and DMSO solution 
on a Bruker AC 300 MHz, 400 MHz and 100MHz spectrometer. Elemental analysis of 
the all the synthesized compounds were carried out on Euro EA 3000 elemental analyzer 
and the results are in agreements with the structures assigned.  
 
[A] Preparation of Potassium 2-[(6-fluorochroman-2-yl) carbonyl]     
            Hydrazinecarbodithioate 
            See PART-B, part-I, section-I [C]. 
 
[B]    General procedure for the preparation of   5-(6-Fluorochroman-2-yl)-4- 
           aryl-4H-1,2,4-triazole-3-thiols. 
A mixture of potassium 2-[(6-fluorochroman-2-yl) carbonyl] hydrazine 
carbodithioate (2.85g, 0.01M) and different aromatic amines (0.01M) was heated at 
140-150oC until the evolution of H2S gas ceased (15 hours.). The product was 
dissolved in DMF (20ml), treated with dilute HCl and then poured in to crushed ice. 
The product was i s o l a t e d  a n d  crystallized from ethanol. The physical constants of the 
products are recorded in Table-8a. 
 
[C]     Biological evaluation of   5-(6-Fluorochroman-2-yl)-4-aryl-4H-  
   1,2,4-triazole-3-thiols. 
 Antimicrobial testing was carried out as described in Part-B, Part-III, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-8b. 
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Table-8a: Physical constant of 5-(6-Fluorochroman-2-yl)-4-aryl-4H-1,2,4- 
     triazole-3-thiols. 
 
 
 
Sr. 
No Substitution R M. F. M. W. Yield (%) Rf  value 
8a CH3
 
 
C18H16FN3OS 
 
341.40 89 0.62 
8b 
Cl 
 
C17H13ClFN3OS 
 
361.82 86 0.42 
8c F
 
 
C17H13F2N3OS 
 
345.36 78 0.37 
 
8d 
CH3
CH3
 
 
C19H18FN3OS 
 
355.42 95 0.51 
8e 
CH3
CH3
 
 
C19H18FN3OS 
 
355.42 84 0.59 
 
8f 
F  
 
C17H13F2N3OS 
 
345.36  79 
 
0.69 
8g 
Cl
 
 
C17H13ClFN3OS 
 
361.82 76 0.44 
8h 
Cl
F
 
 
C17H12ClF2N3OS
 
379.81 87 0.31 
 
8i O
CH3  
 
C18H16FN3O2S 
 
357.40 90 0.58 
8j 
F
F
 
 
C17H12F3N3O2S 
 
363.35 75 0.70 
  TLC solvent system:- E.A. : Hexane = 5 : 5 
 
O
F
N
N
N
SHR
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ANALYTICAL DATA 
5-(6-Fluorochroman-2-yl)-4-(p-tolyl)-4H-1,2,4-triazole-3-thiol (8a). mp 170-172 °C; 
IR (DRS): 3076, 3039, 2924, 2862, 2773, 2731, 1735, 1699, 1637, 1514, 1429, 1319,  
1138, 916,871, 815, 767, 694 cm-1; 1H NMR (300 MHz, CDCl3): δ ppm 2.02-2.44 (m, 
5H, 2CH, 3CH), 2.65-2.96(m, 2H, 2CH), 4.83-4.90(d,d, J=12.6 Hz, 6 Hz, 1H, CH), 6.60-
6.69( m, 1H, ArH), 6.73-6.76(m, 2H, ArH), 7.05-7.49(m, 4H, ArH), 11.43(s, 1H, SH). 
13C NMR (100 MHz, DMSO): δ 22.87, 22.99, 38.96, 67.72, 113.50, 113.73, 114.98, 
115.20, 117.18, 117.26, 122.83, 122.91, 127.92, 129.50, 130.83, 139.07, 148.95, 149.89, 
161.80, 168.76; MS: m/z = 341 [M]+; Anal. Calcd for C18H16FN3OS: C, 63.32; H, 4.72; 
N, 12.31. Found: C, 63.23; H, 4.41; N, 12.28%. 
4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol (8b). mp 205-
207°C; IR (DRS): 3066(Ar, C-H str.), 2914(C-H str.), 2850(C-H str.), 2777(-SH str.), 
2533(-SH str.), 1680(Ar, C=C str.), 1647(Ar, C=C str.), 1558(Ar, C=C str.), 1494(Ar, 
C=C str.), 1375(C-Hben), 1203(C-Cl str.), 1101(C-F str.), 1087(C-N str.), 1072(C-N str.), 
1041(C-O-C str.), 815(C-H o,p, ben), 769(C-H o,p, ben), 707(C-C o,p, ben), 663(C-C o,p, 
ben), 511(C-C o,p, ben)cm-1; 1H NMR (400 MHz, DMSO): δ ppm 2.27-2.30(m, 2H, 
2CH), 2.82-2.95(m, 2H, 2CH), 4.92-4.95(d,d, J=6.12 Hz, 12 Hz, 1H, CH), 6.50-6.54(m, 
1H, ArH), 6.75-6.79( m, 2H, ArH),  7.41-7.43( m, 1H, ArH), 7.53-7.55( m, 3H, ArH), 
14.0 (s, 1H, SH). 13C NMR (100 MHz, DMSO): δ ppm 22.69, 22.85, 38.95, 67.74, 
102.75, 108.64, 113.53, 115.05, 117.14, 118.18, 122.91, 127.17, 128.52, 129.64, 130.44, 
133.33, 134.77, 140.63, 143.11, 148.80, 149.67, 161.90, 168.71; MS: m/z = 361 [M]+; 
Anal. Calcd for C17H13ClFN3OS: C, 56.43; H, 3.62; N, 11.61. Found: C, 56.18; H, 3.49; 
N, 11.59%. 
5-(6-Fluorochroman-2-yl)-4-(4-fluorophenyl)-4H-1,2,4-triazole-3-thiol (8c). mp 188-
190 °C; IR (DRS): 3030, 2964, 2853, 2658, 1642, 1612, 1581, 1471, 1378, 1225, 1156, 
1045, 819, 777, 696, 513, cm-1; MS: m/z = 345 [M]+; Anal. Calcd for C17H13F2N3OS: C, 
59.12; H, 3.79; N, 12.17. Found: C, 59.02; H, 3.53; N, 12.01%. 
4-(2,5-Dimethylphenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol (8d). mp 
123-125°C; IR (DRS): 3074, 2987, 2851, 2710, 1645, 1612, 1585, 1468, 1330, 1281, 
1184, 1074, 820, 766, 692, 587 cm-1; MS: m/z = 355 [M]+; Anal. Calcd for C19H18FN3OS: 
C, 64.21; H, 5.10; N, 11.82. Found: C, 64.16; H, 4.93; N, 11.78%. 
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4-(3,4-Dimethylphenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol (8e). mp 
163-165 °C; IR (DRS): 3081, 2975, 2844, 2687, 1641, 1579, 1556, 1464, 1378, 1282, 
1142, 1023, 887, 750, 687, 555 cm-1; MS: m/z = 355 [M]+; Anal. Calcd for C19H18FN3OS: 
C, 64.21; H, 5.10; N, 11.82. Found: C, 64.09; H, 5.03; N, 11.50%.   
5-(6-Fluorochroman-2-yl)-4-(2-fluorophenyl)-4H-1,2,4-triazole-3-thiol (8f). mp 108-
110°C; IR (DRS): 3080, 2983, 2867, 2661, 1629, 1572, 1525, 1462, 1341, 1245, 1196, 
1094, 830, 774, 682, 575 cm-1; MS: m/z = 345 [M]+; Anal. Calcd for C17H13F2N3OS: C, 
59.12; H, 3.79; N, 12.17. Found: C, 58.96; H, 3.67; N, 12.06%. 
4-(2-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol  (8g). mp 192-
194 °C; IR (DRS): 3077, 2978, 2863, 2712, 1625, 1609, 1563, 1464, 1310, 1238, 1142, 
1044, 870, 798, 756, 656, 544 cm-1; MS: m/z = 361 [M]+; Anal. Calcd C17H13ClFN3OS: 
C, 56.43; H, 3.62; N, 11.61. Found: C, 55.97; H, 3.55; N, 11.59%. 
4-(3-Chloro-4-fluorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol (8h). 
mp 139-141°C; IR (DRS): 3031, 2962, 2854, 2691, 1603, 1545, 1542, 1452, 1332, 1260, 
1146, 1042, 878, 831, 778, 631, 542 cm-1; MS: m/z = 379 [M]+; Anal. Calcd for 
C17H12ClF2N3OS: C, 53.76; H, 3.18; N, 11.06. Found: C, 53.69; H, 3.07; N, 10.90%. 
5-(6-Fluorochroman-2-yl)-4-(2-methoxyphenyl)-4H-1,2,4-triazole-3-thiol (8i). mp 
251-253°C; IR (DRS): 3075, 2964, 2853, 2711, 1721, 1601, 1581, 1423, 1355, 1281, 
1149, 1075, 740, 602 cm-1; MS: m/z = 357 [M]+; Anal. Calcd for C18H16FN3O2S: C, 
60.49; H, 4.51; N, 11.76. Found: C, 60.39; H, 4.29; N, 11.37%. 
4-(2,5-Difluorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol (8j). mp 
229-231°C; IR (DRS): 3061, 2951, 2872, 2635, 1689, 1589, 1579, 1462, 1352, 1099, 831, 
755, 621, 510 cm-1; MS: m/z = 363 [M]+; Anal. Calcd for C17H12F3N3O2S: C, 56.19; H, 
3.33; N, 11.56. Found: C, 56.06; H, 3.14; N, 11.32%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of 5-(6-Fluorochroman-2-yl)-4-(p-tolyl)-4H-1,2,4-triazole-3-thiol (8a). 
 
IR Spectrum of 4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-
thiol (8b). 
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Mass spectrum of 5-(6-Fluorochroman-2-yl)-4-(p-tolyl)-4H-1,2,4-triazole-3-thiol 
(8a).
 
Mass spectrum of 4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-
thiol (8b).
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1H NMR spectrum of 5-(6-Fluorochroman-2-yl)-4-(p-tolyl)-4H-1,2,4-triazole-3-thiol 
(8a).
 
Expanded spectrum of 5-(6-Fluorochroman-2-yl)-4-(p-tolyl)-4H-1,2,4-triazole-3-thiol 
(8a).
 
O
F
N
N
N
SH
 
Studies on nitrogen containing heterocyclic… 
Aryltriazole derivatives….   185 
 
1H NMR spectrum of 4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-
triazole-3-thiol(8b).
 
Expanded spectrum of 4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-
triazole-3-thiol(8b). 
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Expanded spectrum of 4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-
triazole-3-thiol(8b). 
 
13C NMR spectrum of 5-(6-Fluorochroman-2-yl)-4-(p-tolyl)-4H-1,2,4-triazole-3-thiol 
(8a).
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13C NMR spectrum of 4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-
triazole-3-thiol(8b).
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Table-8b: Antimicrobial activity of 5-(6-Fluorochroman-2-yl)-4-aryl-4H-1,2,4-      
triazole-3-thiols. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
8a 500 250 200 250 1000 500 500 
8b 62.5 250 62.5 125 500 1000 1000 
8c 200 200 100 200 250 1000 >1000 
8d 500 500 125 250 1000 >1000 >1000 
8e 250 200 62.5 200 1000 >1000 >1000 
8f 200 200 200 125 1000 1000 1000 
8g 200 200 125 200 500 500 1000 
8h 62.5 100 250 250 1000 1000 1000 
8i 125 200 250 250 >1000 500 500 
8j 100 62.5 200 200 >1000 >1000 >1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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INTRODUCTION 
 
Thiazolidinones, which belongs to an important group of heterocyclic compounds, 
have been widely explored for their applications in the field of medicine. Thiazolidinones, 
with a carbonyl group at position 2 in structure (1) and position 4 or 5 in structure (2, 3) 
have been subjected of widespread study in the recent past. Numerous gossips have 
appeared in the literatures which underscore their chemistry and use. 
 
 
 
 
 
4-Thiazolidinones are derivatives of thiazolidinones with carbonyl group at 4-
position (2). Substituent in the 2, 3 and 5 positions may be varied, but the greatest 
different in structure and properties is exerted by the groups attached to carbon atom at 
the 2-position and to nitrogen atom at the 3-position. The cyclic structure was assigned 
after recognition of mercaptoacetic acid as a primary product of hydrolysis of 3-phenyl- 
2-phenylimino-4-thiazolidinones.1 A well known antibiotic, actithiazic acid (4), isolated 
from a species of streptomyces shows specific in vitro activity against M. tuberculosis, 
but it is inactive in vivo  probably due to antagonisation by biotin, bears the 4-
thiazolidinone skeleton. 
 
SYNTHETIC ASPECT 
 
Several methods for the preparation of 4-thiazolidinones are narrated in 
literature.2-10 
 
1. R.S. Harisha et al.11 have synthesized the one pot synthesis of thiazolidinone, by   
hydrolysis of 2- (trifluoromethyl)-1H-benzimidazole(1) in NaOH/ HCl gives the 
1H- benzimidazole-2-carboxylic acid(2),which on treatment with thionyl chloride 
followed by hydrazine hydrate to gave the desired 1H- benzimidazole-2- 
carboxylic acid hydrazide (3)in 90% yield. Then the compound (3) on reaction 
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2 4
5
3
NH
S
O
(CH2)5-COOH
1
23
4 5
1 2 3 4
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with benzaldehyde and mercapto acetic acid in ethanol as a solvent to give 
compound(4). 
 
N
H
N
CF3 N
H
N
O
OH
N
H
N
O
NHNH2
N
H
N
O
NH
N
S
O
2N NaOH / 2N HCl SOCl 2/ N2H4.H2O
C6H5CHO 
SHCH 2COOH 
 C2H5OH
1
2
3
4
 
2. S.J. Gilani et al.12 have been synthesized main two types of derivatives of 4-  
thiazolidinones.To an equimolar methanolic solution of isonicotinic acid 
hydrazide(0.1 mol) and sustituted benzaldehyde(0.1 mol), a few drops of glacial 
acetic acid were added. The mixture was refluxed on water bath for 5-6 hours, 
then allowed to cool and poured on to crushed ice. The product isolated and  
recrystallisation from methanol yielded compounds (1a-h).A mixture  of(1) (0.01 
mol)  and thioglycolic acid(0.01 mol) was heated on oil-bath at 120-125oC for 12 
hours,then treated with sodium bicarbonate to gave compounds(2a-h).Same as 
reaction carryout in thiomalic acid to gave compounds(3a-h). 
N
O N H
N H 2
R-CHO
Methanol, Gla. A.A.
N
O N H
N
R
SH-CH 2 COOH
N
O N H
N
N
S
RO
SH
O
OH
O
O H
N
O N H
N
N
S
RO
O
OH
1,2,3
(a; R= o- C6H5Cl (a; R= o- C6H5Cl
b;R=p-C6H5Cl
c;R=o- C 6 H 5 OH
d; R=m- C 6 H 5 OH
e; R= P- C 6 H 5 oCH 3
f; R= p- C 6 H 5 F
g; R=o- C 6 H 5 NO 2
h;R=p- C 6 H 5 N(CH 3 ) 2 )
Isonicotinic acid hydrazide
1a-h
2a-h
3a-h
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3.   D. Lingampalle et al.13 have synthesized a convenient one-pot ,three-component  
cyclo condensation mediated by ionic liquid for obtaining 2,3- disustituted-4-     
thiazolidinones with excellent yields reported. 
 
R1
O
R2 + R3 NH2 + SH
O
OH
Ionic liquid,
120
0
C, 3hr
N
S
O
R3
R2
R1
1a-e 2a-e
4a-k
R1 R2 R3
4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
4k
4-hydroxy ph.
4-hydroxy ph.
Ph.
4-methyl ph.
4-methyl ph.
Ph.
4- Cl-ph.
Ph.
4- methoxy ph.
4- Cl-ph.
4- methoxy ph.
CH3
CH3
H
H
H
H
H
H
H
H
H
4- methoxy ph.
4- methoxy ph.
Ph.
4-methyl ph.
Ph.
4-methyl ph.
Ph.
4- Cl-ph.
Isonicotinoyl amino
Isonicotinoyl amino
Isonicotinoyl amino
 
 
 
4.     A. Madhukar et al.14 have been  synthesized biphenyl-4-carboxylic acid 2-(aryl)-
4-oxo- thiazolidin-3-yl-amide.  
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O
NH
NH2
(1) Biphenyl-4-carboxylic acid hydrazide
Ar-CHO O
NH
N
Ar
(II) Biphenyl-4-carboxylic acid hydrazone
SH
O
OH
O
NH
N
S O
Ar
(III) 2- Sustituted-4- thiazolidinone
2a= -C6H5
2b= 3-NO2-C6H5
2c= 3-OH- C6H4
2d= 4-OH-C6H4
2e= 4-F-C6H4
2g= 4-Cl-C6H4
2h= 3-Cl-C6H4
2i= 4-OCH3-C6H4
2j= 3- OCH3-C6H4
2k= 3-Br- C6H4
2l= 2,3- di- OCH3-C6H3
2m= 2,4- di-Cl-C6H3
2n= 2,5- di-Cl- C6H3
 
 
 
5.   L.D.S. Yadav et al.15 reported a convenient CeCl3_7H2O/NAl- promoted 
structurally novel synthesis of thiazolidinones. Which is describe as under. 
 
 
Ar'
O
NH
NH2 + OAr2
Et-OH
-H2O
Ar'
O
NH
N
Ar2
SH
O
OH
CeCl3.7H2O / NAl
Ar'
O
NH
N Ar2
S
OOH
-H2O
Ar'
O
NH
N
S
Ar2O
Ar
1
Ar
2
Ph Ph
4- OCH3-C6H4 Ph
Ph4-Cl-C6H4
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6.  M.S. Mohamed et al.16 synthesized novel thiazolidinones bearing 6,8-dibromo-
4(3H) quinazolinone, which shows a very good anti-bactarial and anti-fungal 
activity. The reaction scheme as under. 
 
O
N
Br
Br
O
N
N
Br
Br
O
O
O
N
N
Br
Br
O
O
NH
NH2
N
N
Br
Br
O
O
NH
N
Ar
N
N
Br
Br
O
O
NH
N
S
ArO
Ar =
O Cl
Cl
Cl
, , , , ,
OH
O
, ,
 
 
7.   V.S. Palekar et al.17 have been synthesized some novel bis-4- thiazolidinone 
derivatives from terphthalic dihydrazide.Which shows good anti-bactarial 
activity.The reaction scheme are as under. 
 
 
O NH
NH2
O NH
NH2
Ar- CHO/ Ethanol
Reflux
O
NHN
Ar'
O
NH
N
Ar'
O
OHSH
Benzene
O
NH
O
NHN
S
Ar'
O
N
S Ar'
O
Ar' = C6H5
2-Br-C6H4
2-Cl- C6H4
4-OH-C6H4
4- OCH3-C6H4  
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8.   N. B. Patel et al.18 have synthesized some new 4- thiazolidinones of nicotinic acid 
with 2- amino -6- methyl benzothiazole. Which have been described as under. 
 
N Cl
O
OH + S
N
NH2 N
O
OH
NH
NS
N
O
NH
NH
NS
NH2
N
O
NH
NH
NS
N
N O
NH
N
S
NHN
S
O
1 2
3 4
5
6(a-j)
a;R= H
b; R= 2-Cl
c; R= 4- Cl
d; R= 2- NO2
e; R= 3- NO2
f; R= 4- OH
g; 4- OCH3
h; R= 3- OCH3, 4- OH
i; R= 3- OCH3, 4- OH, 5- NO2
j; R= 2- Furyl
R
R
 
 
 
 
9.  M. L. Berreca et al.19 have synthesized some novel 2,3-diaryl-1,3-thiazolidin-4-
one   derivatives from 2,3-dihalo substituted benzaldehyde, equivalent amount of 
aromatic amine and mercaptoacetic acid in refluxing with toluene. 
 
+ +
R'
R''
O
Toluene
2 hrs
R'
R''
N
S
R
O
R=Aryl
R',R''=Cl, F
SH2
O
OH
R NH2
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10.  Bioactive venlafaxine analogs such as 2,3-disubstituted-1,3-thiazolidinones have 
been synthesized and reported as antimicrobial agent by C. V. Kavitha and 
coworkers.20 
 
O
NH2OH +
O
R SH
O
OH
DCC,THF or MW irr
O
OH
N
S
O
R
 
 
11.  D. R. St. Laurent et al.21 have synthesized 4-thiazolidinone derivatives by the  
cyclization unsymmetrical thiourea. H. S. Joshi and co-workers22 have synthesized 
thiazolidinones bearing benzo[b]thiophene nucleus from N-arylaminothoxomethyl 
derivatives with chloroacetic acid in ethanol. 
 
S
Cl
O
NH
S
N
H
R
Cl-CH2COOH
NaOAC S
Cl
O
N
S
O
N
R  
 
12.  A. Dandia and co-workers23 have synthesized thiazolidinone derivatives and 
reported     their antifungal activity. 
 
N
H
O
O
R
+ Het NH2 + SH
R
O
OH
MW
4-7 min. NH
O
S
R
O
NHet
R
 
 
 
 
 
 
Studies on nitrogen containing heterocyclic… 
Thiazolidinone derivatives…   198 
 
REACTION MECHANISM 
 
O
O
H
N
F
NH2
ArH
O
O
O
H
N
F
N OH
H Ar
H
-H2O
O
O
H
N
F
N Ar
S
O
OH
O
O
H
N
F
N S
O
Ar
-H2O
O
O
H
N
F
N Ar
HO
SH
O
 
 
THERAPEUTIC IMPORTANCE 
 
Much research has been accepted with intend to pronouncement therapeutic 
values of thiazolidinone moiety since their discovery. The thiazolidinones, substituted at 
2 and 3 position are reported to demonstr.ate a wide variety of biological activities. 
1. Antibacterial.24, 25    7.Anti-HIV31,32 
2. Anticancer.26    8.Antimicrobial33,34 
3. Antiinflammatory.27   9.Antifungal35 
4. Antitubercular.28              10.Antioxidant36 
5. Antihistaminic.29              11.Herbicidal37 
6. Antimalarial.30 
 
Goel et al.38 have synthesized thiazolidinone derivatives and compaired their 
antiinflammatory activity, ulcerogenic liability, cardiovascular and CNS effects.M. 
Siddique et al.39 have prepared substituted thiazolidinones and reported their antibacterial, 
antifungal, antithyroid and amoebicidal properties. S. K. Srivastava et al.40 have prepared 
new thiazolidinones as antibacterial, antifungal, analgesic and diuretic agents. A. Rao et 
al.41 have been synthesized several 1,3-thiazolidin-4-ones bearing 2,6-dihalophenyl group 
at C-2 and a substituted pyrimidin-2-yl ring at the N-3 were synthesized and evaluated as 
anti-HIV agents. 
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NN
R1R2
N
S
O
R3
R4
R1 = H,ME
R2 = H, Cl,OMe
R3= R4= Cl, F  
 
 R.Ottana et al.42 have designed and synthesised 5-arylidene-2-imino-4-
thiazolidinone derivatives as novel antiinflammatory agent. A. Tsutoma et al.43 have 
synthesized thiazolidinones as a telomeres inhibitors. S. K. Chaudhary et al.44 have 
synthesized several 3-(3-(N-morpholin-4-yl-propyl)-2-(arylimino)-4-thiazolidinones and 
evaluated for their ability to potentiate pentobarbital-induced hypnosis in mice at a dose 
of 100 mg/kg. 
 
N
N
S
O
N O
 
Suzuki et al.45 have synthesized and examined the effects of CP-060S 3-{3-
[(benzo[1,3]dioxol-4-yloxymethyl)-methyl-amino]propyl}-2-(3,5-di-tert-butyl-4-hydroxy 
phenyl)-4-thiazolidinone on cardiac function and myocardial oxygen consumption 
(MVO2)  in anesthetized dogs. V. K. Agraval et al.46 have investigated the antihistaminic 
(H1-antagonist) activity of 2,3-disubstituted thiazolidin-4-ones and concluded that the 
hydrophobic substitution at the 4-position of the phenyl ring. In another study, Diurno et 
al.47 have synthesized, characterized and evaluated a new series of 2-(substituted-phenyl)-
3-[3-(N,N-dimethylamino)-propyl]-1,3-thiazolidin-4-ones for their capacity to inhibit 
contraction induced by histamine on guinea pig ileum. G. Kucukguzel et al.48 have been 
synthesized some thiazolidinine  derivatives and reported as anti-inflammatory agent. 
 
O
O
NH
O
NH
S
R
O
 
  N. Ulusoy et al.49 have prepared thiazolidinone derivatives as potent 
antimycobacterial agents. R. Govindarajan et al.50 have synthesized thiazolidinones as 
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antitubercular, antifungal and antibacterial agent. Hassan et al.51 have prepared 2-imino-
4-thiazolidinones which have been found to possess antimicrobial activity. A. Dandia and 
co-workers52 have reported thiazolidinone derivatives as potential antifungal and 
antitubercular agents. C. Muanprasat et al.53 have prepared some new thiazolidinone 
derivatives as CFTR inhibitors. M. G. Vigorita et al.54 have prepared meso 3,3'-(1,2-
ethanediyl)-bis[2-aryl-4-thiazolidinones] derivatives as antiinflammatory and analgesic 
agents. K. Babaoglu et al.55 have been prepared a virtual library of 2,3,5 trisubstituted- 4-
thiazolidinones (12,13) as inhibitors of dTDP-rhamnose synthesis. 
 
O
OH
N
S
O
OO O
S N
O
OO
 
 
C. J. Andres and co-workers56 have prepared some 4-thiazolidinone derivatives 
and reported as novel inhibitors of the bacterial enzyme Mur B which is a precursor 
acting during the biosynthesis of peptidoglycan. D. Maclean et al.57 reported the FSH 
agonist activity of an encoded 4-thiazolidinone library. M. M. Ramla et al.58 have been 
synthesized series of some new derivatives of 2-(1-benzyl-2-methyl-1H-benzimidazol-5-  
ylimino)-3-substituted-thiazolidin-4-ones and studied their inhibitory activity against the 
Epstein–Barr Virus-early antigen (EBV-EA) activation introduced by 12-
Otetradecanoylphorbol-13-acetate (TPA). 
 
N
N
N
N SR
O
R= CH3,C2H5, C6H5 
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A. Kumar et al.59 have been synthesized 2-[(4'-oxo-3'-chloro-2'-phenylazetidin-  
1'-yl) aminomethyl]-3-[4'’-(p-chlorophenyl) thiazol-2'’-yl]-6-bromoquinazolin-4-ones and 
screened for their anti-infammatory and analgesic activities at the dose of 50 mg/kg. R. P. 
Tenorio and co-workers60 have synthesized 4-thiazolidinones in one and two steps and 
synthesized compounds were submitted to evaluation against host cells infected with 
toxoplasma gondii. J. Wrobel et al.61 have been synthesized 5-alkylated thiazolidinones as 
follicle-stimulating hormone (FSH) receptor agonists. 
 
 
 
 
 
R. Dayam et al.62 have reported some novel thiazolidinone derivatives as novel 
class of HIV- integrase inhibitors. N. D. Sonawane et al.63 have synthesized some new 
thiazolidinone derivatives as in vivo pharmacology and antidiarrheal efficacy of a 
thiazolidinone CFTR inhibitor in rodents. Antimicrobial activity of some pyrazine 
containing thiazolidinones have been reported by C. G. Bonda.64 X. F. Wang et al.65 have 
synthesized some novel thiazolidinone derivatives described as new cystic fibrosis 
transmembrane conductance regulator inhibitor on Cl-conductance in human sweat ducts. 
F.Ur et al.66 have constr.ucted some new 6-methylimidazo[2,1-b]thiazole-5- carbo 
hydrazide derivatives and their antimicrobial activities. D. Reigada et al.67 have reported 
some new thiazolidinone derivatives as release of ATP from retinal pigment epithelial 
cells involves both CFTR and vesicular transport. Antiproliferative activities of 2-aryl-4-
oxo-thiazolidin-3-yl-amides for prostate cancer have been reported by V. Gududuru et 
al.68 D. B. Salinas et al.69 documented thiazolidinone derivatives as CFTR inhibitor. H. S. 
Joshi et al.70 have been reported some thiazolidinones bearing benzo[b]thiophene moity 
as antitubercular and antimicrobial agents. S. M. Rida and co-workers71 have been 
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prepared 2-[(1-benzofuran-2-yl-ethylidene)hydrazono]-5-(4-substitutedbenzylidene)-3-
substituted-thiazolidin-4-ones as anticancer agents. 
 
O
N N
N
S
R
R
1
R= CH2C6H5, C6H5
R1=Cl, OCH3  
 
A series of novel 2-arylimino-3-aryl-thiazolidine-4-ones was designed, 
synthesized and tested for in vitro antibiofilm activity against Staphylococcus 
epidermidis.72 Among them tested, some compounds with carboxylic acid groups showed 
good antibiofilm activity. The antibiofilm concentration of 1x was 6.25 lM.  
 
4-((Z)-((Z)-3-(2-ethylphenyl)-2-(2-ethylphenylimino)-4-oxothiazolidin-5-ylidene)methyl)-2-methoxyphenyl hydrogen carbonate
N S
O
N
O
COOH
OCH3
 
 
Liu et al.73 synthesized derivatives of 2-imino-3-(4-arylthiazol-2-yl)thiazolidin-
4-ones and series of their 5-arylidene derivatives and tested for antifungal activity against 
seven agricultural fungi.  
 
N
S
O
NH
N
S
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G.C. Sekhar et al.74 have synthesized compounds and most of them were found 
to possess moderate activity against fungi.aspergillus flavus and candida albican 
respectively. The antifungal activities of test compounds were compared with standard 
salicylic acid (20 - 30 mm) and chlotrimazole (25 - 30 mm).  
3-(3-methylquinoxalin-2-ylamino)-2-phenylthiazolidin-4-one
N
N
NH
N
S
O
 
 
V.V. Mulwad et al.75 have been screened compounds various thiazolidine 
derivetives for their antimicrobial activity by cup plate method and have found to exhibit 
significant activity against B.Subtilis, E.coli at different concentration (50 and 100 μg/ml) 
using DMSO as solvent.  
(E)-5-benzylidene-2-imino-3-(2-oxo-2H-chromen-6-yl)thiazolidin-4-one
O
N
S
O
NH
O
 
Work done from our laboratory 
K.M.Thaker et al76 have synthesized 2-aryl-5H-(3’,5’-dichroro-2-benzo(b)thio 
phenoyl -amino)-4-thiazolidinone bearing the benzo[b]thiophene nucleus as potent 
antimicrobial agents. S.L.Vasoya et al77 have synthesized some new2-aryl-5H-(3’-
chloro-5’-phenoxybenzo(b)thiophenoyl-2-amino)-4-thiazolidinone nucleus as potent 
antimicrobial agents. 
With an intention of preparing the compounds possessing better therapeutic 
activity, We have undertaken the synthesis of thiazolidinones bearing chroman nucleas 
which have been described as under. 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 6- 
FLUORO-N-(4-OXO-2-ARYLTHIAZOLIDIN-3-YL) 
CHROMAN-2-CARBOXAMIDES. 
Part – B 
[Part – IV (Section-i)] 
 
Synthesis and biological evaluation of 6-
fluoro-N(4-oxo-2-arylthiazolidin-3-yl) 
chroman-2-carboxamides. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-FLUORO-N-(4-
OXO-2-ARYLTHIAZOLIDIN-3-YL)CHROMAN-2-CARBOXAMIDES. 
With a view to getting better therapeutic agents and considering the 
association of various biological activities of thiazolidinonone heterocycles, the 
synthesis of thiazolidinones have been undertaken by the condensation of 
different aryl aldehydes with 6-fluorochroman-2-carbohydrazide  and thioglycolic 
acid(mercapto acetic acid), as shown in reaction scheme.  
REACTION SCHEME 
 
O
F
O
NH
NH2
R-CHO, Thioglycolic acid
Toluene
O
F
O
NH
N
S
R
O
(TypeIV) R=Aryl  
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate. 
All the synthesized compounds were tested for their antibacterial and 
antifungal activity (MIC) in vitro by broth dilution method with two Gram-positive 
bacteria, two Gram-negative bacteria and three fungal strains. The biological activities 
of the synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct inlet 
probe technique. 1H NMR and 13C NMR were determined in CDCl3 and DMSO solution 
on a Bruker AC 400 MHz and 100MHz spectrometer. Elemental analysis of the all the 
synthesized compounds were carried out on Euro EA 3000 elemental analyzer and the 
results are in agreements with the structures assigned 
[A]        Synthesis of 6-Fluorochroman-2-carbohydrazide. 
              See PART-B, part-I, section-I [B]. 
[B]     General procedure for the preparation of 6-Fluoro-N-(4-oxo-2-aryl    
  thiazolidin-3-yl)chroman-2-carboxamides. 
A mixture of 6-fluorochroman-2-carbohydrazide (2.0 g,0.01mol), different aryl 
aldehydes (0.01 mol) and thioglycolic acid(mercapto acetic acid) (26.7 g≅20.4 ml, 0.29 
mol) in toluene (50 ml) was refluxed in a Dean-Stark assembly with continuous stirring. 
After completion of  the reaction (48 hours monitoring by TLC), the content was cooled 
to room temperature then neutralized with sodium bicarbonate solution.The organic 
extracts was washed with water (2 x 10 ml), dried with Na2SO4, solvent was removed in 
vacuo and the resulting crude product was purified by column chromatography to give the 
analytical pure compounds. The physical constants of the products are recorded in Table-
9a. 
 
[C]  Biological evaluation of 6-Fluoro-N-(4-oxo-2-arylthiazolidin-3-yl)chroman-
2-carboxamides. 
   Antimicrobial testing was carried out as described in Part-B, Part-IV, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-9b. 
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Table-9a: Physical constant of 6-Fluoro-N-(4-oxo-2-arylthiazolidin-3-yl)chroman-2-
carboxamides. 
 
 
 
Sr. 
No Substitution R M. F. M. W. Yield (%) Rf  value 
9a O
 
C20H19FN2O4S 
 
402.43 85 0.55 
9b 
N
+
O
-
O
 
C19H16FN3O5S   417.41 95 0.62 
9c F
 
C19H16F2N2O3S  
 
390.40 
 
89 0.57 
 
9d 
Cl
 
C19H16ClFN2O3S 406.85 77 0.44 
9e Br
 
C19H16BrFN2O3S 451.30 90 0.38 
 
9f OH C19H17FN2O4S  388.41 
 
73 
 
0.58 
9g 
 
C20H19FN2O3S  386.43 84 0.49 
9h 
Cl
 
C19H16ClFN2O3S 406.85 71 0.33 
 
9i N
+
O
-
O  
C17H14FN3O2 
 
417.41 79 0.71 
9j 
Br
 
C19H16FN3O5S  
 
451.30 
 
88 0.41 
     TLC solvent system:- E.A. : Hexane = 5 : 5 
 
 
 
O
F
O
NH
N S
R
O
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ANALYTICAL DATA 
6-Fluoro-N-(2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)chroman-2-carboxamide 
(9a). mp 98-100 °C; IR (DRS): 3383, 3081, 2858, 1714, 1688, 1542, 1465, 1356, 1278, 
1152, 1077, 887, 712, 689, 584 cm-1;MS: m/z = 402 [M]+; Anal. Calcd for C20H19FN2O4S: 
C, 59.69; H, 4.76; N, 6.96. Found: C, 59.23; H, 4.61; N, 6.88%. 
6-Fluoro-N-(2-(2-nitrophenyl)-4-oxothiazolidin-3-yl)chroman-2-carboxamide 
(9b).mp 190-192°C; IR (DRS): 3392, 3205, 2918, 2850, 1712, 1678, 1523, 1485, 1390, 
1259, 1190, 864, 702, 657, 561 cm-1; 1H NMR (400 MHz, DMSO): δ ppm 1.81-2.05(m, 
2H, 2CH), 2.61-2.74(m, 2H, 2CH), 3.68-3.72(d, J=16.0 Hz, 1H, CH), 3.91-3.95(d, J=15.6 
Hz, 1H, CH), 4.66-4.69(d,d, J=3.6 Hz, 3.2 Hz, 1H, CH), 6.12(s, 1H, CH), 6.72-6.79(m, 
1H, ArH), 6.84-6.91(m, 2H, ArH), 7.60-7.63(t, 1H, ArH), 7.78-7.87(m, 2H, ArH), 8.04-
8.06(d, J= 8.0 Hz, 1H, ArH), 10.43-10.46(d, J= 11.6 Hz, 1H, NH). 13C NMR (100 MHz, 
CDCl3): δ ppm, 22.71, 23.56, 24.14, 29.29, 29.38, 29.71, 30.50, 50.43, 58.29, 75.20, 
114.27, 114.51, 115.60, 115.83, 117.60, 123.26, 125.40, 127.95, 129.88, 134.07, 134.28, 
148.30, 148.40, 156.16, 162.20, 169.32, 169.47.MS: m/z = 417 [M]+; Anal. Calcd for 
C19H16FN3O5S : C, 54.67; H, 3.86; N, 10.07. Found: C, 54.58; H, 3.49; N, 9.99%. 
6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)chroman-2-carboxamide (9c). 
mp 106-110 °C; IR (DRS): 3487(Ar, C-H str.), 3041(Ar, C-H str.), 2958(C-H str.), 
2848(C- H str.), 1710(amide C=O str.), 1676(amide C=O str.), 1537(Ar, C=C str.), 
1429(Ar, C=C str.), 1388(C-H ben), 1261(C-F str.), 1190(C-F str.), 1078(C-N str.), 
891(C-H o,p, ben), 868(C-H o,p, ben), 813(C-H o,p, ben), 759(C-H o,p, ben), 709(C-C 
o,p, ben), 673(C-C o,p, ben), 650(C-Co,p, ben), 592(C-C o,p , ben) cm-1; 1H NMR (400 
MHz, CDCl3): δ ppm 1.82-2.02(m, 2H, 2CH), 2.56-2.70(m, 2H, 2CH), 3.59-3.78(m, 2H, 
2CH), 4.45-4.58(d,d, J=10.52 Hz, 11.52 Hz, 1H, CH), 5.79-5.83(d, J= 17.32 Hz, 1H, 
CH), 6.54-6.72(m, 3H, ArH), 6.86-6.90(t, 1H, ArH), 6.99-7.03 (t, 1H,ArH), 7.20-7.22( t, 
1H, ArH), 7.33-7.36(t, 1H, ArH), 8.05-8.13( d, J= 29.44 Hz, 1H, NH). 13C NMR (100 
MHz, CDCl3): δ ppm,22.71, 23.07, 23.52, 23.87, 24.21, 29.37, 29.71, 30.06, 30.08, 31.94, 
50.26, 62.05, 62.48, 74.81, 75.14, 114.23, 114.31, 114.46, 114.54, 115.44, 115.55, 
115.67, 115.78, 115.89, 116.11, 117.54, 117.60, 117.68, 122.69, 122.77, 123.20, 123.27, 
129.82, 129.90, 130.16, 130.25, 131.95, 131.98, 132.37, 132.40, 148.06, 148.24, 156.10, 
158.49, 162.07, 162.17, 164.55, 164.65, 169.15, 169.33, 169.47; MS: m/z = 390 [M]+; 
Anal. Calcd for C19H16F2N2O3S: C, 58.45; H, 4.13; N, 7.18. Found: C, 58.02; H, 4.03; N, 
7.10%. 
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N-(2-(3-chlorophenyl)-4-oxothiazolidin-3-yl)-6-fluorochroman-2-carboxamide (9d). 
mp 151-153°C; IR (DRS): 3401 , 3284, 3074, 2987, 2851, 1717, 1645, 1612, 1585, 1468, 
1352, 1278, 1184,1066,  820, 754, 710, 636, 541 cm-1; MS: m/z = 406 [M]+; Anal. Calcd 
for C19H16ClFN2O3S: C, 56.09; H, 3.96; N, 6.89. Found: C, 55.90; H, 3.83; N, 6.83%. 
N-(2-(4-bromophenyl)-4-oxothiazolidin-3-yl)-6-fluorochroman-2-carboxamide (9e). 
mp 118-120 °C; IR (DRS): 3412, 3081, 2975, 2844, 1706, 1641, 1579, 1556, 1464, 1332, 
1272, 1045, 831, 750, 592, 545 cm-1; MS: m/z = 452 [M+1]+; Anal. Calcd for 
C19H16BrFN2O3S: C, 50.56; H, 3.57; N, 6.21. Found: C, 50.45; H, 3.28; N, 6.11%.   
6-Fluoro-N-(2-(4-hydroxyphenyl)-4-oxothiazolidin-3-yl)chroman-2-carboxamide 
(9f). mp 132-134°C; IR (DRS): 3564, 3442, 3080, 2983, 2867, 1705, 1629, 1572, 1525, 
1462, 1374, 1245, 1196, 1074, 830, 748, 676  cm-1; MS: m/z = 388 [M]+; Anal. Calcd for 
C19H17FN2O4S : C, 58.75; H, 4.41; N, 7.21. Found: C, 58.56; H, 4.34; N, 7.06%. 
6-Fluoro-N-(4-oxo-2-(p-tolyl)thiazolidin-3-yl)chroman-2-carboxamide (9g). mp 89-
91°C; IR (DRS): 3410, 3077, 2978, 2863, 1714, 1625, 1609, 1563, 1464, 1322, 1238, 
1142, 1054, 870, 798, 675, 542  cm-1; MS: m/z = 386 [M]+; Anal. Calcd C20H19FN2O3S: 
C, 62.16; H, 4.96; N, 7.25. Found: C, 62.07; H, 4.55; N, 7.09%. 
N-(2-(2-chlorophenyl)-4-oxothiazolidin-3-yl)-6-fluorochroman-2-carboxamide (9h). 
mp 158-160°C; IR (DRS): 3391, 3113, 3054, 2962, 2854, 1702, 1603, 1545, 1542, 1452, 
1302, 1260, 1146, 1078, 1021, 841, 798, 756, 674, 651, 531 cm-1; MS: m/z = 406 [M]+; 
Anal. Calcd for C19H16ClFN2O3S: C, 56.09; H, 3.96; N, 6.89. Found: C, 55.93; H, 3.77; 
N, 6.84%. 
6-Fluoro-N-(2-(4-nitrophenyl)-4-oxothiazolidin-3-yl)chroman-2-carboxamide (9i). 
mp 207-209°C; IR (DRS): 3405, 3075, 2964, 2853, 1721, 1601, 1581, 1423, 1385, 1254, 
1149, 1021, 878, 754, 720, 678, 531 cm-1; MS: m/z = 417 [M]+; Anal. Calcd for 
C17H14FN3O2: C, 54.67; H, 3.86; N, 10.07. Found: C, 54.39; H, 3.79; N, 9.89%. 
N-(2-(3-bromophenyl)-4-oxothiazolidin-3-yl)-6-fluorochroman-2-carboxamide (9j). 
mp 166-168°C; IR (DRS): 3395, 3061, 2951, 2872, 1701, 1689, 1589, 1579, 1462, 1356, 
1254, 1099, 1041, 881, 755, 692, 565 cm-1; MS: m/z = 452[M+1]+; Anal. Calcd for 
C19H16FN3O5S: C, 50.56; H, 3.57; N, 6.21. Found: C, 50.17; H, 3.14; N, 6.12%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR Spectrum of 6-Fluoro-N-(2-(2-nitrophenyl)-4-oxothiazolidin-3-yl)chroman-2-
carboxamide(9b). 
 
IR Spectrum of 6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)chroman-2-
carboxamide(9c). 
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Mass spectrum of 6-Fluoro-N-(2-(2-nitrophenyl)-4-oxothiazolidin-3-yl)chroman-2-
carboxamide(9b).
 
Mass spectrum of 6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)chroman-2-
carboxamide(9c).
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1H NMR spectrum of 6-Fluoro-N-(2-(2-nitrophenyl)-4-oxothiazolidin-3-yl)chroman-
2-carboxamide(9b).
 
 
D2O Exchange 1H NMR spectrum of 6-Fluoro-N-(2-(2-nitrophenyl)-4-
oxothiazolidin-3-yl) chroman-2-carboxamide (9b). 
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1H NMR spectrum of 6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-
yl)chroman-2-carboxamide(9c).
 
Expanded spectrum of 6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-
yl)chroman-2-carboxamide(9c). 
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Expanded spectrum of 6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-
yl)chroman-2-carboxamide(9c). 
 
13C NMR spectrum of 6-Fluoro-N-(2-(2-nitrophenyl)-4-oxothiazolidin-3-yl)chroman-
2-carboxamide(9b).
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13C NMR spectrum of 6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-
yl)chroman-2-carboxamide(9c).
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Table-9b: Antimicrobial activity of 6-Fluoro-N-(4-oxo-2-arylthiazolidin-3-yl)   
chroman-2-carboxamides. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
9a 250 250 125 250 >1000 1000 1000 
9b 200 200 200 125 1000 250 500 
9c 125 200 200 200 1000 500 500 
9d 250 200 125 62.5 1000 500 500 
9e 500 250 500 500 1000 1000 1000 
9f 250 200 250 250 500 500 500 
9g 100 250 62.5 200 1000 250 1000 
9h 125 200 200 250 500 1000 1000 
9i 250 250 100 125 1000 >1000 >1000 
9j 200 200 100 200 >1000 >1000 >1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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INTRODUCTION 
 
During discovery of Nifedipine, Loev and co-workers1 reported that the N-phenyl- 
1,4-dihydropyridine was also formed by reaction of benzalaniline and acetoacetic ester.2,3 
1,4-Dihydropyridines are versatile compounds because their derivatives play important 
roles in medicinal chemistry; for example, nifedipine, amlodipine and other 
antihypertensive agents.4 Among the numerous methods developed for the synthesis of 
1,4-dihydropyridines, Hantzsch reaction is one of the most well-accepted methods and 
much effort has been made to modify this reaction.5 However, these classical methods 
were not enough to make pyridine libraries. 
 
SYNTHETIC ASPECT 
 
A series of 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diesters 
substituted at the N-1 positions of the dihydropyridine (4) ring was synthesized by I. O. 
Donkor et al.6 The in vitro cytotoxicity and in vitro and in vivo radioprotective efficacy of 
these agents were evaluated in Chinese hamster (V-79) cells and CD2F1 male mice, 
respectively. 
 
  
 
  
 
 Ceric ammonium nitrate (CAN) catalyzed the three-component domino reaction 
between aromatic amines, a,â-unsaturated aldehydes, and ethyl acetoacetate, providing an 
efficient new N-aryl-5,6-unsubstituted dihydropyridines (9).7 
O O
O
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Mustafa et al.8 developed an efficient synthesis method for 1,4-dihydropyridines. 
It has been developing using 3 or 4 component condensation reactions of aldehydes, 1,3-
dicarbonyl compounds, and ammonium acetate in the presence of alumina sulfuric acid 
catalyst in minimum methanol at reflux temperature. This procedure offers several 
advantages including high yields, an environment friendly procedure, short reaction time, 
and a simple work-up procedure.   
1,4-Dihydropyridines (DHPs) are class of nitrogen containing heterocycles having 
a 6-membered ring. 1,4-DHPs, which are the most potent calcium antagonists  or  calcium 
channel blockers, have received much attention due to their wide range of pharmaceutical 
and biological properties such as inhibition of human cytochrome P450 enzyme,9 
angiotensine-converting  enzyme inhibition, and blood pressure control on chronic, 
nondiabetic nephropathies.10 1,4-DHP compounds play important roles in medicinal 
chemistry, for example nifedipine, amlodipine, felodipine, and nicardipine, which are the 
best selling drugs used in the treatment of cardiovascular diseases.11        
 Matloubi et al.12 have synthesized one-pot four-component reaction of aldehydes, 
ethyl acetoacetate/5,5-dimethyl-1,3-cyclohexanedione, ethyl acetoacetate and ammonium 
acetate in the presence of 10 mol% of ZnO as a heterogeneous catalyst for the synthesis 
of corresponding 1,4- dihydropyridine and polyhydroquinoline derivatives via the 
Hantzsch condensation is described. The present methodology offers several advantages 
such as simple procedure, excellent yields, and short reaction time. 
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The usefulness of these calcium antagonists has led to the development of novel 
synthetic strategies to improve classical methods of preparation13-15 and microwave 
activation stands among the alternative routes proposed the past decade.  
Aromatization of 1,4-DHP has also attracted considerable attention in recent years 
as Böcker16 has demonstrated that metabolism of drugs involves a cytochrome P-450 
catalyzed oxidation in the liver. The so-obtained pyridines are devoid of the 
pharmacological activity of the parent heterocycles and are further transformed by 
additional chemical modifications. Due to the biological importance of the oxidation step 
of 1, 4-DHP, that reaction has been the subject of a large number of studies and a plethora 
of reagents has been utilized to mimic the in vivo transformation. In that field, surprising 
results have been collected when the reactions are performed under microwave 
irradiation.  
The pioneering report on the use of microwave activation to obtain Hantzsch 1,4-
DHP was published by Alajarin et al. in 1992.17This group prepared a series of 4-aryl 
derivatives in a domestic oven by the classical multicomponent method (aldehyde: 15 
mmol; alkyl acetoacetate: 43 mmol; ammonia: 30 mmol; ethanol: 3 mL). Yields ranged 
from 15 to 52 % for a reaction time of 4 minutes. The authors claim that classical 
protocols for the formation of the same compounds require a reflux period of 12 hours but 
they did not notice any yield improvement when microwave irradiation was applied. 
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Three years later the same group extended its work18 to the preparation of 3,5-
unsymmetrically substituted 1,4-DHP starting from arylmethyleneacetoacetate (8 mmol) 
and 3-aminocrotonate (4 mmol) in ethanol (4.5 mL). This report again emphasizes that 
the rapidity of the microwave-assisted syntheses does not affect the isolated yields. The 
same year Zhang19 obtained four 4-aryl 1,4-DHP from 3-aminocrotonate (20 mmol), 
methyl acetoacetate (20 mmol) and arylaldehydes (20 mmol) in a domestic oven. For the 
first time, the preparations were conducted in the absence of solvent. Yields ranging from 
59 to 77 % are reported and optimized heating periods do not exceed 10 minutes. To 
avoid any loss of volatile material, the reaction flasks were fitted with a condenser 
containing xylene. Also in 1995, Khadilkar20 used the same building blocks as Zhang but 
in the presence of a solvent (ethanol, volume not reported; 3-aminocrotonate: 10 mmol; 
methyl acetoacetate: 14 mmol; arylaldehyde: 10 mmol). The heterocycles were prepared 
in a domestic oven within 3 to 5 minutes in 32 to 80 % yield.  
Interestingly, Khadilkar21 also described the formation, in a domestic oven, of 1,4-
DHP in an aqueous hydro trope solution (50% butylmonoglycolsulphate : 5 ml). The 
experiments were performed with 3-aminocrotonate (10 mmol), methyl acetoacetate (14 
mmol) and aliphatic or aromatic aldehydes (10 mmol). The final products were obtained 
within 3 to 6 minutes in 35 to 97 % yield. All reactions described by Khadilkar 20,21 were 
carried out by exposing the reactants to microwaves in containers equipped with a 
condenser charged with precooled carbon tetrachloride. The coupling of microwave 
heating (in a domestic oven) with the use of a mineral solid support (alumina: 2 g) has 
later been exploited by Suarez 22 to synthesize, within 6 minutes and with a yield higher 
than 85 %, an unsymmetrical 1,4-DHP from methyl 3-aminocrotonate (3 mmol), ethyl 
acetoacetate (3 mmol) and benzaldehyde (3 mmol).  
A catalytic amount of DMF (0.5 ml), as an energy transfer medium to attain 
higher temperatures, was added to the reaction mixture.  
In 2001, a single-mode microwave reactor (SmithSyntheziser from Personal 
Chemistry, Uppsala, Sweden) was used for the first time to accelerate the preparation of 
series of 1,4-DHP from various alkyl acetoacetates (12.5 mmol), aldehydes (2.5 mmol) 
and 25 % aqueous ammonium hydroxide (10.0 mmol).23 In comparison with experiments 
performed in domestic ovens, use of a laboratory synthesizer does not appear to provide 
improved results.  
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Oxidation of 1,4-DHP under microwave irradiation was reported for the first time 
in 1991 by Alvarez et al. 24,25 They oxidized a series of 1,4-DHP (0.5 g) in a domestic 
oven by treatment on a mixture of manganese dioxide and Mexican bentonite clay (5.0 g, 
prepared from 1:2 or 1:4 mixtures of potassium permanganate and clay) in the absence of 
solvent. The procedure is characterized by short reaction times (10 minutes) and fair to 
quantitative yields (47-100 %). The most noticeable results were observed when starting 
from 1,4-DHP bearing a methyl, ethyl, or propyl group in position 4. Indeed those 
reactions afforded, unexpectedly, mixtures of 4-alkylpyridines and 4-unsubstituted 
pyridine. In contrast, the same group related,26 two years later, that those 4-alkyl 1,4-DHP 
(0.25 g) do not undergo the dealkylation process when they are treated for 1 minute in a 
domestic microwave oven in the presence of a HNO3/Mexican bentonite clay system (2.5 
g; prepared from a 1:1 mixture of the components). Aromatization of 1,4-DHP has also 
been studied by Varma.27 He observed that solid state oxidation of 1, 4-DHP (1mmol) 
using elemental sulfur (1.3 mmol) and microwave activation in a domestic oven affords 
the dehydro derivatives, whichever the 4-substituent is. 
  
N
H
R4 H
R2 R6
CO2R5R3O2C
Oxidation
NR2 R6
R4
CO2R5R3O2C and/or
NR2 R6
H
CO2R5R3O2C
 
 
Glycinium chlorochromate28 (GCC) supported onto silica gel was used as an 
effective oxidizing agent for the aromatization of 1,4-dihydropyridine. 
Many of the reported reagents involve the use of strong oxidants such as KMnO4,29 
CrO3,30 HNO3,31 Pyridinium chlorochromate (PCC),32 Ceric ammonium nitrate (CAN),33 
bentonite clay-supported manganese dioxide,34 Sulphar,35 Palladium/Charcoal 
dehydrogenations36 and bismuth nitrate.37 However this aromatization reaction with most 
of these reagents leads to dealkylation at the 4-position or formation of side products. 
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Lakshmi kantam et al.38 have reported the one pot, three component synthesis of 
2-amino-4-aryl-3,5-dicyano-6-sulfanylpyridines and the corresponding 1,4-dihydro-
pyridines  are from readily accessible starting materials. Heating of an ethanolic solution 
of structurally diverse aldehydes with various thiols and malononitrile in the presence of 
nanocrystalline magnesium oxide provides the highly substituted pyridine derivatives in 
moderate to high yields, each representing a privileged medicinal scaffold with their 
structural motif. After completion of the reaction, the catalyst can be recovered efficiently 
and reused with consistent activity. 
HAr
O
CN
CN
2 R SH
NAP-MgO
EtOH, reflux N
NC
H2N SR
CN
Ar
 
 
Gunaras et al.39 investigated 1,4-dihydropyridine structure as a less harmful 
alternative to synthetic phenolic antioxidants in liposomes under conditions simulating 
food storage. The antioxidant activities (AOA) of 2,6-dimethyl-3,5-dialkoxycarbonyl- 
1,4-dihydropyridines possessing various side chain length alkyls (CH3 - C16H33) in ester 
moiety were tested in transition metalion catalyzed liposome peroxidation and compared 
with AOA of Trolox™ and Probucol™. The compounds with ethyl - butyl residues in the 
3,5-position ester moieties exert the most pronounced AOA. The AOA of tested 
compounds is associated with their ability to incorporate into liposomes. 
Quaternary ammonium bromate have been prepared from the corresponding 
bromide  and used as a mild and efficient oxidizing agent for the aromatization of  
Hantzsch esters and related compounds to pyridine derivatives.40 
Solvent/reflux
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Mohammad et al.41 had prepared 1,4-dihydropyridine under solvent free 
condition. Ethyl acetoacetate and a range of aldehydes in the presence of ammonium 
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acetate were converted into 1,4-dihydropyridines under mild and solvent free conditions 
with good to excellent yields. 
 
O
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R CHO CH3COONH4
N
H
H3C CH3
COOEtEtOOC
R
 
   
The preparation of Hantzch type 3,5-dicyano-1,4-dihydropyridine is sometime 
reported via formation of tetrahyropyridine, which are isolated at room temperature in the 
presence of ammonium acetate.42 
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A novel synthesis of polyfunctionally-substituted pyridine was reported by Famhy 
et al.43 During this reaction, sometimes the formation of tautomer was also reported. 
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Radhakrishnan et al.44 prepared 2,2’-(2,6-dimethyl-4-aryl-1,4-dihydropyridine-
3,5-dicarbonyl)bis(hydrazinecarbothioamide)  via thiosemicarbazide  by the 
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hydrazinolysis method, it was the very good synthesis process for preparation of 1,4-
dihydropyridine with DMSO solvent. 
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Multi-component reactions (MCRs) have emerged as an efficient and powerful 
tool in modern synthetic organic chemistry allowing the facile creation of several new 
bonds in a one-pot reaction. Clearly, for multi-step synthetic procedures, the number of 
reactions and purification steps are among the most important criteria for the efficiency 
and practicability of the process and should be as low as possible. Therefore, in the last 
decade, research in academia and industry has increasingly emphasized the use of MCRs 
as well as domino reaction sequences for a broad range of products. Khadilkar at el45 
prepared 4-Aryl-1,4-dihydropyridines(Hantzsch Esters) form an important class of 
calcium channel blokers. A number of such compounds have found clinical use. They 
report here, for the first time, the synthesis of different Hantzsch esters, including the 
drugs nifedipine and nitrendipine, carried out available sodium butylmono glycol sulphate 
(NaBMGS) 50% aqueous solution (Huls, Germany) as a solvent system, by reacting alkyl 
aminocrotonate with an aldehyde and alkyl acetoacetate.  
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THERAPEUTIC IMPORTANCE       
In 2001, Balalaie and Kowsari reported that microwave irradiation promoted the 
three-component reaction of an aromatic amine, an aromatic aldehyde, and ethyl 
propiolate to give N-substituted 1,4-dihydropyridine in a high yield.46 This method may 
be useful for easily preparing 1,4-dihydropyridine but required expensive microwave 
apparatus and severe reaction conditions.47 
Out of many 1,4-dihydropyridine drugs only Flordipine  is N-substituted 
derivative  that has proved to be very good calcium channel antagonist, contrary to be 
belief proposed by D.J.Triggle48 that N-substituted 1,4-dihydropyridine did not show 
good antihypertensive activity, probably the concept of that time and -NH was believed to 
be essential for calcium channel antagonism. 
 
N
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N
O
O
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N-methylnimodipine was found to possess antidepressive49 characteristics (20 mg. 
P.O reduce the immobile phase by approximately 22% comparison to control values), 
which provides excellent example of mechanism of action similar to that of Flordipine. V. 
Michael et.al.50 prepared antihypertensive and coronary vasodilator N-substituted 1,4-
dihydropyridine. 
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 G. Guangyu and co-workers51 have determined the expression of genes related to 
mitochondrial function in the substantia nigra of mice treated with N-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) using a cDNA array.  
 A detailed investigation on the electrochemical oxidation of some Hantzsch 1,4- 
dihydropyridine derivatives  with the aim of study the influence of the hydrogen 
substituent on the N1 position of the heterocyclic ring have been carried out in protic and 
aprotic media by Lopez-Alarcon et al.52 
 
N
O
O
O
O H R4
R1  
 N-(Phenyl)-3,5-dicarbethoxy-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine 
as been synthesized and characterized by the X-ray diffraction method by A. Shah et al.53 
In 2005 same author54 has been reported the synthesis of N-(Phenyl)-3,5-dicarbethoxy-
2,6-dimethyl-4-(phenyl)-1,4-dihydropyridine and N-(4-methoxyphenyl)-3,5 
dicarbethoxy-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine and characterized by 
the X-ray diffraction method. 
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A first series of novel N-alkyl substituted syn dimeric 4-aryl-1,4-dihydropyridines 
 have been synthesised and evaluated as HIV-1 protease inhibitors in in vitro assays 
by A. Hilgerotha and co-workers.55 
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Bossert et al.56-59 prepared many N-substituted 1,4-dihydropyridine derivative by 
Hantzsch reaction of an amine, acetoacetic ester and an aldehyde, where the condensation 
also proceeded in ethyl alcohol instead of pyridine.  
 
N
COOR2 COOR2
R
H
 
 
Duburs et al.60 prepared N-benzyl-2,6-dimethyl-4-(3-nitro phenyl)- 3,5-
dicarbethyoxy-1,4-dihydropyridine by the condensation of m-nitro benzaldehyde with 
ethyl acetoacetate and benzyl amine using pyridine as a solvent. 
 
N
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Michael et al.61 prepared antihypertensive and coronary vasodilator N-substituted 
-1,4-dihydropyridine. 
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Shah et al.62 also prepared some Mannich compounds and studied their 
antimicrobial profile. 
 
N
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N
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1,4-dihydropyridines were subjected to Mannich reaction to get new 2-alkyl-1-(1’-
dihydropyridinyl methyl) benzimidazole as hybrid molecule and was expected to give 
promising biological active molecules. They were reported to have good antimicrobial 
activity63 instead of usual cardiovascular profile. 
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Pitzenberger et al.64 investigated similar analogs in which benzyl amine reacted 
with acetoacetic ester via formation as titan amine complex, leading to usual Hantzsch 
synthesis. 
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Alkaer et al.65 converted Amlodipine into a derivative as potent vasodilator. 
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Tsuchida et al.66 has shown that CD-349 can be appeared to be a potent 
cerebrovasodilator in dogs and could be useful in the treatment of cerebrovascular 
disorders in human. 
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Another class of 1,4-DHPs having a cyano group at 3 and 5 position was prepared 
by Court et al.67  in 1952. They have prepared 3,5-dicyano-2,6-diphenyl-4-(2-
nitrophenyl)-1,4-dihydropyridine as well as 3,5-dicyano-2,6-dimethyl-4-(2-nitrophenyl) 
1,4-dihydropyridine and other similar compounds.   
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At this laboratory, the researchers have reported the Tumor-specific Cytotoxicity 
and MDR-reversal activity of dihydropyridines.68  
  
 
 
Gaveriya et al.69 have reported the synthesis and MDR reversal activity in Tumor 
cells. 
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Dihydropyridine (DHP) chemistry began in 1882 when Hantzch published the 
synthesis. The DHP nucleus is common to numerous bioactive compounds which include 
various vasodilator, antihypertensive, bronchodilator, antiatheroschlerotic, 
hepatoprotective, antitumor, antimutagenic, eroprotective and antidiabetic agents.68-73 
 
DHP have found commercial utility as calcium channel blockers, as exemplified 
by therapeutic agents such as Nifedipine,74 Nitrendipine75 and Nimodipine.76 Second 
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generation calcium antagonists include DHP derivatives with improved bioavailability, 
tissue selectivity, and/or stability such as the antihypertensive, antianginal drugs like 
Elgodipine,77 Furnidipine,78-79 Darodipine,80 Pranidipine,81 Lemildipine,82 
Dexniguldipine,83 Lacidipine84 and Benidipine.85 Number of DHP calcium agonists has 
been introduced as potential drug candidates for treatment of congestive heart failure.86-87  
  
The key characteristic of calcium channel blockers is their inhibition of entry of 
calcium ions via a subset of channels, thereby leading to impairment of contraction. There 
are three main groups of calcium channel blockers, i.e. dihydropyridines, 
phenylalkylamines and benzothiazepines, typical examples of which are nifedipine, 
verapamil and diltiazem respectively.88-91 Each has a specific receptor on the calcium 
channel and a different profile of pharmacological activity. Dihydropyridines have a less 
negative inotropic effect than phenylalkylamines and benzothiazepines but can sometimes 
cause reflex tachycardia.Dihydropyridines are able to reduce peripheral resistance, 
generally without clinically significant cardiodepression.  
 
 Among DHPs with other types of bioactivity, Cerebrocrast92 has been recently 
introduced as a neuroprotectant and cognition enhancer lacking neuronal-specific calcium 
antagonist properties. In addition, a number of DHPs with platelet antiaggregatory 
activity have also been discovered.93 These recent examples highlights the level of 
ongoing interest  toword new DHP derivatives  and have prompted us to explore this 
pharmacophoric scaffold to develop a fertile source of bioactive molecules. 
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1,4-DHPs posses different pharmacological activities such as antitumor,94 
vasodilator,95 coronary vasodilator and cardiopathic,96 antimayocardiac ischemic, 
antiulcer,97 antiallergic,98 antiinflammatory99 and antiarrhythmic,100 PAF antagonist,101  
Adenosine A3 receptor antagonist102 and MDR reversal activity.103-104 
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In particular, DHP-CA (calcium channel antagonist DHP) are extensively used for 
the treatment of hypertension,105 subarachnoid hemorrhage,106-107 myocardial infarction108-
111 and stable112-113 and unstable angina114-115 even though recently their therapeutic 
efficacy in myocardial infarction and angina has been questioned.116 This class of 
compounds is also under clinical evaluation for the treatment of heart failure,117 ischemic 
brain damage118 nephropathies and atherosclerosis.119 
 
Catalysts such as Sc(OTf)3,120 Silica gel/NaHSO4,121 heteropolyacid,122 I2,123 
CAN,124Yb(OTf)3125 and Baker’s yeast 126 have also been used in this reaction. 
 
Domestic microwave ovens as well as laboratory reactors have been successfully 
employed to prepare dialkyl 1,4-dihydropyridine-3,5-dicarboxylates and to induce the 
synthesis of the corresponding aromatic derivatives. In that latter particular case, 
unexpected results have been reported.  
Described more than one century ago by Hantzsch,127  dialkyl 1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarboxylates (1,4-DHP) have now been recognized as vital drugs 
in the treatment of angina and hypertension. Some of them (Amlodipine, Felodipine, 
Isradipine, Lacidipine, Nicardipine, Nifedipine, Nimodipine, Nitrendipine) have been 
commercialized and it has been proven that their therapeutic success is related to their 
efficacy to bind to calcium channels and consequently to decrease the passage of the 
transmembrane calcium current, associated in smooth muscle with a long lasting 
relaxation and in cardiac muscle with a reduction of contractility throughout the heart.128-
130 
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Shah et al.131 prepared many cyano-1,4-dihydropyridines. Out of many 
compounds3,5-dicyano-2,6-diethoxy-4-(2-hydroxyphenyl)-N-(2-pyridyl)-1,4-
dihydropyridine showed good anti-inflammatory activity and also showed moderated 
increase in blood pressure at 1mg/kg and 5 mg/kg. 
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Another compounds showed moderate hypotensive activity. 
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Cozzi et al.132 prepared unsymmetric 4-[3-(1H-imidazol-1-yl-) Phenyl]-1,4-
dihydropyridines and studied their antitumor activity. They correlated activity with 
Letrozole, Anastrozole and other aromatase inhibitors. 
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Work done from our laboratory 
S. V. Rokad133 have synthesized some new N-aryl-1,4-dihydropyridines 
containing furan nucleus as a antitubercular and antimicrobial activity. J. D. Akbari134 
reported molecular iodine –catalyzed one pot synthesis of some new Hantzsch 1,4-
Dihydropyridine at ambient temperature this one was the very good iodine catalysed 
1,4-dihydropyridine synthesis with excellent yields.  
Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
under taken the synthesis of several 1,4-dihydropyridines which has been described as 
under. 
 
SECTION-1:   MOLECULER IODINE CATALYZE AND CLASSICAL   
                        SYNTHESIS, CHARACTARIZATION AND X-RAY CRYSTAL  
                        LOGHRAPHIC   STUDY OF DIISOPROPYL 1,4-DIHYDRO-1-(4-  
                        METHOXYPHENYL)-2,6-DIMETHYL-4-(3-NITROPHENYL)  
                        PYRIDINE-3,5-DICARBOXYLATE[DHP-02C]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part – C 
(Section-i) 
 
Molecular iodine catalyze and classical 
synthesis, characterization and X-ray 
crystallographic study of diisopropyl 1,4-
dihydro-1-(4-methoxyphenyl)-2,6-
dimethyl-4-(3-nitrophenyl)pyridine-3,5-
dicarboxylate. 
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SECTION-I 
MOLECULER IODINE CATALYZE AND CLASSICAL SYNTHESIS, 
CHARACTARIZATION AND X-RAY CRYSTALLOGHRAPHIC STUDY OF 
DIISOPROPYL 1,4-DIHYDRO-1-(4-METHOXYPHENYL)-2,6-DIMETHYL-4-(3-
NITRO PHENYL)PYRIDINE-3,5-DICARBOXYLATE[DHP-02C]. 
 Molecular iodine and classical method are the very good synthesis method for the 
preparation of 1,4-dihydropyridine derivative Looking to this, the synthesis of 1,4-
dihydropyridine derivative was  undertaken by the condensation of  isopropyl 3-
oxobutanoate(isopropyl acetoacetate) with 3-nitro benzaldehyde and 4-methoxy aniline in 
the presence of ethanol solvent and iodine as a catalyst as shown in reaction scheme  
 
REACTION SCHEME 
                                                   
O
N
+
O
-
O
+ O
O
O
O
N H 2
EtOH
I2 , r.t. N
O
O
O
O
N
+
O
-
O
O
(i)Classical method
(ii)Catalitic method
O
O
O
 
 
The constitution of the synthesized compound have been characterized by using 
elemental analysis, FT-IR, 1H NMR spectroscopy and further supported by mass 
spectroscopy. Purity of the compound have been checked on thin layer chromatographic 
plate. 
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REACTION MECHANISM  
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR was 
determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. Elemental analysis 
of the all the synthesized compounds was carried out on Euro EA 3000 elemental 
analyzer and the results are in agreements with the structures assigned.  
 
Classical method 
[A]  Synthesis  of diisopropyl 1, 4-dihydro-1-(4- methoxyphenyl)-2, 6-dimethyl-4-
(3-nitro phenyl) pyridine-3, 5-dicarboxylate[DHP-02C]. 
A mixture of 3-nitrobenzaldehyde (0.01 mol, 1.51 gm), isopropyl acetoacetate 
(0.02 mol, 2.88 gm) and 4-methoxyaniline (0.01 mol, 1.23 gm) was heated (without 
solvent) on steam bath for 2:30 hours. After elimination of water, methanol (25 ml) was 
added directly to the reaction mixture and refluxed further for 13 hours. The progress of 
the reaction was monitored continuously by TLC. After completion of reaction the 
solvent was removed at reduced pressure. The resulting product was crystallized from 
ethanol to give analytical grade pure products.  
Catalytic method 
[B]   Synthesis   of diisopropyl 1, 4-dihydro-1-(4- methoxyphenyl)-2, 6-dimethyl- 
4- (3-nitro phenyl) pyridine-3, 5-dicarboxylate [DHP-02C]. 
 
A mixture of benzaldehyde (5 mmol, 0.53 gm), isopropyl acetoacetate (10 mmol, 
1.44 gm), 4-methoxy aniline (5 mmol, 0.615 gm) was heated (without solvent) on steam 
bath for 2:30 hours. After elimination of water, iodine (1.5 mmol, 0.38 gm) and ethanol (5 
ml) directly charge to the reaction mixture. The reaction mixture was then stirred at room 
temperature until the reaction was completed (4 hours monitored by TLC). The reaction 
mixture was treated with aqueous Na2S2O3 solution, extracted into ethyl acetate (2 × 20 
ml).The solvent was removed in vacuo and the resulting crude product (94%) was 
recrystallized from the ethanol to give the analytical grade pure product. In catalytic 
method the overall yield of the product is higher than the conventional counterpart. 
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[C]    Growth of diisopropyl 1, 4-dihydro-1-(4- methoxyphenyl)-2, 6-dimethyl-4- 
         (3-nitro phenyl) pyridine-3, 5-dicarboxylate[DHP-02C] crystals: 
In the present study, methanol were selected as solvent, however, methanol 
yielded good quality single crystals. The seed crystals were grown from controlled 
evaporation of saturated solution of diisopropyl 1, 4-dihydro-1-(4- methoxyphenyl)-2, 6-
dimethyl-4-(3-nitro phenyl) pyridine-3, 5-dicarboxylate in methanol and good quality 
crystals were picked up for growth. A glass jar of 4 cm diameter and 7 cm length was 
selected as a crystallizer. This jar was kept in a water bath with temperature control of ±  
0.1 °C. Water in the bath was stirred slowly. Supersaturated solution of diisopropyl 1, 4-
dihydro-1-(4- methoxyphenyl)-2, 6-dimethyl-4-(3-nitro phenyl) pyridine-3, 5-
dicarboxylate was poured into crystallizer and a seed crystal was hung by using very fine 
nylon thread. The temperature of the water bath was maintained at 40 °C and the 
evaporation rate was carefully controlled. 
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Figure [1]: Photograph of the grown DHP crystals 
 Good quality single crystals with maximum dimension 0.60 cm X 0.75 cm were 
obtained. Figure [1] show the types of crystals grown. The crystals were light-yellow in 
color. 
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Table-I[DHP-02C]: Physical constant of diisopropyl 1-substitutedphenyl 
2,6dimethyl-4-aryl-1,4-dihydropyridine-3,5-
dicarboxylate[DHP-02C]. 
 
N
O
O
O
O
Ha
R
R'  
                
 
 
Sr. 
No. 
Substitution 
R 
 
R’ 
 
 
M.F. 
 
M.W. 
Conventional 
Method 
Catalytic 
Method 
Rf 
value 
Yield (%) Yield (%) 
1. 3-Nitro 4-
Methoxy 
C28H32N2O7 508.56       22      81 0.51 
TLC solvent system:- E.A. : Hexane = 5 : 5 
 
 
 
ANALYTICAL DATA 
Diisopropyl 1, 4-dihydro-1-(4- methoxyphenyl)-2, 6-dimethyl-4-(3-nitro phenyl) 
pyridine-3, 5-dicarboxylate.(DHP-02C). mp 185-188°C; IR (DRS): 3142(C-H Str.), 
2980(Asym., C-H str.), 2870(Asym.,C-H str.), 1699(-C=O, Str.), 1529(C=C Ar.), 1483 
(i.p.d.asym., C-H str.), 1350(o.o.d.sym.C-H ), 1016(C=H str., i.p. ben.), 835(C-H 
o.p.ben.) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 1.14-1.16(d, J=6.24 Hz, 6H, 
CH3(isopropyle)),1.26-1.28(d, J=6.24 Hz, 6H, CH3(isopropyle)), 2.08(s, 6H, CH3), 
3.86(s, 3H, OCH3), 4.97-5.03(m, 2H, CH(isopropyle)), 5.14(m, 1H, Ha), 6.97-6.99(d,d, 
J=2.16 Hz, 2.2 Hz, 2H, Haa’), 7.12-7.14(d,d, J=2.28Hz, 2.2Hz, 2H, Hbb’), 7.41-
8.32(m,4H, ArH). MS: m/z = 508 [M]+; Anal. Calcd for C18H15FN2O3: C, 66.13; H, 6.34; 
N, 5.51. Found: C, 66.10; H, 6.26; N, 5.30%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUND 
IR  spectrum of compound DHP-02C. 
1H NMR spectrum of compound DHP-02C. 
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Expanded 1H spectrum of compound DHP-02C. 
 
Mass spectrum of compound DHP-02C. 
 
 
N
O
O
O
O
N
+
O
-
O
O
M.W.=508.56
 
Studies on nitrogen containing heterocyclic… 
X­Ray Crystallography……   247 
 
Single crystal X-ray Diffraction analysis 
Single crystal X-ray diffraction is the most common experimental method of 
obtaining a detailed picture of a small molecule that allows resolution of individual 
atoms. It is performed by analyzing the diffraction of x-rays from an ordered array of 
many identical molecules. Many molecular substances, including proteins, polymers and 
other solidify in to crystals under the proper conditions. When solidifying in to the 
crystalline state, these individual molecules typically adapted as one of only a few 
possible orientations. A crystal is a three dimensional array of those molecules that are 
held together by Van der Waals and noncovalent bonding. The smallest representative 
unit of this crystal is referred to as the unit cell. Understanding the unit cell of these arrays 
simplifies the understanding of a crystal as a whole. 
Characterization of DHP crystals 
 
Single Crystal X-ray Diffraction and Structure Determination 
  The three dimensional intensity data were collected on an Enraf-Nonius CAD-4 
diffractometer. The reflection data were collected at 293 K and ω/2θ scan mode was 
employed for data collection by using MoKα radiation (λ = 0.71073 Å). The structure has 
been elucidated by direct methods using SHELEX 97135. All non-hydrogen atoms of the 
molecule were located from the E-map. Isotropic refinement of the structure by least 
squares methods using SHELEX 97136 was followed by anisotropic refinement of all the 
non-hydrogen atoms. All the hydrogen atoms were fixed stereo chemically. Atomic 
scattering factors were taken from International tables for crystallography (1992 Vol. C 
Tables 4.2.6.8 and 6.1.1.4). Geometrical and other structural calculations were performed 
by using PARST137 programme. The experimental details and other measurement data are 
given in Table [II]   Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (A2) are given in Table [III]. Atomic displacement parameters 
(A2) are given in Table [IV]. Geometric parameters (Å,°) of DHP-02C crystals are given 
in Table [V].An ORTEP diagram of the compound with atom numbering scheme is 
shown in figure [2], and figure [3] represents the packing diagram of  
DHPcrystals.138 
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Figure [2]: ORTEP Diagram of DHP crystals 
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Table – II: Experimental details and other measurement data of DHP crystal 
 
Crystal data and experimental data 
  
Chemical formula      C28H32N2O7 
Relative chemical formula weight    508.56 
Symmetry cell setting      Triclinic 
Symmetry space group     P-1 
Cell dimensions      a=9.5043(8) Å 
b=10.7570(7) Å 
c=15.1279(12) Å 
Cell angle α                      90.501(6)° 
Cell angle β                       105.873(7)° 
Cell angle γ                      114.601(7)° 
Cell volume (V)                          1339.27(18) Å3 
Cell formula units Z                  2 
Cell measurement temperature T         293(2) K 
Cell parameters from      3153 reflections 
No. of recorded reflections     3153 
Recording Range θmin      3.3722° 
Recording Range θmax      29.0277° 
Mo Kα radiation      λ = 0.71073 Å 
Crystal description      block 
Crystal color       Light-Yellow 
Crystal Size       0.30 X 20 X 20 mm 
Crystal density measurements  
Crystal density(Dx)      1.261 mg/m3 
Crystal F (000)                   540 
µ         0.09 mm−1 
Absorpt process details         Crys Alis Red 
Special details        
Computing data collection  CrysAlis Pro, Oxford Diffraction   Ltd.,  
Version: 1.171.34.40  
(release 27-08-2010 CrysAlis171 .NET) 
(compiled Aug 27 2010,11:50:40) 
Structure Determination    SHELXS-97 (Sheldrick, 2008) 
Structure Drawing     ORTEP3 (Farrugia, 1997) 
computing_publication_material   PLATON(Spek,1999)& 
PARST(Nardelli,1995)' 
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Table:III  Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (A2) 
N1N 0.5454(3) 0.3122(2) 0.46535(16) 0.0543(7) 
C2 C 0.6907(4) 0.4335(3) 0.4872(2) 0.0506(8) 
C3 C 0.7718(4) 0.4905(3) 0.5771(2) 0.0488(8) 
C4 C 0.7183(3) 0.4147(3) 0.6544(2) 0.0473(7) 
H4 H 0.7355 0.4837 0.7038 0.057 
C5 C 0.5384(4) 0.3176(3) 0.6209(2) 0.0476(7) 
C6 C 0.4637(4) 0.2640(3) 0.5308(2) 0.0505(8) 
C7 C 0.7469(4) 0.4920(3) 0.4068(2) 0.0689(10) 
H7A H 0.6708 0.4345 0.3500 0.103 
H7B H 0.8518 0.4952 0.4134 0.103 
H7C H 0.7541 0.5836 0.4054 0.103 
C8C 0.2886(4) 0.1574(4) 0.4926(2) 0.0729(10) 
H8A H 0.2620 0.1341 0.4269 0.109 
H8B H 0.2187 0.1945 0.5048 0.109 
H8C H 0.2742 0.0761 0.5220 0.109 
C9 C 0.4847(4) 0.2280(3) 0.3756(2) 0.0514(8) 
C10 C 0.5215(4) 0.1169(3) 0.3684(2) 0.0547(8) 
H10 H 0.5830 0.0971 0.4205 0.066 
C11 C 0.4672(4) 0.0366(3) 0.2846(2) 0.0628(9) 
H11 H 0.4908 -0.0384 0.2800 0.075 
C12 C 0.3773(4) 0.0671(3) 0.2067(2) 0.0572(8) 
C13- C 0.3389(4) 0.1750(3) 0.2140(2) 0.0665(9) 
H13 H 0.2775 0.1951 0.1619 0.080 
C14 C 0.3912(4) 0.2535(4) 0.2984(2) 0.0674(10) 
H14 H 0.3627 0.3256 0.3033 0.081 
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O15 O 0.3339(3) -0.0171(2) 0.12593(16) 0.0828(8) 
C16 C 0.2611(6) 0.0187(4) 0.0422(3) 0.1070(15) 
H16A H 0.2367 -0.0487 -0.0085 0.161 
H16B H 0.3344 0.1079 0.0333 0.161 
H16C H 0.1626 0.0213 0.0448 0.161 
C17 C 0.9226(4) 0.6192(3) 0.6040(2) 0.0523(8) 
O18 O 0.9944(3) 0.6917(2) 0.55631(16) 0.0822(8) 
O19 O 0.9781(3) 0.6499(2) 0.69719(15) 0.0682(7) 
C20 C 1.1316(4) 0.7699(3) 0.7403(2) 0.0651(9) 
H20 H 1.1983 0.7903 0.6983 0.078 
C21 C 1.2148(5) 0.7310(5) 0.8269(3) 0.1041(14) 
H21A H 1.2336 0.6538 0.8112 0.156 
H21B H 1.1475 0.7064 0.8670 0.156 
H21C H 1.3168 0.8079 0.8581 0.156 
C22C 1.0989(5) 0.8909(4) 0.7570(4) 0.1150(17) 
H22A H 1.0482 0.9118 0.6987 0.172 
H22B H 1.1995 0.9693 0.7880 0.172 
H22C H 1.0281 0.8694 0.7950 0.172 
C23 C 0.4521(4) 0.2803(3) 0.6907(2) 0.0518(8) 
O24O 0.3176(3) 0.1942(3) 0.68094(17) 0.0891(9) 
O25 O 0.5433(3) 0.3580(3) 0.77256(16) 0.0820(8) 
C26 C 0.4739(5) 0.3377(4) 0.8499(3) 0.0810(12) 
H26 H 0.3717 0.2532 0.8336 0.097 
C27C 0.5956(7) 0.3234(5) 0.9321(3) 0.1202(17) 
H27A H 0.6084 0.2420 0.9185 0.180 
H27B H 0.5577 0.3160 0.9854 0.180 
H27C H 0.6982 0.4030 0.9447 0.180 
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C28 C 0.4423(6) 0.4586(5) 0.8653(3) 0.1123(16) 
H28A H 0.3603 0.4595 0.8119 0.169 
H28B H 0.5405 0.5418 0.8750 0.169 
H28C H 0.4055 0.4528 0.9189 0.169 
C29 C 0.8208(3) 0.3391(3) 0.6953(2) 0.0485(8) 
C30 C 0.8803(4) 0.3461(3) 0.7905(2) 0.0568(8) 
H30 H 0.8585 0.3974 0.8303 0.068 
C31 C 0.9715(4) 0.2768(4) 0.8259(3) 0.0675(9) 
C32 C 1.0054(4) 0.2001(4) 0.7710(3) 0.0778(11) 
H32 H 1.0644 0.1518 0.7971 0.093 
C33 C 0.9512(4) 0.1942(3) 0.6758(3) 0.0767(11) 
H33 H 0.9768 0.1448 0.6371 0.092 
C34 C 0.8584(4) 0.2629(3) 0.6389(2) 0.0584(9) 
H34 H 0.8204 0.2578 0.5748 0.070 
N35 N 1.0345(5) 0.2876(4) 0.9286(3) 0.0962(11) 
O36-O 1.1211(4) 0.2294(4) 0.9581(3) 0.1430(14) 
O37 O 0.9971(5) 0.3491(4) 0.9761(2) 0.1302(13) 
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Table: IV Atomic displacement parameters(A2) 
N1   0.0572(17) 
 
0.0623(16) 0.0429(16) 0.0017(13) 0.0145(13) 0.0260(15) 
C2  0.056(2)  0.0542(18) 
 
0.048(2) 0.0066(15) 0.0208(17) 0.0272(16) 
C3  0.0532(19)  0.0475(16) 
 
0.052(2) 0.0089(15) 0.0195(16) 0.0259(15) 
C4  0.0547(19)  0.0484(16) 0.0477(18) 
 
0.0089(14) 0.0224(15) 0.0263(15) 
C5 0.0486(18)  0.0518(17) 
 
0.054(2) 0.0088(15) 0.0228(16) 0.0284(15) 
C6  0.0521(19)  0.0541(18) 
 
0.052(2) 0.0042(15)  0.0183(17) 0.0278(16)  
C7  0.080(2)  0.076(2) 
 
0.052(2) 0.0109(17) 0.0221(19) 0.033(2) 
C8  0.054(2)  0.086(2) 
 
0.067(2) -0.0025(19) 0.0183(19) 0.0203(19) 
C9  0.0554(19)  0.0587(19) 
 
0.0429(19) 0.0034(15) 0.0126(16) 0.0289(16) 
C10  0.064(2) 0.0585(19) 
 
0.0454(19) 0.0081(15) 0.0107(16) 0.0339(17) 
C11  0.077(2) 0.0546(19) 
 
0.061(2) 0.0045(17) 0.018(2) 0.0349(19) 
C12  0.067(2)  0.0543(19) 
 
0.047(2) 0.0020(16) 0.0171(17) 0.0239(17) 
C13  0.072(2)  0.071(2) 
 
0.052(2) 0.0044(17) 0.0041(18) 0.035(2) 
C14  0.078(2)  0.074(2) 
 
0.058(2) 0.0052(18) 0.0054(19) 0.050(2) 
O15 0.112(2)  0.0769(16) 
 
0.0501(16) -0.0045(13) 0.0150(14) 0.0386(15) 
C16 0.145(4)  0.098(3) 
 
0.051(3) 0.002(2) 0.014(3) 0.038(3) 
C17 0.057(2)  0.0531(18) 0.054(2) 0.0110(16) 0.0220(18) 0.0285(17) 
 
O18 0.0751(17)  0.0845(17) 0.0591(15) 0.0159(13) 0.0230(14) 0.0070(14) 
 
O19 0.0722(16)  0.0624(14) 
 
0.0524(15) -0.0007(11) 0.0222(12) 0.0109(12) 
C20 0.056(2)  0.063(2) 0.060(2) 0.0001(17) 0.0172(18) 0.0106(18) 
 
C21 0.086(3)  0.120(3) 0.085(3) 0.008(3) 0.006(3) 0.037(3) 
 
C22 0.099(3)  0.063(2) 0.150(5) -0.014(3) 0.000(3) 0.028(2) 
 
C23 0.052(2)  0.0596(19) 0.053(2) 0.0084(17) 0.0172(18) 0.0315(17) 
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O24 0.0658(17)  
 
0.1032(19) 0.0690(17) 0.0024(15) 0.0291(14) 0.0041(16) 
 
O25 0.0675(16)  
 
0.1061(19) 0.0551(15)  -0.0085(14) 0.0309(13) 0.0144(14) 
C26 0.071(2)  0.099(3) 0.058(2) -0.006(2) 0.035(2) 0.014(2) 
 
C27 0.172(5)  0.161(5) 0.087(3) 0.053(3) 0.072(4) 0.105(4) 
 
C28 0.152(4)  0.158(4) 0.080(3) 0.027(3) 0.058(3) 0.103(4) 
 
C29 0.0398(17)  
 
0.0478(17) 0.056(2) 0.0078(15) 0.0162(16) 0.0168(14) 
 
C30 0.0509(19)  0.062(2) 0.064(2) 0.0153(17) 0.0235(17) 0.0265(17) 
 
C31 0.057(2)  0.070(2) 0.074(3) 0.0243(19) 0.015(2) 0.029(2) 
 
C32 0.053(2)  0.067(2) 0.115(4) 0.022(2) 0.015(2) 0.033(2) 
 
C33 0.062(2)  0.065(2) 0.113(4) 0.003(2) 0.029(2) 0.035(2) 
 
C34 0.0502(19)  0.0586(19) 0.064(2) -0.0004(17) 0.0107(17) 0.0262(17) 
 
N35 0.079(3)  0.105(3) 0.100(3) 0.044(2) 0.016(2) 0.043(2) 
 
O36  
 
0.127(3)  0.195(4) 0.128(3) 0.077(3) 0.019(2) 0.100(3) 
O37  
 
0.154(3)  0.177(4) 0.072(2) 0.025(2) 0.012(2) 0.098(3) 
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[Table: V]:  Geometric parameters(Å, °) of DHP‐02C crystals 
Bond Lengths (Å)   
N1-C6    1.395(4) O19 -C20   1.455(3) 
N1 -C2   1.401(3) C20- C22    1.492(5) 
N1 -C9   1.453(4) C20 -C21   1.495(5) 
C2 -C3 1.356(4) C20- H20   0.9800 
C2 -C7   1.501(4) C21- H21A   0.9600 
C3 -C17   1.468(4) C21- H21B   0.9600 
C3- C4   1.511(4) C21 -H21C   0.9600 
C4- C5    1.517(4) C22 -H22A   0.9600 
C4 -C29   1.527(4) C22- H22B   0.9600 
C4- H4  0.9800 C22- H22C   0. 9600 
C5 -C6    1.346(4) C23- O24   1.193(3) 
C5- C23   1.468(4) C23-O25   1.332(4) 
C6- C8    1.514(4) O25- C26   1.470(4) 
C7- H7A   0.9600 C26- C28   1.481(5) 
C7- H7B   0.9600 C26- C27   1.507(6) 
C7- H7C   0.9600 C26- H26   0.9800 
C8 -H8A  0.9600 C27- H27A   0.9600 
C8 -H8B   0.9600 C27 -H27B   0.9600 
C8- H8C   0.9600 C27- H27C   0.9600 
C9 -C14   1.368(4) C28 -H28A   0.9600 
C9 -C10   1.388(4) C28- H28B   0.9600 
C10- C11    1.368(4) C28- H28C   0.9600 
C10- H10    0.9300 C29- C30   1.385(4) 
C11 -C12   1.384(4) C29- C34   1.389(4) 
C11- H11   0.9300 C30 -C31   1.373(5) 
C12- C13   1.366(4) C30- H30   0.9300 
C12-O15   1.370(4) C31 -C32   1.353(5) 
C13- C14    1.370(4) C31 -N35   1.488(5) 
C13- H13    0.9300 C32 -C33   1.382(5) 
C14 -H14   0.9300 C32- H32   0.9300 
O15 -C16   1.408(5) C33- C34   1.384(5) 
C16 -H16A   0.9600 C33 -H33   0.9300 
C16- H16B   0.9600 C34- H34   0.9300 
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C16- H16C   0.9600 N35 -O37   1.187(4) 
C17- O18   1.196(3) N35 -O36   1.225(4) 
C17 -O19   1.347(4)   
 
Bond Angles (°) 
C6 -N1- C2   121.3(2) O19- C20- C22 109.1(3) 
C6 -N1- C9   118.7(2) O19 -C20- C21 106.6(3) 
C2 -N1- C9   119.8(2) C22- C20- C21 113.8(3) 
C3- C2- N1   119.8(3) O19 -C20- H20 109.1 
C3 -C2 -C7   124.0(3) C22- C20- H20 109.1 
N1- C2 -C7   116.2(3) C21- C20- H20 109.1 
C2- C3- C17   122.2(3) C20 -C21- H21A 109.5 
C2 -C3 -C4   120.3(3) C20-C21-H21B  109.5 
C17- C3- C4   117.2(3) H21A-C21-H21 109.5 
C3 -C4 -C5   110.7(2) C20-C21-H21C  109.5 
C3- C4 -C29   111.3(2) H21A-C21-H21 109.5 
C5 -C4 -C29  111.7(2) H21B-C21-H21  109.5 
C3- C4 -H4   107.6 C20-C22-H22A 109.5 
C5- C4 -H4   107.6 C20-C22-H22B  109.5 
C29- C4 -H4   107.6 H22A-C22-H22B  109.5 
C6- C5 -C23   121.8(3) C20-C22-H22C  109.5 
C6- C5- C4   120.5(3) H22A-C22-H22C  109.5 
C23- C5- C4   117.7(3) H22B-C22-H22C  109.5 
C5 -C6- N1   120.0(3) O24 -C23- O25  120.5(3) 
C5- C6 -C8   124.1(3) O24- C23- C5   128.0(3) 
N1- C6- C8   115.8(3) O25- C23- C5   111.5(3) 
C2- C7- H7A   109.5 C23- O25- C26  118.8(3) 
C2- C7- H7B   109.5 O25- C26- C28  107.1(3) 
H7A- C7- H7B   109.5 O25- C26- C27  106.9(3) 
C2- C7 -H7C   109.5 C28- C26- C27   113.5(3) 
H7A -C7 -H7C   109.5 O25- C26 -H26  109.7 
H7B -C7- H7C   109.5 C28 -C26 -H26  109.7 
C6- C8- H8A   109.5 C27- C26- H26   109.7 
C6- C8 -H8B   109.5 C26-C27-H27A 
  
109.5 
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H8A -C8- H8B   109.5 C26-C27-H27B  109.5 
C6- C- H8C   109.5 H27A-C27-H27B  109.5 
H8A -C8 -H8C   109.5 C26-C27-H27C  109.5 
H8B -C8- H8C   109.5 H27A-C27-H27C  109.5 
C14 -C9 -C10   119.0(3) H27B-C27-H27C  109.5 
C14-C9- N1   122.2(3) C26-C28-H28A  109.5 
C10- C9-N1   118.8(3) C26-C28-H28B  109.5 
C11- C10 -C9   120.1(3) H28A-C28-H28B  109.5 
C11 -C10- H10  120.0 C26-C28-H28C  109.5 
C9 -C10- H10   120.0 H28A-C28-H28C  109.5 
C10- C11- C12   120.0(3) H28B-C28-H28  109.5 
C10- C11- H11  120.0 C30 -C29- C34  118.1(3) 
C12 -C11 -H11  120.0 C30- C29- C4   120.5(3) 
C13 -C12 -O15  124.9(3) C34- C29- C4   121.4(3) 
C13- C12 -C11   120.0(3) C31 -C30 -C29   119 .6(3) 
O15 -C12 -C11  115.1(3) C31- C30- H30  120.2 
C12 -C13 -C14   119.7(3) C29- C30 -H30  120.2 
C12- C13-H13   120.1 C32 -C31- C30   122.4(4) 
C14 -C13 -H13  120.1 C32- C31 -N35  119.5(4) 
C9- C14- C13   121.2(3) C30- C31- N35  118.1(4) 
C9- C14 -H14   119.4 C31 -C32- C33   119.2(4) 
C13 -C14 -H14  119.4 C31- C32- H32  120.4 
C12 -O15- C16  118.1(3) C33- C32- H32  120.4 
O15-C16-H16A  109.5 C32 -C33 -C34   119.1(3) 
O15-C16-H16B  109.5 C32 -C33- H33  120.5 
H16A-C16-H16B  109.5 C34 -C33- H33  120.5 
O15-C16-H16C  109.5 C33- C34- C29   121.5(3) 
H16A-C16-H16C  109.5 C33- C34 -H34   119.2 
H16B-C16-H16C  109.5 C29 -C34- H34  119.2 
O18- C17- O19  121.0(3) O37-N35-O36   124.4(5) 
O18- C17- C3   129.6(3) O37- N35- C31  119.0(4) 
O19- C17- C3   109.4(3) O36 -N35- C31  116.6(4) 
C17 -O19 -C20  119.2(2)   
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Torsion Angles (°) 
C6- N1 -C2-C3  13.7(4) C12 -C13- C14 -C9 1.5(6) 
C9- N1- C2-C3  -161.0(3) C13- C12 -O15- C16 7.9(5) 
C6- N1- C2-C7  -166.6(3) C11- C12- O15- C16 -171.8(3) 
C9 -N1- C2-C7  18.7(4) C2 -C3- C17 –O1 0.8(5) 
N1-C2-C3-C17   178.6(2) C4- C3- C17- O1 174.6(3) 
C7-C2-C3-C17   1.8(5) C2 -C3 -C17 -O19  -178.8(3) 
N1- C2- C3-C4  7.8(4) C4- C3- C17- O19 -4.9(3) 
C7- C2- C3-C4  -171.9(3) O18- C17- O19-C20 -2.8(4) 
C2- C3- C4-C5  -26.5(4) C3 -C17 -O19 -C20  176.8(2) 
C17-C3-C4-C5   159.5(2) C17- O19- C20 -C22 94.3(4) 
C2-C3-C4-C29   98.4(3) C17 -O19 -C20- C21 -142.4(3) 
C17-C3-C4-C29  -75.6(3) C6 -C5- C23- O24  7.0(5) 
C3-C4 -C5- C6   27.3(4) C4 -C5- C23 -O24  -170.3(3) 
C29- C4- C5 -C6  -97.4(3) C6- C5- C23 -O25  -172.2(3) 
C3-C4-C5-C23   -155.4(2) C4- C5- C23- O25  10.5(4) 
C29-C4-C5-C23  80.0(3) O24- C23 -O25-C26 -1.3(5) 
C23 -C5- C6- N1 173.7(3) C5 -C23 -O25- C26  178.0(3) 
C4- C5 -C6 -N1 -9.0(4) C23- O25- C26- C28 -107.6(4) 
C23- C5- C6- C8  -2.6(5) C23- O25- C26 -C27 130.4(3) 
C4- C5- C6- C8  174.7(3) C3- C4 -C29- C30  134.9(3) 
C2- N1- C6- C5  -13.1(4) C5- C4- C29 -C30  -100.8(3) 
C9- N1- C6- C5 161.7(3) C3 -C4 -C29- C34 -44.5(4) 
C2- N1- C6 -C8  163.5(3) C5- C4- C29- C34 79.9(3) 
C9 -N1- C6- C8 -21.7(4) C34- C29- C30- C31 -0.9(4) 
C6 -N1- C9- C14 99.7(4) C4- C29- C30- C31 179.7(3) 
C2- N1 -C9 -C14  -85.5(4) C29- C30- C31 -C32 -0.5(5) 
C6-N1-C9-C10  -79.6(3) C29- C30- C31- N35 179.5(3) 
C2-N1-C9-C10 95.3(3) C30- C31- C32 -C33 2.2(5) 
C14- C9- C10- C11 1.3(5) N35- C31- C32 -C33 -177.8(3) 
N1 -C9- C10 -C11 -179.4(3) C31- C32- C33- C34 -2.4(5) 
C9- C10 -C11- C12 0.8(5) C32- C33- C34- C29 1.0(5) 
C10- C11- C12- C13 -1.8(5) C30- C29- C34- C33 0.6(4) 
C10- C11- C12- O15 177.9(3) C4- C29- C34- C33 -180.0(3) 
O15 -C12- C13- C14 -179.0(3) C32- C31- N35-O37 -176.1(4) 
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C11- C12- C13- C14  0.7(5) C30- C31-N35- O37 3.9(6) 
C10 -C9 -C14-C13 -2.5(5) C32- C31- 35- O36 2.9(5) 
N1- C9- C14- C13 178.3(3) C30- C31-N35 -O36 -177.1(3) 
      
  
 
 
[Figure‐3]:   Packing diagram of  diisopropyl-1-(4-methoxyphenyl)-2,6-dimethyl-4-(3- 
nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (DHP-02C) crystals 
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